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1. INTRODUCTION 
Medicinal chemistry is mainly based on synthesis. Without synthetic chemists to 
prepare, purify and characterize novel compounds or commercially unavailable 
known compounds they simply do not exist. In addition, during this survey to 
prepare target compounds there is a great opportunity to find new reactions and 
synthesis methods. Although medicinal chemistry belongs to the field of target 
oriented synthesis, like total synthesis of natural products its contribution to the 
science of synthetic chemistry is noticeable.  
Cannabis (Cannabis sativa L.) has had a large role in medicine and recreation for 
over 4000 years.1 The main psychoactive constituent of cannabis, ∆9-
tetrahydrocannabinol (∆9-THC, 1), was isolated and characterized by Mechoulam in 
1964.2 After this it took almost 30 years to find the receptor which is activated by 
these compounds called cannabinoids. Shortly after that, the endogenous 
cannabinoid system was presented, opening a new group of target proteins for 
pharmacological manipulation. Since then the cannabinoid receptors, hydrolyzing 
enzymes of endogenous cannabinoids and their transport mechanisms have been 
extensively studied.3  
Arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG) are 
considered to be the most important endogenous agonists for the G-protein-coupled 
cannabinoid receptors CB1 and CB2.4,5,6 The endocannabinoids are inactivated 
rapidly by cellular reuptake, followed by intracellular hydrolysis by specific 
enzymes.7,8 AEA is rapidly hydrolyzed by the enzyme fatty acid amide hydrolase 
(FAAH; EC 3.5.1.4).7,9 Also, like AEA, 2-AG is thought to be removed from its 
sites of action by cellular reuptake and to be then hydrolyzed enzymatically. 
Although 2-AG can be hydrolyzed by FAAH,10 the main enzyme responsible for 2-
AG hydrolysis in vivo is probably monoglyceride lipase11 (MGL; EC 3.1.1.23) or 
MGL-like enzyme.12 Due to the rapid inactivation, the cannabimimetic effects of the 
endocannabinoids remain very weak. The increase of concentration of 
endocannabinoids in the extracellular space can lead to several beneficial therapeutic 
14 
 
effects13 such as alleviation of pain14,15 and anxiety,16 reduction of intraocular 
pressure,17 as well as increase of appetite.18 The activation of CB2 receptors is 
involved in the decrease of inflammation, lowering of blood pressure and 
suppression of peripheral pain.19  
The main objective of this study was to design and prepare novel compounds which 
would efficiently inhibit fatty acid amide hydrolase. The second objective was to 
gather structure-activity relationship (SAR) data of both FAAH and MGL inhibitors 
for further development of inhibitors against these enzymes.  
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2. GENERAL BACKGROUND OF THE CANNABINOID SYSTEM  
A large number of reports concerning physiological signaling system called the 
cannabinoid system is released monthly. To date, this system has been elucidated to 
consist of at least two receptors named CB1 and CB2, numerous endogenous ligands 
as their agonists (endocannabinoids), and enzymes involved in biosynthesis and 
degradation of these ligands.  
2.1. CB-receptors  
Both CB1 and CB2 are seven-transmembrane proteins belonging to the superfamily 
of G-protein coupled receptors.20,21 They share a 68% sequence homology at the 
amino acid level in domains involved in ligand identification, and a 44% homology 
throughout the proteins. 
Plant C21 terpenophenols found from Cannabis sativa and their synthetic analogues 
are classified as cannabinoids (1-6, Figure 1).1 Due to the lipophilic nature of 
cannabinoids, their psychotropic activity was first thought to be based on 
pertubation of lipid membranes.22 When a group of stereo- and other isomers of ∆9-
THC was prepared and found to raise different psychotropic responses within test 
animals, the idea of specific cannabinoid receptor was raised.23 The first cannabinoid 
receptor (CB1) was then identified utilizing a tritium labeled derivative of the 
synthetic non-classical cannabinoid CP-55940 (4).24 CP-55940 was developed by 
Pfizer during their cannabinoid project before discovery of cannabinoid receptor.25 
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Figure 1. Structures and CB1-affinities30 of some natural (1-3) and synthetic (4-6) 
cannabinoids.  
CB1  
CB1 has been cloned from rat20 (cerebral cortex cDNA library) and from human26 
(brain stem cDNA library). CB1, constituting of 473 amino acids, is mainly 
expressed in the central nervous system and, to a much lower extent, in several 
peripheral tissues such as adrenal gland, heart, lung, prostate, uterus, ovary, testis, 
bone marrow, thymus and tonsils.27,28   
Several enantiopure cannabinoid derivatives have been synthesized and studied as 
CB1 agonists. Some of the most important are shown in Figure 1. Addition of a 
hydroxy group and changing the alkyl chain from pentyl to the slightly more 
lipophilic dimethylheptyl resulted in very active compound HU-21029 (5, Figure 1). 
The hydrogenated derivative HU-243 (6, Figure 1) was found to be four times more 
active than HU-210, which in turn is already 250-fold more active than THC in 
terms of binding to CB1.30  
CB2 
Existence of peripheral effects of cannabis together with discovery of CB1- receptor 
led to the cloning (cDNA of human promyelotic leukaemic line HL60) and 
identification of the second cannabinoid receptor, called CB2, by Munro et al.21 CB2 
(360 amino acids) is predominantly located in peripheral tissues and cells involved 
17 
 
in immune system like spleen, tonsils, mast cells, B-cells, macrophages and killer 
cells.27,31,32 However, later it has been reported that CB2 receptors are expressed also 
in the central nervous system.33  
CB1 and CB2 receptor activation 
The general role of CB1 and CB2 is to regulate the release of chemical messengers. 
The activation of these receptors is coupled with several signal transduction 
pathways via the Gi/o family of G-protein coupled receptor  superfamily. These 
pathways include negative coupling to adenylyl cyclase and activation of focal 
adhesion kinase, mitogen activated protein kinase and phosphatidylinositol-3-kinase. 
CB1 is also coupled to ion channels regulating Ca2+ and K+ -release through 
membranes. To summarize, the actions resulting from CB1 activation and 
cannabinoid administration in general are ubiquitous and complex because of the 
wide distribution of cannabinoid receptors in the body.34  
Other cannabinoid receptors 
Most of the cannabinoid-induced physiological effects can be explained to occur by 
binding to CB1 or CB2. However, there are examples where these receptors do not 
explain observed pharmacology. This, together with studies using mice genetically 
deleted for the known receptors, has confirmed the hypothesis of additional 
receptors.35 So far, the only identified receptor candidate responsible of these non-
CB1/CB2 cannabinoid ligand effects is an orphan G-protein coupled receptor 
GPR55.36,37 
2.2. Cannabinoid ligands 
The most studied and/or effective ligands binding to cannabinoid receptors can be 
divided in five main groups (Table 1): Classical cannabinoids (e.g. 1-3, Figure 1), 
non-classical cannabinoids, aminoalkylindoles, eicosanoids, and diarylpyrazoles. 
These groups can be further subdivided as agonists (first four groups) and 
antagonists/inverse agonists. 34 In addition, several other potent CB1/CB2 binding 
compounds that do not fit into these categories are presented in the literature.25,38  
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Table 1. Five groups of typical ligands that bind to cannabinoid receptors.34,39,40  
Classical cannabinoids 
∆
9
-THC (1), ∆8-THC, HU-210 (5) 
  
 
Non-classical cannabinoids 
CP-55940 (4) 
10, CP-55244
OH
HO
OH
A
C
D
  
Aminoalkylindoles 
       
 
Eicosanoids 
O
O
N
H
OH
CN18, O-1821
16, 2-AG; R=
15, AEA; R=
17, R=
R
N
H
OH
O
OH
OH
N
H
OH
 
Diarylpyrazoles 
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2.3. Endocannabinoids 
The identification of CB1 launched the search for specific endogenous ligands 
(endocannabinoids). The first endocannabinoid, N-arachidonoylethanolamide (15, 
AEA) was identified and isolated from porcine brain.4 It is also called anandamide 
after the Sanskrit word ananda for “bliss”.25 Search for endogenous agonists for the 
periferal CB2 led to the isolation of the second known endocannabinoid, 2-
arachidonoyl glycerol (16, 2-AG)5. At the same time, 2-AG was also isolated from 
rat brain.6 Other reported endocannabinoids include O-arachidonoylethanolamide 
(virodhamine, 20)41, N-arachidonoyl-dopamine (NADA, 21)42,43, 2-arachidonyl 
glyceryl ether (noladinether, 22)44, homo-γ-linoleoylethanolamide (23) and 
7,10,13,16-docosatetraenoylethanolamide (24)45. The physiological role of these 
endocannabinoids 20-24 has not been thoroughly evaluated, and for example the 
existence of noladin ether (22) as endogenous compound in mammalian brain tissue 
has been questioned.46 
 
 
 
Figure 2. The structures of known endocannabinoids. 
 
2-AG and AEA are no doubt the most important endocannabinoids due to their 
abundance, activity and selectivity.3,47,48 2-AG is more efficacious in vitro than 
AEA, latter being in activity in the same level as ∆9-THC. Hence, AEA is 
20 
 
considered to be a partial agonist and 2-AG a full agonist of both CB1 and CB2.49,50 
In addition, concentrations of 2-AG in brain tissues are higher than those of AEA. 
The concentration differences vary between the reports from 170-fold to 2-fold in 
favor to 2-AG. The extracellular concentrations are close to equivalent (2-5-fold in 
favor to 2-AG), which is probably closer to the truth when comparing the active 
concentrations of these endocannabinoids.51,52 In addition, it has been reported that 
2-AG is rapidly generated in rat brain after decapitation, which obviously has had 
influence on the findings.53   
Endocannabinoids AEA and 2-AG have also other targets in addition to extracellular 
CB-receptors. Both are reported to act as agonists of nuclear peroxisome 
proliferator-activated receptor (PPAR) family members PPARα and PPARγ. AEA is 
also an endogenous agonist for the vanilloid receptor channel TRPV1.54,55  
2.3.1. Anandamide (AEA) 
Shortly after the discovery of AEA, its biosynthesis was also described.56,57 AEA is 
generated from membrane phospholipids by a two-step biosynthesis (Figure 3). In 
fact, all N-acylamides are synthesized in a similar way in animal tissues. First, the 
acyl chain is transferred from a glycerophospholipid, e.g. N-phosphatidylcholine 
(25, Figure 4), to the amino group of phosphaditylethanolamine (PE, 26) by N-
acyltransferase. The N-arachidonylphosphatidylethanolamine (NArPE, 27) formed 
in the reaction is then hydrolyzed to AEA by a selective phospholipase D (NAPE-
PLD).58  
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Figure 3. Life cycle of AEA and 2-AG. N-acyltransferase (NAT) is also known as 
calcium-dependent transacylase (CDTA). Other abbreviations: PE, 
phosphatidylethanolamine, NArPE, N-arachidonylphosphatidylethanolamine; 
NAPE-PLD, N-acylphosphatidylethanolamine-selective phospholipase D; PIP2, 
phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C, DAG, diacylglycerol; 
DAGL, diacylglycerol lipase. Dashed line for hydrolysis of 2-AG to arachidonic 
acid (AA) by FAAH designates minor route of hydrolysis. Major hydrolyzing 
enzyme for 2-AG is MGL. 
 
The production of AEA takes place in postsynaptic neurons in response to a 
stimulus, e.g. elevation of intracellular Ca2+-levels. Thus, AEA is not stored but 
synthesized “on demand”.47 AEA is simultaneously released to extracellular space 
where its binding sites (CB-receptors) are located. AEA is then rapidly removed 
from its site of action by cellular reuptake, followed by intracellular hydrolysis by 
fatty acid amide hydrolase (FAAH), an enzyme localized on the endoplasmic 
reticulum. Reuptake is thought to be carried out by either passive diffusion59, 
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facilitated diffusion60, endocytosis,61 or by transport protein62,63. The existence of 
these different theories64 inherits from the fact that as a very lipophilic molecule, 
AEA is most likely able to diffuse through membranes readily without aiding 
mechanisms. In addition, some inhibitors of the yet unidentified transport protein 
have been reported to inhibit FAAH as well.65,66,67 The question should rather be that 
how does such a lipophilic molecule as AEA (or 2-AG) travel through an aqueous 
medium from the membrane to the site of catabolism. Indeed, in recent report it was 
suggested that a chaperon mechanism could be involved. It was found that 
overexpression of two known lipid carrier proteins FABP5 and FABP7 enhanced the 
hydrolysis of FAAH.68 It will not come as surprise if inhibition studies against these 
chaperon-proteins are reported in near future.  
 
 
Figure 4. Structures of the main intermediates of AEA and 2-AG biosynthesis. 
 
2.3.2. 2-Arachidonoylglycerol (2-AG) 
Biosynthesis of 2-AG (as AEA) is initiated by Ca2+ flux into the postsynaptic cell. 
The predominant routes involve the usage of arachidonic acid-enriched membrane 
phospholipid such as phosphatidylinositol-4,5-bisphosphonate (PIP2, 28, Figure 4) 
as starting material. PIP2 is dephosphorylated by phospholipase C (PLC), forming 
diacylglycerol (DAG), which is then hydrolyzed to 2-AG by sn-1 selective 
diacylglyceride lipase. The alternative route is mediated by phospholipase A which 
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cleaves the 1-acyl from PIP2, resulting in lysophosphatidylinositol (29), which in 
turn is transformed to 2-AG by PLC.69 The cellular release and uptake of the 2-AG 
is suggested to occur via same mechanisms as with AEA; the cellular accumulation 
of 2-AG was prevented by AEA in human astrocytoma cells.10 By contrast, the 
corresponding inhibition was not detected in macrophages.70 The main hydrolyzing 
enzyme for 2-AG is MGL, which is responsible for ~80% of overall 2-AG 
hydrolysis.11,71 The remaining 2-AG hydrolyzing activity is attributed to FAAH 
along with some other lipases and esterases. In a recent study, 98% of 2-AG 
hydrolysis in brain was accounted for: MGL hydrolyzed 85%, and two previously 
uncharacterized enzymes, α/β-hydrolases ABHD6 (4%) and ABHD12 (9%) were 
responsible for 13% of 2-AG hydrolyzing activity.72  
2.4. Hydrolyzing enzymes 
2.4.1. FAAH 
N-Acylethanolamide-specific membrane-associated enzyme activity in rat liver 
microsomes and mitochondria was described already in 1985, indicating the 
occurrence of NAEs as natural cell constituents.73 Later, an enzyme activity 
converting AEA to arachidonic acid was characterized from cell membrane fractions 
of rat brain tissue.74,75 Around the same time oleamide, cis-9-octadeceneamide (30, 
Figure 5), was described as a sleep-inducing substance. Oleamide was suggested to 
be hydrolyzed by the same enzyme as NAEs.76,77 Indeed, shortly afterwards Cravatt 
and colleagues succeeded in purifying this hydrolase activity to near homogeneity 
from rat liver membranes, using a column covalently modified with an oleoyl 
trifluoromethyl ketone inhibitor derivative.7 This enzyme was named fatty acid 
amide hydrolase (FAAH), since it was found to hydrolyze numerous fatty acid 
amides, including anandamide and oleamide, subsequently proven via cloning and 
transfection of the corresponding cDNA.7,9 Substrate specificity and selectivity 
studies have been conducted, revealing that FAAH hydrolyzes primary amides more 
rapidly than ethanolamides.78  
Increase of acyl chain saturation decreases the rate of hydrolysis, possibly due to 
requirement of a hairpin conformation for substrate recognition at the active site.79 
This hairpin conformation is most preferred by four non-conjugated cis double 
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bonds as in arachidonyl carbon skeleton.80 AEA-analogues containing a tertiary 
amide nitrogen are poor enzyme substrates. Increased steric hinderance around the 
carbonyl also decreases the rate of hydrolysis. In addition, substrates containing H-
bonding and/or electronegative headgroup substituents or atoms, such as hydroxyl or 
fluoro, are in turn more prone to hydrolysis. Interestingly, the stereoselectivity with 
methylanandamide substrates is opposite to that observed for the CB1 receptor: the 
enantiomer with the lower enzyme turnover shows higher receptor affinity.79 
Human, mouse, and porcine FAAH genes have since been characterized and shown 
to be highly conserved in their primary structure. Both human and rat FAAH are 
expressed broadly and at high levels in the nervous system, where the enzyme is 
localized predominantly to intracellular membranes (e.g., smooth endoplasmic 
reticulum, outer membrane of the mitochondria) in the somatodendritic 
compartment of neurons.52 The active pH range of FAAH is 7.0-9.5, the enzyme 
being most active at pH 9.81   
FAAH is comprised of 579 amino acids and it was characterized by sequence 
analysis as the first mammalian member of amidase signature (AS) enzyme family, 
containing over 100 mainly fungal and bacterial enzymes. AS enzymes share a 
characteristic feature of having a highly conserved region that is rich in serine, 
glycine, and alanine residues.52 In order to gain sufficient amounts of pure enzyme 
for further mechanistic and configurational studies, a bacterial expression system 
was developed for the rat enzyme. Both wild-type FAAH and transmembrane 
domain-deleted FAAH (∆TM-FAAH) were expressed in E. coli. Unlike most AS 
enzymes, FAAH is an integral membrane protein, having a transmembrane domain 
of first 29 amino acids. However, deletion of these amino acids (∆TM-FAAH) 
resulted in an enzyme that had the same catalytic activity and binding property to 
membranes as wild type FAAH. These results indicate that FAAH possesses 
multiple domains for membrane association and is capable of being active in other 
than its natural configuration. Further comparison of wild type and ∆TM-FAAH 
showed that the latter had smaller solution size.82 Recombinant human FAAH has 
also been expressed using baculovirus-insect cell and E. coli systems.52  
In 2002 the X-ray crystalline structure of ∆TM-FAAH was determined in 2.8 Å 
resolution opening a new era in FAAH study.83 The results revealed FAAH to be a 
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dimeric enzyme. The enzyme was treated with the irreversible inhibitor methoxy 
arachidonyl fluorophosphonate (MAFP) prior to crystallization. MAP was bound by 
covalent phosphorus-oxygen bond to Ser241 in FAAH active site. Ser241 forms an 
unusual Ser-Ser-Lys catalytic triad with Ser217 and Lys142 (Scheme 1).84,85 The 
same catalytic triad was found from two bacterial AS-family enzymes 
malonamidase E2 (MAE2)86 and peptide amidase (PAM)87 by X-ray crystal 
structures published around the same time as that of FAAH.  
 
Scheme 1. Proposed mechanism for the FAAH active site acylation step in the 
amide hydrolysis.85 
 
Serine hydrolases typically have a serine-histidine-aspartic acid catalytic triad, 
where the nucleophilicity of the serine is based on histidine’s imidazole group 
functioning as a proton shuttle between anionic aspartate and serine -OH.88 The 
unique Ser-Ser-Lys catalytic triad of FAAH seems to be the basis of its ability to 
hydrolyze amides in the presence of otherwise similar esters. FAAH has been found 
to hydrolyze both oleamide and oleoyl methyl ester at an equal rate, which is not 
typical for serine hydrolases. They normally prefer to hydrolyze esters much faster 
than amides.85 FAAH also hydrolyzes the second endocannabinoid 2-AG at a similar 
rate as AEA.89  
The FAAH structure contains channels that allow the enzyme to access both the 
membrane and cytosolic compartments of the cell. One of these channels is called 
the acyl chain-binding (ACB) channel leading from the membrane-binding surface 
of the protein to the enzyme active site. ACB channel is comprised almost entirely 
of hydrophobic residues and is thought to participate in substrate recognition.90 
Another channel emerges from the active site at an angle of approximately 80° from 
the substrate-binding cavity to create a solvent-exposed “cytoplasmic port”. The 
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FAAH structure suggests a model where fatty acid amide substrates gain access to 
the active site by first entering into the membrane. After hydrolysis, the fatty acid 
would exit the enzyme via ACB channel to membrane. Hydrophilic amine products 
would be excreted directly to cytosolic space via the cytoplasmic port (also called 
cytoplasmic access (CA) channel).83 The cytoplasmic port may also play a role by 
providing an entry for the molecular water required in the hydrolysis.52  
In addition to N-acyl ethanolamides, FAAH is suggested to hydrolyze N-acyl 
taurines (NAT, 31) which activate the transient receptor potential (TRP) family of 
calcium channels.91 
 
 
Figure 5. Structures of oleamide and NAT. Acyl (RCO) in most abundant 
compounds is C18:1 (oleoyl), C18:2 (linoleoyl), C20:4 (arachidonoyl), C22:6 
(docosahaexenoyl). 
 
In order to further study the pharmacology of FAAH, gene depletion was used and 
FAAH knockout mice were developed. These FAAH(-/-) mice have 15-fold higher 
brain levels of anandamide than wild type mice.92 In addition, FAAH(-/-) mice 
exhibit a CB1 receptor mediated analgesic phenotype in a variety of acute and 
inflammatory pain models.93 
2.4.2. MGL 
Several findings indicated that FAAH is not the enzyme responsible for most of the 
2-AG degradation. The rate of monoacylglycerol hydrolysis in brain extracts is 
nearly two orders of magnitude higher than the rate of hydrolysis of NAEs.94 In 
addition, porcine brain fractions possessing hydrolysis activities of 2-AG and 
anandamide were separated chromatographically.95 Finally, the inactivation of 
FAAH did not change the endogenous levels or hydrolysis of 2-AG and other 
monoacylglycerides in brain tissue, similar results having been achieved with both 
FAAH (-/-) mice and pharmacological inactivation.52 
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Monoglyceride lipase (MGL; EC 3.1.1.23, also called monoacylglycerol lipase) was 
originally purified from rat adipose tissue. This enzyme was found to hydrolyze both 
1- and 2- isomers of monoacylglycerol at equal rates.96 MGL catalyzes the last step 
in the hydrolysis of stored triglycerides in the adipocyte, and presumably also 
complements the action of lipoprotein lipase in degrading triglycerides from 
chylomicrons and very low density lipoproteins. Monoglyceride lipase was cloned 
from a mouse adipocyte cDNA library. The predicted amino acid sequence consisted 
of 302 amino acids, corresponding to a molecular weight of 33.218 kDa. The 
sequence showed no homology to other known mammalian proteins, but a number 
of microbial proteins, including two bacterial lysophospholipases and a family of 
haloperoxidases, were found to be distantly related to this enzyme. The structural 
elements, as well as the putative catalytic triad of MGL, were identified by multiple 
sequence alignment and secondary structure prediction. The residues of the proposed 
triad, Ser122, Asp239, and His269, were confirmed by site-directed mutagenesis 
experiments. This is a typical triad for serine hydrolases.97 MGL is ubiquitously 
expressed among tissues, including the brain where it is located in presynaptic 
terminals of neurons acting as the major (>80%) degrading enzyme of 2-AG.71 MGL 
is capable of hydrolyzing other long chain glyceryl esters as well, still having the 
fastest rate for hydrolysis of arachidonoyl glycerols.98,99 The crystallization of MGL 
has not been reported to date.  
2.4.3. FAAH-2 and NAAA 
FAAH-2 
During activity based protein profiling (ABPP) studies on a human cancer cell lines, 
a second AS family enzyme with fatty acid amide hydrolyzing activity was 
discovered.100 This enzyme, named FAAH-2, has a transmembrane domain and a 
serine-serine-lysine catalytic triad like FAAH, despite that these enzymes share only 
20% sequence homology. FAAH-2 exhibits different features in regard to its 
substrate specificity and tissue distribution compared with those of FAAH. FAAH-2 
hydrolyzes primary fatty acid amide substrates such as oleamide at equivalent rates 
as FAAH, but FAAH hydrolyzes NAEs, including anandamide, significantly more 
efficiently than FAAH-2. Tissue distributions for human are also different: FAAH-2 
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appears at higher relative levels in peripheral tissues (e.g., heart, ovary) in contrast to 
FAAH showing robust expression in the nervous system. The FAAH-2 gene has not 
been found in a number of lower placental mammals including mouse and rat. 
Interestingly, both enzymes are inhibited by selective FAAH inhibitors α-
ketoheterocycles (OL-135) and O-aryl carbamates (URB597) (for structures see 
chapter 3.1.2 and 3.1.3). The discovery of a second FAAH enzyme selectively 
present in higher mammals suggests that fatty acid amide metabolism may differ 
between humans and rodents.100 
NAAA 
Fully saturated N-palmitoylethanolamine (PEA) is an anti-inflammatory and 
immunosuppressive endogenous substance which is not efficiently degraded by 
FAAH. In year 2001 Ueda et al. reported the discovery of an amidase that was more 
active in hydrolyzing PEA than AEA in contrast to FAAH.  The enzyme with a 
molecular mass of 31 kDa was purified from rat lung, where it was also found to 
possess the highest specific enzyme activity. Relative reactivities of the enzyme with 
various N-acylethanolamines (100 µM) were as follows (acyl skeletons in 
parentheses): N-palmitoylethanolamine (Acyl: C16:0) > N-myristoylethanolamine 
(C14:0) > N-stearoylethanolamine (C18:0) = N-oleoylethanolamine (C18:1(cis-9)) > 
N-linoleoylethanolamine (C18:2(all cis-9, 12)) > AEA (C20:4(all cis-4, 8, 11, 
14)).101 This NAE hydrolase was cloned, characterized, and termed as N-
acylethanolamine-hydrolyzing acid amidase (NAAA), reflecting its acidic pH 
optimum of pH 5. High sequence similarity between NAAA and acid ceramidase 
was detected in the lysate when human NAAA cDNA was transfected into HEK293 
cells. NAAA is not a serine hydrolase and is therefore much less sensitive to general 
serine hydrolase inhibitors such as MAFP. NAAA is completely inhibited by 10 µM 
p-chloromercuribenzoic acid, a thiol-blocking reagent.102 In human, NAAA shows 
highest relative expression in peripheral tissues like prostate, leukocyte, liver, 
spleen, kidney and pancreas.103 The high expression of the NAAA in macrophages 
and certain peripheral tissues indicates to a potential role of this enzyme in fatty acid 
amide hydrolysis in vivo at these sites.52 
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3. ENZYME INHIBITORS 
By inhibiting the main endocannabinoid hydrolyzing enzymes FAAH or MGL, the 
effect of endocannabinoids could be enhanced and more selective therapeutic effects 
achieved.38,104,105 Thus the inhibition of these enzymes is of great interest to 
medicinal chemists nowadays.  
3.1. FAAH inhibitors  
FAAH inhibitors represent several classes of structures and functionalities but most 
of them fall in the two most studied compound groups: α-ketoheterocycles and N-
alkyl carbamates.  
3.1.1. Early FAAH inhibitors 
First FAAH inhibitors were typical covalent non-selective serine hydrolase derived 
compounds (Figure 6). Albeit being selective, some of them have had a significant 
role as tools for pharmacological studies. Phenylmethylsulfonyl fluoride (32), is a 
well-known serine protease, and the first FAAH inhibitor described having IC50 
value of 290 nM.106 Combining the fatty acid moiety and the sulfonyl fluoride group 
resulted in more selective inhibitors: saturated acyl chains from laurylsulfonyl (C12, 
33, IC50 3 nM) and stearylsulfonyl fluoride (C18, IC50 4 nM) were equally potent, 
but a drop in activity was found with arachidylsulfonyl fluoride (C20, IC50 48 
nM).107 Change to a substrate-like unsaturated arachidonyl skeleton gave even 
higher inhibition activity (34, IC50 0.1 nM).108 Methylarachidonyl 
fluorophosphonate (MAFP, 35), already mentioned in the context of FAAH crystal 
studies83, was found to inhibit FAAH with the IC50 value of 2.5 nM.109 Series of 
analogues of MAFP with n-chain lengths varying from C8 to C20 and number of 
cis-double bonds from 0 to 4 have also been developed: the most potent of these was 
C12:0-compound methyldodecylfluorophosphonate (IC50 1-3 nM).110 In addition, an 
alternative polar functionality containing diazomethylarachidonyl ketone (36, IC50 
0.5-6 µM) was presented.111,112 All these compounds have significant agonist affinity 
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for the CB1 receptor, which limits their usefulness in studies of cannabinoid system. 
Compound 34, for example, inhibits [3H]-CP-55,940 binding to mouse CB1 
receptors with an IC50 value of 304 nM.108 These results suggest that arachidonyl tail 
can be replaced from already potent FAAH inhibitor by saturated C12-n-chain 
without significant loss of inhibitory potency. 
 
 
Figure 6. Structures of some early FAAH inhibitors derived from typical serine 
hydrolase inhibitors. 
 
Due to their low selectivity towards serine hydrolases, compounds 32-36 were 
considered as pharmacological tools rather than potential in vivo substances. First 
truly designed FAAH inhibitors were based on the idea to use the activated carbonyl 
compounds as putative active site traps. Different long carbon chain possessing 
amides, α-ketoamides, α-ketoesters and trifluoroketones were tested against FAAH. 
It is noteworthy that these studies were conducted before the enzyme was fully 
characterized or the catalytic mechanism understood. To this end, trifluoromethyl 
ketone, α-ketoester, and α-ketoamide derivatives of arachidonic acid or similar fatty 
acids were made and tested for inhibition of AEA hydrolysis. Most potent of these 
were arachidonyl trifluoromethyl ketone 37 and ketoester 39 with a C18:0 chain, 
both inhibiting roughly 80% of FAAH activity in 100 µM concentration (Figure 
7).113 
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Figure 7. Structures of first designed FAAH inhibitors and the transition state 
analog (38) for which the design was based.  
 
The Boger group studied oleamide hydrolyzing activity inhibitors and published a 
series of very similar compounds. Oleyl trifluoroketone 40 was the most potent in 
this study. Oleyl ketoester derivative of 39 was also found equipotent inhibitor of 
this activity.114 Oleamide hydrolyzing enzyme had already been suggested to be 
hydrolyzed by the same enzyme as AEA,77 and was indeed later revealed to be 
FAAH.  
A logical approach to FAAH inhibition is the modification of substrates to create 
inhibitors. Early work in this area identified a number of FAAH inhibitors (Figure 
8).104  
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Figure 8. Examples of substrate inspired FAAH inhibitors. 
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Arachidonylserotonin 41 (AA5HT) was initially described as FAAH inhibitor115  but 
it was later described to have antagonist properties towards transient receptor 
potential vanilloid-1 (TRPV1). Compound 41 was highly effective against both 
acute and chronic peripheral pain possibly due to its dual activity as a FAAH 
inhibitor and TRPV1 antagonist.116 The manipulation of the ethanolamine portion of 
AEA resulted in useful early inhibitors of FAAH of which the most potent was the 
alkyl chloride derivative 42 (IC50 0.9 µM). It was speculated that most of these 
analogues were probably substrates for FAAH.117 In 2001 DiMarzo described the 
urea compound 43 (O-1987, IC50 2 µM), found by preparing derivatives of 
arvanil.118 The series of palmitoylamide analogues (e.g. 44 and 45) similar to the one 
previously described with arachidonic acid amides were prepared and some weak 
inhibitors were identified.119 In the in vivo evaluation 45 was shown to be effective 
in reversing thermal and tactile hypersensitivity in a number of neuropathic pain 
models in rats.120 
 
Figure 9. Miscellaneous early FAAH inhibitors. 
 
As an early study, some non-substrate like inhibitors were also prepared (Figure 9). 
(E)-6-(Bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one (46), which 
was reported to inhibit chymotrypsin-like proteases and cytosolic Ca2+-independent 
phospholipase A2, was found to inhibit FAAH with an IC50 value of 0.8 µM.121 
Another miscellaneous class early inhibitor was 2-octyl γ-bromoacetoacetate 47, 
which was suggested as an endogenous sleep inducing substance, since it was 
isolated from human cerebrospinal fluid. A small series of derivatives of 47 was also 
developed, resulting in compound 48 as the most potent of this series. FAAH-IC50 
for 47 and 48 were 2.6 and 0.6 µM respectively.122   
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3.1.2. α-Ketoheterocycles 
The α-ketoheterocycle functionality contains a moderately electrophilic ketone 
carbonyl possessing reactivity that is adjustable by small changes in the electron 
withdrawing properties of the heterocycle. It also provides a rigid structural template 
for introducing new interactions in the enzyme active-site close to the actual 
nucleophilic attack to the carbonyl. Potent inhibitors containing this group have been 
presented for at least for serine proteases (elastase, thrombin, factor Xa, tryptase, 
chymase), cysteine proteases (cathepsin K and cathepsin S), and hydrolases 
(FAAH).123 
After introducing trifluoromethyl oleyl ketone (40) the Boger group replaced the 
trifluoromethyl group with various heterocycles identifying highly potent and 
selective FAAH inhibitors (Table 2).124  
 
Table 2. Replacement of CF3 by heterocycle.124 N.a.; No affinity detected by 100 
µM.  
 
Compd R Ki (nM) Compd R Ki (nM) 
40 CF3 82 56 
 
370 
49 
 
17 57 
 
N.a. 
50 
 
n.a. 58 
 
N.a. 
51 
 
n.a. 59 
 
N.a. 
52 
 
65 60 
 
13 000 
53 
 
N.a. 61 
 
2.3 
54 
 
N.a. 62 
 
7.2 
55a 
 
110 63 
 
3.7 
34 
 
55b 
 
130 64 
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The most active ketones were the ones possessing a clearly electron withdrawing 
heterocycle. Oxazoles were found to be superior to thiazoles or imidazoles, and 
oxazole ketone 49 (17 nM) had a moderately improved activity over the 
trifluoromethyl ketone 40 (82 nM). Benzoxazole 56 (370 nM) was significantly 
weaker FAAH inhibitor than pyridyloxazoles 61-64 (2.3-11 nM). Albeit the fact that 
the position of the pyridyl nitrogen had only a slight effect to inhibitory activity, 61 
(2.3 nM) was chosen as parent compound for next modifications focusing on alkyl 
tail. These results indicated that the pyridyl nitrogen is interacting with enzymes 
active site via hydrogen bonds or is enhancing the electrophilicity of the ketone, or 
both. The steric hindrance survey of benzoxazoles by compounds 56-60 suggests 
that oxazole-nitrogen serves as important hydrogen bond acceptor in active site.124 
 
Table 3. Optimizing the alkyl chain of 61 (2.3 nM).124  
O
N
R
N
 
Compd R  Ki (nM) 
61 C18:1 ∆9, cis (oleoyl)  2.3 
65 C18:1 ∆9, trans 3.2 
66 C20:4 (arachidonoyl) 1.0 (unstable) 
67 C18:1 ∆9, triple bond 0.14 
68 C9:1 ∆9, double bond 0.15 
69 C18:0 11 
70 C12:0 0.57 
71 C8:0 0.69 
72 C6:0 2.1 
73 Ph(CH2)3CO 6.9 
74 Ph(CH2)5CO 0.20 
75, OL-92 Ph(CH2)6CO 0.28 
76 Ph(CH2)8CO 0.50 
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Optimization of the alkyl chain of 61 revealed several important facts (Table 3). 
Compound 65, the trans-analogue of 61, was as active as parent compound 61, and 
66 bearing arachidonyl tail was slightly more active than its oleyl derivative 61, but 
not stable enough to be considered as a lead compound for further studies. The triple 
bond oleoyl analogue 67 and terminal double bond compound 68 were the most 
active in these series (140 and 150 pM). The authors commented compounds 67 and 
68 very briefly, and derivatives of these moieties have not been reported since. By 
adding the screening of saturated acyls and acylphenyls (69-76) to this table it was 
concluded that the optimal lipophilic part contains a saturated acyl chain with length 
of 8-12 carbons or an alkyl phenyl with 5-8 carbon long CH2-bridge between the 
phenyl and ketone. Compound 75 is also known as OL-92, and it is one of the most 
potent and selective FAAH inhibitors reported to date (IC50 0.3 nM125).124 
Unfortunately, in animal studies this compound failed to demonstrate FAAH 
inhibition or analgesia in vivo, possibly because of poor pharmacokinetics.126 The 
importance of the carbonyl group was further verified by preparing non-ketone 
analogues of 61: oxime-, methyloxime-, alcohol-, CH2-, and dimethylhydrazone 
derivatives were found to be at least 200-fold less effective inhibitors than the parent 
ketone 61. In addition, a methyl substituent in α-position (racemic) of ketone 61 
resulted in 4-fold decrease of the inhibition activity.127 
After these results Boger continued the optimization of α-ketoheterocycles with 
oxazole as the heterocycle and (CH2)6Ph as the alkyl group from parent compounds 
49 and 75. A large number of compounds with varying 5-substituents in 2-oxazolyl 
ring were prepared, resulting in compound OL-135 (77, Figure 10), which is one of 
the best characterized FAAH inhibitor so far.104,125,128  
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Figure 10. Some of the most potent and selective α-ketoheterocycle FAAH-
inhibitors. 
  
Compound 77 inhibited FAAH with an IC50 value of 2.0 nM and was 300:1 
selective towards heart TGH enzyme, which is a typical competing target of α-
ketoheterocycles. For comparison, trifluoromethyl oleyl ketone 40 had no selectivity 
and OL-92 (75) had 10:1 selectivity towards TGH.125 Some improvement in terms 
of selectivity towards serine hydrolases TGH and KIAA1363129 was gained by 
compounds 78 (IC50 0.7 nM) and 79 (IC50 1.0 nM). The selectivities towards TGH 
were 1700:1 for 78 and 140:1 for 79.130,131 Extensive proteomic analysis has 
demonstrated that 77 is highly selective for FAAH. Compound 77 was found to 
increase endogenous endocannabinoid levels in the brain and spinal cord of mice 
and to produce significant analgesic effects in tail immersion, hot plate, and formalin 
tests in mice, without the associated motor impairment typical of CB1 agonism.126 
Subsequently 77 was found to be effective in both mild thermal injury induced 
tactile allodynia (acute tissue injury) and spinal nerve ligation (neuropathic pain) 
models in rats.132 
The substituent effect of the ketone carbonyl and its correlation to the inhibitory 
potency have also been studied. Clear correlation was demonstrated between the 
Hammett σp constant and FAAH inhibition in simple substituted oxazoles.133,134  
Extensive SAR studies have been reported, covering more or less the chemical space 
around the core molecule OL-135, compound 77.135 Latest reports have been 
focused on modifications of the central heterocycle (oxazole in 77) such as 
screening the various heterocycles and exploring the effect of 4-substituents of the 
oxazole.136,137  Heterocycle modifications resulted in a large amount of new SAR 
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data and some improvement in selectivity.136 4-Substituted derivatives of 77 were 
found to be practically equally potent and selective as corresponding 5-substituted, 
which indicates that compounds do flipping in the active site to fit in.137  
In order to decrease the lipophilicity and to create novel structures, two patent 
applications have been published138,139 applying propylpiperidine- and piperidine 
moieties instead of alkylphenyl chain with 2-carbonyloxazole in FAAH inhibitors. 
The most potent of these compounds 80 and 81 inhibited FAAH with IC50 values of 
0.4 nM and 2.0 nM respectively (Figure 11). 
  
 
Figure 11. Examples of compounds having piperidine containing tails. 
 
In conclusion, the activated ketone series of FAAH inhibitors has been widely 
explored and valuable compounds and essential SAR data has been revealed. 
However, the pharmacokinetics of this type of molecules are still under 
investigation.140 This will be an important factor in evaluating their suitability as 
clinical candidates.104 
3.1.3. Carbamate- and urea based irreversible FAAH inhibitors 
Reactive carbamates 
Second large class of traditional FAAH inhibitors consists of carbamate compounds. 
The development of carbamate-based FAAH inhibitors started by preparing the 
derivatives of known AChE inhibitor 82 (Table 4).141 
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Table 4. Examples of the first carbamate-based FAAH inhibitors. aNo inhibition 
detected by 30 µM. 
 
Compd R1 X Z R2 IC50 (nM) 
82 CH3 O O 
 
n.a.a 
83 CH3 O O 
 
18290 
84 c-hexyl O O 
 
324 
85 c-hexyl O CH2 
 
n.a. 
86 c-hexyl O NH 
 
n.a. 
87 c-hexyl O S 
 
15580 
88 c-hexyl S NH 
 
n.a. 
89 c-hexyl S S 
 
n.a. 
90 c-hexyl S O 
 
n.a. 
91 
 
O O c-hexyl n.a. 
92 c-hexyl O O 
 
3776 
93, URB524 c-hexyl O O 
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SAR and QSAR studies of the first carbamate compounds were also conducted.141 
Briefly, the AChE inhibitor (82) and its analogues did not show inhibitory activity 
except for a weak inhibitory activity by 2-naphthyl compound (83). Replacing the 
39 
 
methyl group of 83 with more lipophilic cyclohexyl resulted in a 60-fold decrease in 
IC50 (compound 84). To examine the role of the carbamate function in FAAH 
inhibition, several bioisosters of 84 were prepared (88-93). Both the ester 85 and the 
urea 86 were ineffective and replacement of oxygen with sulfur (compounds 87-90) 
also led to inactive analogues, with the partial exception of the thiocarbamic acid S-
naphthyl ester 87. Interestingly, also the “reversed” carbamate 91 appeared to be 
inactive.142 
These results suggest that the carbamate group with O-aryl and N-alkyl is essential 
for inhibition of FAAH activity by this series of compounds. Less lipophilic O-
phenyl moiety (compound 92) decreased the activity significantly compared to 2-
naphthyl. Derivatives of 84 were then prepared, containing two phenyls or phenyl 
and alkyl as lipophilicity-increasing groups, leading to biphenyl compound 93, 
dubbed as URB524, which was found to be superior in this series.141 URB524 was 
subsequently used as the parent compound in a study of the substituent effect on the 
distal phenyl group (Table 5).16,143 The distal ring was selected for modifications 
since previous 3D-QSAR analyses suggested that this moiety was critical for 
achieving significant inhibitory potency.141 Additionally, substitutions on the distal 
ring do not change the electrophilicity of the carbamate group directly via resonance. 
The activity differences raised by different substituents were then assumed to 
correlate directly with non-covalent binding interactions in the active site.143 
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Table 5. The effect of different meta- or para-substituents in the distant phenyl ring 
of URB524 (93, R = H, 63 nM). 
 
 
Compd R IC50 (nM) Compd R IC50 (nM) 
94 4-CH3 155 103 3-F 97 
95 4-CF3 1587 104 3-C6H5O 420 
96 4-C(O)NH2 5909 105 3-n-C3H7 110 
97 4-NH2 360 106 3-NO2 50 
98 4-F 65 107 3-SO2NH2 27 
99 3-CH3 62 108 3-C(O)CH3 9.1 
100 3-CF3 146 109 3-CH2OH 8.7 
101, 
URB579 
3-C(O)NH2 4.6 110 3-CH2NH2 21177 
102 3-NH2 65 111 3-OH 8.7 
112, IC50 0.63 nM 
  
N
H
O
O NH2
O
 
 
These results clearly indicated that meta substitution in the distal ring was more 
favourable than para (94-98 vs. 99-103). The set of meta-substituents was then 
enlarged to contain total of 19 different compounds including hydrogen (93, 
URB524). QSAR model of this series was built, and the activity of the compounds 
was found to inversely correlate with the lipophilicity of the phenol. This was 
unexpected, since the initial hypothesis was that biphenyl group was mimicking the 
alkyl tail of the substrate and pointing towards the ACB-channel. These findings 
were in contrast with this, indicating that phenol points to a CA channel. Very soon 
this controversy was explained; Alexander and Cravatt proposed the mechanism 
where the O-aryl carbamate compounds are carbamoylating the active site Ser241 
(Figure 12).144 Less lipophilic biphenyls would then serve as better leaving groups 
in carbamoylation, thus explaining the correlation found. The phenol’s role as a 
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leaving group also explains for the loss of the activity with “inversion” of carbamate 
functionality (91 vs 93, Table 4). The most well studied carbamate-based FAAH 
inhibitor, URB597 (101), was presented within this study. URB597 has been shown 
to display activity in rodent models of acute,16 inflammatory,145,146 and neuropathic 
pain,147,148 as well as anxiety16 and depression142. In addition, URB597 also 
enhances non-opioid, stress-induced analgesia.149 The optimization of the N-alkyl 
moiety of the biphenyl compounds URB524 and URB597 resulted in the compound 
112 with almost 10-fold improvement in IC50 value.150  
 
 
Figure 12. Ser241 carbamoylation by the carbamates. 
 
The proposed Ser241 carbamoylation mechanism was judged by mass spectrometry 
studies and in vivo activity based protein profiling (ABPP). For this purpose four 
new carbamate-based inhibitors 113-116 (Figure 13), derived from URB597, were 
developed. Compound 113 (IC50 58 nM) was found as potent as URB597 which 
inhibited FAAH with an IC50 value of 48 nM in this study. Compound 114 was less 
potent (190 nM) and 115 (14 nM) and 116 (7.3 nM) more potent than URB597.144 
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Figure 13. Compounds 113-116 and general method for characterizing the proteome 
reactivity of 116 in vivo. Mice were administered 116 at escalating doses (e.g., 0.25–
10 mg/kg, i.p.). After 1 h, the animals were sacrificed, and their tissues were 
removed, homogenized, and reacted under click chemistry (CC) conditions with an 
azide modified rhodamine reporter tag (RhN3). Labeled proteins were visualized in 
SDS-PAGE by in-gel fluorescence scanning.144 
 
The research group in University of Kuopio, Finland, conducted a virtual screening 
of commercial compounds to a comparative model of the CB2 receptor and human 
MGL enzyme, resulting in moderate hits for the original targets.151,152 Group of 
these hits were also tested against FAAH revealing 11 compounds considered as 
FAAH inhibitors with IC50 values in the range of 44-0.52 µM. Compounds 117-120 
are the most potent of these, of which 120 inhibited FAAH with an IC50 value of 
0.52 µM (Figure 14).152  
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Figure 14. Some FAAH inhibitors found by virtual screen in University of Kuopio. 
 
Compounds 117 and 118 (IC50 4 µM, for both) were MGL hit molecules and 
compounds 119 (IC50 0.69 µM) and 120 (IC50 0.52 µM) CB2 hits. All hit compounds 
were also evaluated as MGL inhibitors and 120 was found to inhibit MGL with an 
IC50 value of 31 µM.152 Using 120 as a parent compound, a group of para-
substituted phenyl N-alkyl carbamates were prepared.153 The results and SAR of 
these compounds will be presented more detailed in Chapter 4.  
 
High-throughput screen on a targeted subset of Bristol-Myers Squibb’s proprietary 
library revealed a class of bisarylazole derivatives as potent inhibitors FAAH. After 
the modifications made on lead 121 (IC50 64 nM), the authors concluded with a 
carbamate derivative 122, having the IC50 value of 2 nM (Figure 15).154 
 
 
Figure 15. BMS hit 121 and carbamate 122 derived from it.  
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Reactive ureas 
In addition to carbamates, several urea group containing compounds have been 
found to inhibit FAAH efficiently in terms of potency and selectivity. 
Thiadiazolopiperazinyl urea 123 (Figure 16) was found to be a potential FAAH-
inhibitor (IC50 34 nM) by high throughput screening of the chemical library of 
Johnson & Johnson Pharmaceuticals. Analogues of 123 revealed to be more potent 
than the parent compound, if the polarity of aromatic substituent of urea -NH was 
modified to be less lipophilic. This correlates to the mechanism, where the leaving 
group properties of aryl in urea or carbamate dominate the SAR. Cl- or F-atom in 2-
position of the ureyl phenyl increased the potency about 5-fold, as well as replacing 
the phenyl to 3-pyridyl, 4-pyrimidyl or benzothiadiazolyl (124).155 These 
compounds belong to the family of FAAH inhibitors which have also been reported 
in two patent applications.156,157 
 
 
Figure 16. First piperidinyl- and piperazidinyl ureas as FAAH inhibitors. 
  
In year 2007 Cravatt et al. reported very similar compounds as highly selective 
FAAH inhibitors (125 and 126, Figure 16), found by a high-throughput screen of 
Pfizer chemical library.158 Piperidinyl urea PF-750 (125) and piperazidinyl urea PF-
622 (126) were 7- and 3- times more potent FAAH inhibitors than URB597 with the 
incubation time of 60 min used. The authors showed by using four different 
preincubation times that this parameter has a relatively large influence on detected 
inhibitory activities with covalent irreversible inhibitors. Covalent bonding to FAAH 
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was proven by several methods, e.g. time-dependent inhibition and the rapid dilution 
studies. In addition, compounds 125 and 126 were tritium-labeled from different 
sides of the urea bond in order to see which part is attached to enzyme and which is 
excreted via the CA channel. Both radiometric study and MS-MALDI studies 
revealed that the anilinic moiety was not present in the enzyme/enzyme fraction 
after the assay. Prior to MS-MALDI, the sample was tryptase-cleaved to contain 
amino acid 213-214 fraction of the enzyme. The selectivity of PF-750 (125) against 
several other serine hydrolases was determined by competitive ABPP and MS 
studies. The selectivity of PF-750 was compared to those of several other FAAH 
inhibitors including URB-597 (101), OL-135 (77), and 74 (dubbed here CAY-
10402), which were profiled at 100 µM. Consistent with previous reports of serine 
hydrolase targets for URB-597159, OL-135126, and CAY-10402160, multiple off-
targets for these inhibitors were observed. In contrast, no off-targets were observed 
for PF-750 (125) when tested at 500 µM. The remarkable specificity of the 
piperidine/piperazine urea inhibitors for FAAH may derive, at least in part, from the 
FAAH’s ability to function as a C(O)-N bond hydrolase, which distinguishes it from 
the majority of metabolic serine hydrolases in mammals that are restricted to 
hydrolyzing esters or thioesters.160  
To gain insight into the active-site features responsible for the high FAAH specifity 
of PF-750 (125), the Cravatt group determined the crystal structure of the h/rFAAH 
protein bound to 125.161 Not surprisingly, modifications on 125 were reported by the 
Cravatt group, resulting in improvements in potency and valuable SAR data by 
preparing 57 novel compounds. The first change in structure was replacing the 2- or 
3-quinolyl moiety by 3-methylbenzothiophene and modifying the “right hand side” 
of the urea. The aromatic moiety was found to be crucial for activity, and altogether 
the structure was relatively sensitive to changes on this side of the molecule 
(compounds 127-130, Figure 17). A three-fold drop in activity was found by 
removing the methyl from the benzothiophene of 130. On the other hand, 
replacement of piperazidinyl urea with piperidinyl urea gave over two-fold 
improvement compared to 130. Interestingly, the substituent effect on 6-position of 
pyridyl-ring of 130 (130a-j) did not follow the earlier pattern. With these 
compounds the potency did not correlate with the leaving group ability, indicating 
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that the active site is rather hindered near the 6-position of the pyridine.162 These 
findings then led to discovery of PF-3845 (131), providing improved potency and 
pharmacokonetics. In animal studies, PF-3845 raised brain anandamide levels for up 
to 24 hours and produced a significant cannabinoid receptor-dependent reduction in 
inflammatory pain.163 
 
 
 
Figure 17. The evolution of the most potent urea-based FAAH inhibitor PF-3845 
(131).  
 
In addition to highly selective urea based FAAH inhibitors, there are examples of 
ureas that are not so selective. LY2183240 (132, Figure 18) was first reported as a 
putative AEA transport protein inhibitor,164 but was later revealed to be a 
irreversible covalent FAAH inhibitor with the IC50 value of 18 nM.67 
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Figure 18. LY2183240 (132) and the recent urea compounds 133-136.  
 
In a very recent paper Minkkilä et al. tested a selection of known hormone sensitive 
lipase (HSL) inhibitors against FAAH and MGL.165 HSL (EC 3.1.1.79) is an 
intracellular serine hydrolase catalyzing the hydrolysis of diglycerides in adipose 
tissues. It has emerged as a promising target for treatment of insulin resistance and 
dyslipidemic disorders.166 FAAH IC50 value for carbamoyl triazole 133 was 30 nM, 
and for carbamoyl isooxazolone 134 exceptionally high 0.45 nM. IC50 values against 
MGL were 1.1-4.6 µM for 133 and 6.1-71 µM for 134, indicating selectivity against 
another serine hydrolase operating in the same region. The variation in MGL IC50 
values rises from two different assays used. Original target HSL was inhibited by 
para-chloro analogue of 133 with an IC50 value of 20 nM, being also unselective 
towards acetyl- and butyrylcholine esterases, though.167 HSL-IC50 value for 134 was 
2 nM.168  
In another very recent paper, chiral azetidinyl ureas 135 and 136 were reported, 
providing high selectivity based on enantioselectivity. The (S)-enantiomer 135 
inhibited FAAH with an IC50 value of 145 nM, and the (R)-enantiomer 136 did not 
show inhibition activity at 10 µM concentration. The racemic mixture had an IC50 
value of 291 nM.169 
As a conclusion, these urea compounds 132-136 deserve further development in 
order to gain selectivity.  
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3.1.4. Activity based protein profiling (ABPP) 
The selectivity determination of FAAH inhibitors towards other serine hydrolases by 
conventional substrate-based assays would be a laborous task considering the huge 
size of the serine hydrolase superfamily (>200 members in humans) as well as the 
large number of these enzymes that represent uncharacterized proteins (i.e., enzymes 
without known substrates). For this purpose, a functional proteomic screen based on 
the activity-based protein profiling (ABPP)170,171 technology has been implemented 
to evaluate the selectivity of FAAH inhibitors against serine hydrolases directly in 
native cell/tissue samples. Competitive ABPP for serine hydrolases involves the 
coordinated application of a candidate inhibitor and a reporter-tagged 
fluorophosphonate,159 which serves as a general activity-based probe for the serine 
hydrolase superfamily172,173. Serine hydrolases that show significant reduction in 
probe labeling intensity in the presence of an inhibitor are scored as targets of the 
compound. In this way, competitive ABPP provides a global view of the proteome-
wide selectivity of serine hydrolase inhibitors and has been successfully employed 
to address the selectivity of various FAAH inhibitors. 125,126,130,144,158,159,160 
3.1.5. Other FAAH inhibitor classes 
(Thio)hydantoins 
Hydantoin structure (137, Figure 19) was reported to provide a new template for 
reversible FAAH inhibitor development.174 The compounds were not highly active, 
and at best reached micromolar IC50 level in FAAH inhibition (138, pIC50 5.94). 
SAR revealed that thiohydantoins (X = S) were roughly 10-fold more active than 
corresponding hydantoins (X = O) and that the best compounds contained phenyls in 
both R1 and R2. Having a chlorine or bromine substituent in 4-position of the 
phenyls surprisingly reduced the potency significantly. The optimal N-3 substituent 
was a C6-C14 alkyl, and N-1 substituents were found to decrease the activity. 
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Figure 19. (Thio)hydantoins as FAAH inhibitors template. 
Sulfonyls 
Sulfonyl-containing benzothiazole compound 139 (Figure 20) was found to be a 
potential FAAH inhibitor by using high-throughput screening.175 Derivatives of 139 
were prepared by varying each part of the molecule, but no major improvement in 
potency was gained. Structure-activity relationship (SAR) studies indicated that the 
sulfonyl group, the piperidine ring and the benzothiazole were the key components 
to the activity. Compound 139 was found to be a reversible and highly selective 
inhibitor of FAAH, proven by time-dependent preincubation study and ABPP 
evaluation in brain, liver, heart and intestine tissues of rat. The modeling study 
indicated that hydrophobic interactions of the benzothiazole ring with the enzyme 
contributed to its extraordinary potency.175 
 
Figure 20. Sulfonyl containing selective FAAH inhibitor 
Boronic acids 
In 2008 Minkkilä et al. reported boronic acid (compounds 140-144 as examples, 
Figure 21) as a novel functional moiety in FAAH inhibitors.176 Similar findings 
with a huge number of compound examples were published in a patent application 
around the same time. Roughly 300 different aryl boronic acids, including a few 
boronic esters (145), were reported to inhibit FAAH with Ki value less than 100 
nM.177 Boronic acid is a strong Lewis acid because of the boron empty orbital. Most 
phenylboronic acids have a pKa in the range of 4.5–8.8 depending on the phenyl 
substitution. This means that with appropriate substitution, boronic acids would have 
the right properties for ready conversion from a neutral and trigonal planar sp2 boron 
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to an anionic tetrahedral sp3 boron under physiological conditions. The process of 
cleaving an amide bond also requires similar conversion of a sp2 carbonyl carbon to 
a tetrahedral sp3 carbon. This makes boronic acids good transition state analogues 
for the inhibition of hydrolytic enzymes. Thus, boronic acids have been used 
extensively as inhibitors of various hydrolytic enzymes such as peptidases and 
lipases.178 The activity of boronic acids as FAAH inhibitors seems to depend mostly 
on boronic acid being the aromatic substituent, or at least to be attached to a sp2-
carbon (140, IC50 14 nM). The second major SAR driving force is the lipophilicity, 
activity correlating positively with increasing lipophilicity (141, IC50 9 nM). 
Lowering the pKa of the boronic acid seems to have a minor improving effect to the 
activity compared to the lipophilicity. As an example, trifluoro compound 142 had 
an IC50 value of 36 nM and a calculated pKa 8.1, even though the IC50 values of 
more Lewis acidic nitro- (pKa 7.4) and cyano- (pKa 7.7) analogues were 210 nM and 
290 nM, respectively. In addition, ortho-substituents of phenylboronic acids seem to 
interfere with the formation of the tetrahedral sp3 adduct, thus decreasing the 
potency. Compound 143, having a para-phenyl substituent (IC50 21 nM), was 
clearly more active than its ortho-analogue (IC50 110 µM). Interestingly, also meta-
substituted phenylboronic acids (144, IC50 130 nM) were less potent than 
corresponding para-analogues, as shown by three pairs.176 As a conclusion, the best 
activities can be reached with phenylboronic acids, having one small strongly 
electron withdrawing substituent in ortho- or meta-position and a lipophilic moiety 
in para-position. Fluorine is very electronegative and small enough not to disturb 
the tetrahedral intermediate in ortho-position. In fact, this was widely exploited by 
the authors of the patent, and numerous this kind of compounds reached Ki value 
below 10 nM.177 
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Figure 21. Boronic acids and ester as FAAH inhibitors.  
 
3.2. MGL-inhibitors 
Although MGL is agreed to be the major enzyme responsible for degradation of 2-
AG, which in turn is considered at least as important an endocannabinoid as AEA, 
selective inhibitors have not been discovered until very recently. 
Covalent irreversible inhibitors 
As other serine hydrolases, non-selective covalent inhibitors MAFP (35, IC50 2.2 
nM) and hexadecylsulphonylfluoride (IC50 245 nM) have also been reported to 
efficiently inhibit MGL.12 Another interesting class of covalent inhibitors was 
reported by Saario et al., by testing a group of maleimides against MGL. The 
maleimide group is a general reactive electrophile for thiols, thus this work suggests 
that MGL possess sulfhydryl sensitive site. The most potent compound was a 
substrate analogue, N-arachidonylmaleimide (NAM, 146, Figure 22) inhibiting 
MGL with IC50 value of 140 nM. The corresponding succinimide derivative did not 
inhibit MGL (1 mM), indicating that the activity was based on reactivity of the 
maleimide double bond. Modelling studies conducted within this study suggested 
that MGL contains a non-catalytic cysteine residue in its active site, which could 
account for its unusual sensitivity to maleimide reagents.179 NAM (146), despite 
containing a highly reactive maleimide group, exhibits rather high selectivity for 
MGL relative to other brain serine hydrolases.72 In addition, NAM has been shown 
to potentiate the pharmacological effects of 2-AG in vivo.180 In a recent paper, an 
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extension to the structural library and SAR of maleimides as FAAH and MGL 
inhibitors was reported, supporting earlier findings.181 However, as a general thiol-
sensitive group, maleimides will most likely react with other cysteine-containing 
proteins and small molecules in vivo. 
 
Figure 22. Examples of MGL-inhibitors reported so far. 
Carbamates 
So far the largest group of MGL inhibitors are carbamates (120, 147-150, Figure 
22). Compound 120, previously mentioned in context with FAAH inhibitors (IC50 
for FAAH, 520 nM), inhibited MGL with an IC50 value of 31 µM.152 URB602 (147) 
was reported initially to inhibit rat brain MGL selectively with an IC50 value of 28 
µM through a non-competitive mechanism.149,182 When purified rat recombinant 
MGL enzyme was used, the activity was decreased (IC50 223 µM). Derivatives of 
147 were also evaluated, resulting in slight improvement in potency with 
corresponding urea analogue (IC50 115 µM).183 
 
In a recent report Cravatt et al. introduced an exceptionally potent and selective 
MGL inhibitor, JZL184 (148, IC50 6 nM), displaying also robust activity in vivo.184 
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The authors commented that its discovery was based on implementation of activity-
based proteomic methods to broadly evaluate and optimize the selectivity of 
inhibitors across the serine hydrolase superfamily. Compound 148 (JZL184) was 
modified from the non-selective carbamate 149, which inhibited several serine 
hydrolases selectively and was found during validation studies of the ABPP-
method.185,186 JZL184 was found to produce a rapid and sustained blockade of brain 
2-AG hydrolase activity in mice, resulting in eight-fold elevations in endogenous 2-
AG levels that were maintained for at least 8 h. Moreover, AEA levels were 
unaffected by JZL184 (148). JZL184-treated mice showed a wide array of CB1-
dependent behavioural effects, including analgesia, hypomotility and hypothermia, 
suggesting a broad role for 2-AG–mediated endocannabinoid signaling throughout 
the mammalian nervous system.184 
Oxadiazolones 
In the same recent paper where Minkkilä et al. reported urea compounds 132 and 
133 as novel FAAH inhibitors, they described another class of potential FAAH and 
MGL inhibitors, oxadiazolones (150-152, Figure 22). Commercially available 
carbamate CAY10499 (150) was used as a lead, since it inhibited MGL with IC50 
value of 330 nM.165,187 Another group reported an IC50 of 400 nM for CAY10499 
against MGL.188 Minkkilä prepared a small series of derivatives of 150, and 
concluded that the inhibitory activity was based on the 1,3,4-oxadiazol-2(3H)-one 
moiety rather than on the carbamate. The most potent MGL inhibitor, albeit not 
selective over FAAH (IC50 65 nM), was the para-substituted oxadiazolone 151 with 
an IC50 value of 78 nM against 2-AG hydrolysis. Corresponding meta-substituted 
152 was ten-fold more potent against FAAH (IC50 6.1 nM) with similar activity 
against MGL (IC50 110 nM) as 152. Moreover, most of the oxadiazolone compounds 
were shown to inhibit both FAAH and MGL in reversible manner, as determined by 
rapid dilution studies. Since these compounds were derivatized from known HSL 
inhibitors, no selectivity among other serine hydrolases was expected.165  As an 
example, 152 has been reported to inhibit HSL with an IC50 value of 70 nM.189 
Anyhow, oxadiazolones as non-carbamate structures are a very interesting novel 
template for inhibitor development against both FAAH and MGL. 
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4. THIS STUDY 
In addition to review of the literature, this thesis contains the design, synthesis and 
characterization of over 100 novel compounds which were prepared and tested 
against FAAH and MGL enzymes in order to find better inhibitors.  
4.1. Initial plan 
By the time this study was initiated, only two groups had presented potential FAAH 
inhibitors: Dale Boger’s (α-ketoheterocycles like 74) and Daniele Piomelli’s group 
(meta-substituted N-alkyl phenyl carbamates like URB597 101).16,124 These 
structures have very different structural motifs, and were used as the starting point in 
this study (Figure 23).  
 
Figure 23. 
The structural motifs of 101 and 74 were combined, and a general structure 153 was 
constructed in order to gain SAR data for further development of potent FAAH and 
possibly MGL inhibitors. Compounds of this structure type were named hybrids. In 
addition, the plan was to study the activity of chiral compounds of a general 
structure like 154, in order to gain information on FAAH active site stereochemistry. 
Moreover, 3-phenyl amide 155, containing the alkyl part similar to one in 74, was 
designed to see what kind of activity would this type of combination result in. Most 
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importantly, the idea was to elaborate the plans based on activity data found during 
the study. 
4.2. Results and discussion 
4.2.1. Acyl and alkyl heterocycles 
In order to find out whether the enantiomers of 2’-methylated 2-oleyl 
oxazolopyridines have significantly different activity against FAAH, compounds 
156 and 157 were designed and prepared. In addition, it was decided to prepare 
compound 61 for study-to-study comparison of FAAH bioassay as reference. 
Surprisingly, compounds 158a and 158b showed FAAH inhibition activity (IC50 ~ 
400 nM), and derivatives 158c-160d were added to the series. The activity of 158a-
b was later revealed as an unknown error in assay. Compound 161 was also 
prepared and tested within this series. (Table 6).  
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Table 6. IC50 or percentage of inhibition of FAAH and MGL by compounds 61 and 
156-161. 
Compd Structure FAAH (nM)a MGLb 
61 
 
0.213 (0.162-0.280) 0% 
156 
O
N
O
N
 
5.8 (4.3-7.9) (n=4) 0% 
157 
 
4.3 (2.9-6.3) 0% 
158a-d 
 
0% 0% 
159a-d 
 
0% 0% 
160a-d 
 
0% 0% 
161 
 
0% 0% 
101 see Fig. 22, lit. 4.6 nM16 3.8 (2.9-5.0)152 30%d 
a IC50 values represent the mean of three independent experiments performed in duplicate with 95% 
confidence intervals shown in parentheses or enzyme inhibition (%) at 10 µM compound 
concentration (n=2).  
b
 Enzyme inhibition (%) at 100 µM compound concentration (n=2). 
c
 For 8a, 8b; No inh. at 100 µM (n=4). 
d
 Enzyme inhibition (%) at 1.0 mM compound concentration.12 
Synthesis 
Compounds 61, 156 and 157 were prepared applying known procedures124: (R)-2-
Methyl-cis-octadecenoic acid 162b and (S)-2-methyl-cis-octadecenoic acid 162c 
were prepared in house via Evans auxiliary based enantioselective synthesis (data 
not shown). Reduction of acids 162a-c to alcohols 163a-c was performed with 
lithium aluminium hydride in THF. The alcohols were then oxidized to aldehydes 
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164a-c by iodoxybenzoic acid (IBX)190 or by pyridinium chlorochromate 
(PCC).191,192 
Formation of cyanohydrins 165a-c occurred by treatment of aldehydes with 
potassium cyanide in THF/H2O. Cyanohydrins were then condensed with 2-amino-
3-hydroxypyridine via imidate-intermediate 166a-c. In this method cyanohydrins 
were first treated with HCl in CHCl3. HCl was formed in situ with ethanol and 
acetyl chloride. The product alcohols 167a-c from the coupling were formed with 
low yields (4-25%). These alcohols were then oxidized to end products 61, 156 and 
157 using IBX in DMSO with moderate to good yields (62-91%). Scheme 2. 
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Scheme 2. Reagents and conditions; a) LiAlH4, THF, rt; b) IBX, DMSO, rt, or PCC, 
CH2Cl2, rt; c) KCN, THF/H2O, rt; d) AcCl, EtOH, CHCl3, rt; e) 2-Amino-3-
hydroxypyridine, 2-ethoxyethanol (EtOH for b, c), rfx; f) IBX, DMSO, rt. 
 
Compounds 158a-160d were prepared via condensation of 2-aminophenol, 2-
aminopyridin-3-ol or 4-aminopyrimidin-5-ol (168) with orthoesters193. p-TsOH was 
used as acid catalyst (0.5 mol-%). In small scale reactions (0.2 mmol) the amount of 
catalyst used was higher (up to 8 mol-%), which did not negatively affect the 
reactions. The yields varied quite a lot (16-77 %) which could be due to the 
purifications rather than the actual reactions. All compounds were purified by 
recrystallization or vacuum distillation. In small scale cases flash chromatography 
(FC) was sometimes needed to purify the compounds. Scheme 3. 
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Scheme 3. a) R-Orthoester, p-TsOH, 100-190 oC. 
Literature procedures194,195,196 were followed to prepare compound 168 in four steps 
(Scheme 4). 
  
 
Scheme 4. a) i. Methyl formate, NaH, THF, 20 oC, 20 h; ii. formamidine acetate, 
EtOH, rt, 14 h, reflux, 24 h, 31%; b) POCl3, reflux, 2.5 h, 86%; c) NH3, EtOH, 
autoclave, 130 oC, 18 h, 75%; d) n-BuSH, NaH, DMF, 110 oC, 20 h, 74%. 
 
Commercially available 5-phenylpentanol 172 was converted to alkyl bromide 173, 
which in turn was treated with magnesium to obtain the Grignard reagent for 
reaction with 3-cyanobenzaldehyde. Unfortunately the Grignard reaction did not 
work as expected, and a mixture of compounds was detected. Eventually after 
separation by flash chromatography, compound 174 was obtained in 6% yield, and 
further oxidized to compound 161 in good yield. Scheme 5. 
 
bOH NC
O
172, X= OH
173, X= Br
174
H2N
OO
161
a
c
 
Scheme 5. Reagents and conditions: a) PPh3, CBr4, CH2Cl2, rt; b) Mg, I2, Et2O, 3-
cyanobenzaldehyde, rfx; c) H2O2, NaOH, EtOH, 50 oC. 
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Discussion 
As can be seen from Table 6, compound 61 and its methylated analogues 156 and 
157 were the only active FAAH inhibitors of this series within detection limits (10 
µM for FAAH and 100 µM for MGL). The activity difference between (S)- and (R)-
enantioriched samples was small, (S)-enantiomer (156) giving slightly better 
inhibition than (R) (157). Enantiomers were not pure, though. Both compounds were 
determined by chiral HPLC, having 37 ee-%. This was quite surprising, but since 
this 2:1 ratio already gave such small difference in activity, the compounds were not 
prepared again and the reason for partial racemization was not determined. This 
decision was supported also by the 20-fold decrease in activity of both enantioriched 
compounds 156-157 compared to unmethylated 61.  
As expected, small fused heterocycles 158a-160d failed to give any inhibitory 
activity against either of enzymes. Compound 161 was also inactive, indicating that 
aryl amide and proper alkyl tail are not moieties that alone raise the FAAH activity. 
Apparently ketone carbonyls need to be activated by electron withdrawing groups to 
react with active site Ser241. As Saario et al. have reported previously, carbamate 
compound URB597 (101) was found to inhibit AEA hydrolysis with an IC50 value 
of 3.8 nM in our method, which is comparable to the previously reported 4.6 nM16, 
and only 30% inhibition of 2-AG hydrolysis in rat brain membranes was evident at 1 
mM152. 
4.2.2. Carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl 
(3-hydroxyphenyl)methanones
197
 
Next the attention was turned to “hybrids” series. Compounds 175-200 were 
prepared after finding out that the first compound in this series, N-
cyclohexylcarbamate derivative 179 gave such a high FAAH-inhibition activity 
(IC50 47 nM). The various N-alkyl carbamoyl phenols having either 2-
benzoxazolylmethanone (175-182) or 2-benzothiazolylmethanone (183-190) as 
meta-substituent were prepared to screen the most suitable alkyl group for next 
modifications. The importance of the carbamate moiety was studied by preparing 
compounds 191-196d, as well as was the difference of meta- and para-substitution 
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by preparing compounds 197 and 198. In addition, benzyl ether intermediates 199 
and 200 were tested against both enzymes. (Table 7). 
61 
 
Table 7. IC50 values or the percentage of inhibition of FAAH and MGL by 
compounds 175-200.197 
X
N O
Y
R
 
Compd X Y R FAAH (nM)a MGL (µM)a 
175 O 3-O CONHC2H5 379 (303-474) 25% 
176 O 3-O CONH-n-C3H7 109 (90-132) 43% 
177 O 3-O CONH-n-C4H9 54 (46-64) 41% 
178 O 3-O 
H
N
O
 
28 (23-34) 46% 
179 O 3-O 
 
47 (36-62) 17% 
180 O 3-O 
H
N
O
 
152 (122-189) 43% 
181 O 3-O 
 
ndb ndb 
182 O 3-O 
H
N
O
 
32 (26-40) 16 (14-18)c 
183 S 3-O CONHC2H5 238 (177-321) 20% 
184 S 3-O CONH-n-C3H7 143 (113-180) 30% 
185 S 3-O CONH-n-C4H9 103 (81-131) 24% 
186 S 3-O 
H
N
O
 
47 (38-57) 29% 
187 S 3-O 
 
56 (41-77) 21% 
188 S 3-O 
H
N
O
 
121 (105-140) 25% 
189 S 3-O 
 
ndb ndb 
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190 S 3-O 
H
N
O
 
38 (33-43) 23 (20-27)c 
191 O 3-O 
O
 
12% 0% 
192 O 3-NH 
O
 
5% 0% 
193 O 3-NH 
H
N
O
 
6% 0% 
194 O 3-NH 
 
5% 0% 
195a-d O 3-O 
a; Et 
b; n-Pr 
c; n-Bu 
d; Bn 
ndb ndb 
196a-d S 3-O 
a; Et 
b; n-Pr 
c; n-Bu 
d; Bn 
ndb ndb 
197 O 4-O 
H
N
O
 
288 (237-349) 14 (12-17) 
198 O 4-O 
H
N
O
 
137 (112-169) 25 (21-29)c 
199 O 3-O Bn 0% 0% 
200 S 3-O Bn 0% 0% 
a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses) or enzyme inhibition (%) at 10 µM (for FAAH) and 
100 µM (for MGL) compound concentrations (n= 2).  
b
 Not stable in used assay conditions. 
c Remaining enzyme activity at 1 mM was ~11-24%. 
Synthesis 
The synthesis of the series was started from 3- or 4-hydroxybenzoic acid or 3-
aminobenzoic acid (Scheme 6). The phenol functionality was protected as benzyl 
ether, and the acids were then converted to acyl chlorides 201-203 according to 
literature procedures.198,199,200 3-Aminobenzoic acid did not need protection. Acyl 
chlorides were then coupled with benzoxazole or benzothiazole in order to prepare 
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compounds 199, 200 and 204 following the method described by Harn et al.201  
Deprotection of the phenolic hydroxyl was first attempted with hydrogenation 
catalyzed by Pd/C. Unfortunately under these conditions the methanone was reduced 
to alcohol before the cleavage of benzyl group. Although the alcohols were easily 
oxidized back to ketone with IBX190 or DDQ,202,203 another method was needed to 
avoid the extra step. Finally the removal of the benzyl protecting group without 
reducing the ketone was carried out using BF3•Et2O and Me2S.204 Ionic liquid based 
microwave-assisted cleavage of benzyl ether also proved to be as efficient a 
method.205 Deprotected phenols 205-207 and aniline 208 were then coupled with 
electrophiles (isocyanates, chloroformates and acyl chlorides). 
 
 
Scheme 6. Reagents and conditions: a) Benzoxazole or benzothiazole, n-BuLi, 1 M 
ZnCl2/Et2O, CuI, THF, -75 oC -> 0 oC, 54-55%; b) BF3•Et2O, Me2S, CH2Cl2, rt, 84-
91% or N-1-BuPyrBr, MW, 30 s, 90%; c) Et3N or pyridine, RNCO, c-pentylNCO, c-
pentylCOCl or c-pentylOCOCl, toluene or CH2Cl2, rt or heating up to 93 oC, 41-
99%. 
 
Although the preparation of 2-benzoxazolylketone and 2-benzothiazolylketone 
intermediates 199-200, 204 and 208 was straightforward, it turned out not to be 
possible to prepare the corresponding oxazolopyridine- or oxazolopyrimidines 
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(general structure 153, X= N, Y= CH or X= N, Y= N) this way. An attempt to 
prepare these compounds via imidate-method also failed. 
Discussion  
The alkyl moiety of the most potent compound of Table 7 was selected for testing 
the other carbonyl derivatives. The most potent FAAH inhibitor in this series was 
the cyclopentylcarbamate 178 (IC50 28 nM). Compounds within the same range of 
lipophilicity inhibit FAAH with IC50 values almost equal (32-56 nM) to that for 
compound 178. The inhibition of FAAH activity was dependent on the carbamate 
group, as the compounds lacking this functionality were unable to inhibit FAAH 
even at 10 µM. This supports the postulated mechanism by which carbamates inhibit 
FAAH by carbamoylation of the enzyme’s nucleophilic serine. Compounds 175-177, 
as well as the corresponding sulphur analogues (183-185) were found to have a 
trend for increasing potency for FAAH with increasing length of the alkyl group (= 
lipophilicity). Interestingly, compounds 182 and 190 containing 3-
methylbenzylcarbamate had clearly higher inhibition activity against MGL enzyme 
activity compared to the other compounds in this series. Thus, the introduction of 
the methyl group in the 3-position of the benzyl ring increased FAAH as well as 
MGL enzyme inhibition. However, none of these compounds could inhibit MGL 
activity at the nanomolar concentration range. Furthermore, there were no 
significant differences in FAAH or MGL enzyme inhibition between the 
benzoxazoles and the benzothiazoles. Compounds 181 and 189 were not stable 
enough to give reliable inhibition activity. Apparently the carbamate was rapidly 
hydrolyzed in the test conditions. 
To clarify the importance of the carbamate group we prepared some other carbonyl 
derivatives for comparison. Carbonyl compounds 191 (ester), 192 (amide), 193 
(urea), 194 (reverse carbamate) and 195a-196d (carbonates) were not effective 
FAAH inhibitors. The fact that 194 did not inhibit FAAH or MGL supports the 
proposed carbamoylation mechanism, where the phenol part is the leaving group144. 
Carbonates 195a-196d as well as 181 and 189 were not stable in the assay 
conditions and their decomposition was detected by TLC (data not shown). 4-
Substituted compounds 197-198 were also synthesized. The activity of these 
compounds against FAAH was still in nanomolar range (IC50 288 and 137 nM).  
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It was noteworthy that a 10-fold difference was found between meta- (178, IC50 28 
nM) and para-substituted (197, IC50 288 nM) c-pentylcarbamates. In addition 
compound 197 was found clearly more active against MGL than 178.   
4.2.3. Importance of the ketone linker
206
 
Since it was found from the previous series that Ser241 in FAAH-active site was 
likely not interacting with the methanone carbonyl but with the carbamate carbonyl, 
it was decided to explore this further and prepare compounds 209-212 (Table 8). n-
Propyl was chosen as initial N-alkyl group, and N-pentyl analogue of the most active 
compound of this series was planned to prepare later since the supply of 
cyclopentylisocyanate was delayed during that time.   
 
Table 8. 
Compd Structure FAAH (nM)a MGLb 
209 
 
3000 (2600-3600) 26% 
210 
 
680 (590-780) 29% 
211 
 
4500 (4000-5200) 18%c 
212 
 
33 (28-38) 32% 
a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses) or enzyme inhibition (%) at 10 µM compound 
concentration (n= 2).  
b
 Enzyme inhibition (%) at 100 µM compound concentration (n= 2). 
c
 Inhibition of human recombinant MGL. 
66 
 
Synthesis 
The preparation of phenolic intermediates of 209-212 is presented in Scheme 7. In 
the course of preparation of 213-215 it was found that microwave assisted direct 
condensation of 3-hydroxybenzoic acid and 2-amino-3-hydroxypyridine is a novel 
method and thus worth of a separate report.207 This study is presented in the next 
chapter. In preparation of phenol 216 the MW-assisted method was attempted – 
unsuccessfully. This compound was then prepared via method described by 
Vorbrügger and later by coupling of imidate salt with aminoalcohol.208,209 
 
Scheme 7. a) 3-Hydroxybenzoic acid, boric acid, Na2SO4, m-xylene, autoclave, 200 
oC, 16 h, 21-83%; b) 3-Hydroxybenzoic acid, MW, 250 oC, 2-6 min, 71-77%; c) n-
PrNCO, Et3N, toluene, rt or 90 oC, 20 h, 50-95%; d) 3-Hydroxybenzoic acid, PPh3, 
CCl4, MeCN, pyridine, rt, 21 h, 29%; e) Methyl 3-hydroxybenzimidate 
hydrochloride, TEA, CH2Cl2, rfx, 24 h, 90%. 
Discussion 
The results of the inhibition studies showed that the absence of a ketone group 
within these fused bicyclic aromatic compounds (e.g. 176 vs. 209) decreases the 
FAAH-inhibition activity. Introducing a nitrogen atom into the fused oxazole-
containing bicycle (210) increased the inhibitory activity compared to compound 
209 (IC50 of 0.68 µM vs. 3 µM). Addition of a second nitrogen did not enhance the 
activity further: pyrimidineoxazole-containing 211 was clearly less active than 210. 
Additionally compound 212, which only contained the unsubstituted 2-oxazoline 
ring, showed good inhibitory activity against FAAH with an IC50 value of 33 nM. 
Design of the next series was therefore focused on derivatives of 212. 
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4.2.4. The preparation of 2-substituted oxazolo[4,5-b]pyridines
207
 
Traditional condensations 
Oxazoles are rigid and stable structures often found in natural products and widely 
used in medicinal chemistry. 2-Phenyl benzoxazoles have traditionally been 
synthesized by heating aminoalcohols with benzoic acids in the presence of 
polyphosphoric acid210 or trimethylsilyl polyphosphate211 as dehydrating reagents. 
Activated acids such as orthoesters and acid anhydrides have been used in the 
preparation of 2-phenyl-pyrido- and pyrimidino oxazoles.212 In addition, Zhuravlev 
presented a convenient method to prepare these compounds using palladium-
catalyzed C-2 arylation of oxazolo[4,5-b]pyridine.213 In order to prepare the phenols 
needed for the carbamates, the method published by Terashima and Ishii214 was 
explored. Refluxing 3-hydroxybenzoic acid 217a and 2-aminophenol 218 with 100 
mol% of boric acid in m-xylene for 18 h with a Dean-Stark apparatus for water 
removal gave only a 13% yield of compound 213. Addition of Na2SO4 to the 
reaction mixture to chemically scavenge the water produced in the reaction 
increased the yield to 37%. Eventually, carrying out the reaction at higher 
temperature (200 ºC) and under pressure (50 psi) in an autoclave overnight gave a 
satisfactory yield (83%). The same method was then applied for 2-amino-3-
hydroxypyridine 219 and 2-amino-3-hydroxypyrimidine 158, giving compounds 
214a and 215 in 58% and 23% yield. Scheme 8. 
 
 
Scheme 8.  Reagents and conditions: 217a (415 mg, 3 mmol, 100 mol-%), 
218/219/158 (330 mg, 3 mmol, 100 mol-%), boric acid (185 mg, 3 mmol, 100 mol-
%). Methods and yields: A, reflux with a Dean-Stark trap, 18 h, 13% for 213; B, 
Na2SO4, reflux 18 h, 37% for 213; C, autoclave, 200 ºC, 50 psi, 18 h, 83% for 213, 
58% for 214a and 23% for 215. 
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MW-assisted condensations 
Microwave irradiation has previously been applied in condensation reactions by 
Bougrin et al.215 and this method was applied for the preparation of 214a. The 
reactions were carried out in a CEM Discover© microwave reactor with varying 
parameters (Table 9). Reaction times were shortened dramatically, and the best 
results were obtained without solvent, catalyst or water scavenger with 2 min hold 
time at 250 ºC, giving 214a in 77% isolated yield (entry 7). 
 
Table 9. Optimization of the condensation reaction under MW irradiation. 
 
 
 
Entry Solvent Temp. and power  Other 
reagents 
Timea 
(min)  
Yieldb 
(%) 
1 m-
xylene 
200 ºC / 300 W H3BO3, 
Na2SO4 
15 25 
2 toluene 160 ºC / 1st 150 W, 2nd 
300 W  
H3BO3, 
Na2SO4 
2x 15 0c 
3 - 200 ºC /150 W H3BO3, 
Na2SO4 
15 13  
4 - 200 ºC /300 W - 15 67 
5 - 200 ºC /200 W - 15 40 
6 - 250 ºC /300 W - 1 69 
7 - 250 ºC /300 W - 2 77 
8 - 250 ºC /300 W - 10 12 
a Hold time is the time at the specific temperature. Ramp time varied from 3-10 min. 
b Isolated yields. 
c Only the starting materials were detected. 
 
Next the optimized reaction conditions were applied to different aromatic and 
aliphatic acids, and the results are shown in Table 10. 
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Table 10. The condensation reactions of 219 with different acids 217a-j. 
 
 
Entry Time (min) T (ºC) Product Nr Yield (%)a 
1 2 250 
 
214a 77 
2 2 250 
N
O
N
 
214b 60 (60) 
3 4x2 170 
 
214c trace (44) 
4 3 170 
 
214d 67 
5 3 250 
 
214e 56 
6 2 170 
 
214f 82 
7 2 170 
 
214g trace (18) 
8 4 170 
N
O
N
CF3
 
214h 58 (40) 
9 12 250 
 
214i 85 (51) 
10 2 250 
 
214j 
=160b 
34 (20) 
a Isolated yields. Yields in parentheses are for reactions using 100 mol-% of boric acid. 
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Discussion 
For some acids the selected temperature (250 ºC) was too high and resulted in low 
yields. These reactions were tested at lower temperature, improving the yield in 
several cases (entries 3-4 and 6-8). Some low-yielding reactions were also repeated 
in the presence of boric acid, since it has been reported to catalyze the condensation 
under normal heating reactions. Surprisingly, boric acid was found both to increase 
the yield in some cases (entries 3 and 7) but also to decrease it in others (entries 8-
10).  
When 2- and 4-hydroxy-, 4-dimethylamino-, 2-chloro-, 4-acetyl-, and 2-, 3- and 4-
nitrobenzoic acids were subjected to the same reaction conditions, none of the 
desired products were obtained. The main products isolated from reactions of 219 
with 2-, and 4-hydroxy- and 4-dimethylaminobenzoic acid were the decarboxylated 
products (phenol or N,N-dimethylaniline, 1H NMR). This implies that the presence 
of a strong electron donor in the 2- or 4-position of the carboxylic acid results in 
decarboxylation rather than condensation. Usually aromatic acids containing ortho- 
or para-electron donating groups undergo decarboxylation in acidic conditions via 
arenium ion mechanism, but there is also reports of rapid heat induced 
decarboxylation of ortho- and para-hydroxybenzoic acids in neutral conditions.216 
With the remaining acids there was no clear main product, only a tarlike material or 
recovered starting materials. 
In summary, 2-substituted oxazolo[4,5-b]pyridines are easily produced by 
microwave-assisted direct condensation. The reactions are fast and operationally 
simple (solvent-free conditions, easy work-up). 
4.2.5. 3-(2-Dihydrooxazolyl)phenyl N-alkyl carbamates
206
 
The optimization of the heterocyclic portion by compounds 209-212 (Table 8) 
revealed that 3-(2-(4,5-dihydro)-oxazolyl)-phenyl N-propylcarbamate 212 was a 
suitable lead for further modifications. The results of the in vitro experiments are 
summarized in Table 11 (compounds 220-234). 2-(4,5-Dihydro)-oxazolyl moiety 
has been widely utilized in ligands of stereoselective catalysts, proving their high 
chemical stability in various chemical environments.217 Thus the potential 
importance of stereochemistry in FAAH inhibition was investigated by preparing 
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chiral 2-oxazoline derivatives of 221 (compounds 225–234). The enantiopurity of 
chiral compounds was determined using chiral normal phase HPLC. The 
modification of 212 was started by changing the N-alkyl group from n-propyl to 
cyclopentyl. As found earlier, the cyclopentyl derivative 178 (IC50 = 28 nM) was 
more active than the n-propyl derivative 176 (IC50 = 109 nM). Similar enhancement 
in activity was observed for compound 220 in comparison to 212 (IC50 12 nM vs. 33 
nM). The next modification was done in 2-oxazoline part by adding 4-(S)-methyl 
and 4-dimethyl substituents to it. Later it was noted that changing the carbamate N-
alkyl group from cyclopentyl to cyclohexyl gave a further increase in activity (221 
vs. 220), and hence cyclohexyl was used as the N-alkyl group for the rest of this 
series. 
 
Table 11. The structures and inhibition activities of the derivatives of 212. 
 
Compound R1 R2 FAAH (nM)a MGLb 
220 
 
c-pentyl 13 (11-14) 10%c 
221 
 
c-hexyl 1.2 (0.98-1.4) 22% 
222 
 
c-hexyl 215 (184-251) 37% 
223 
O
N
 
c-pentyl 65 (53-81) 28% 
224 
 
c-hexyl 46 (37-57) 20% 
225 
 
c-pentyl 110 (97-130) 28% 
226 
 
c-hexyl 51 (45-58) 28% 
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227 
 
c-hexyl 16 (14-18) 16% 
228 
 
c-hexyl 2100 (1700-2700) 17% 
229 
 
c-hexyl 590 (510-690) 14% 
230 
 
c-hexyl 90 (77-110) 35% 
231 
 
c-hexyl 9.4 (7.8-11) 25% 
232 
O
N
 
c-hexyl 73 (58-93) 13%d 
233 
 
c-hexyl 6.8 (5.6-8.3) 14%d 
234 
 
c-hexyl 1900 (1600-2400) 25% 
a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses) or enzyme inhibition (%) at 10 µM compound 
concentration (n= 2).  
b
 Enzyme inhibition (%) at 100 µM compound concentration (n= 2). 
c
 Inhibition of enzymatic activity (% of control) at 1 µM (n=2).  
d Inhibition of human recombinant MGL. 
 
Synthesis 
Compounds 220 and 221 were prepared as described for 212. Scheme 9 illustrates 
the synthesis of compounds 222-234. Imidazoline derivative 222 was prepared from 
the corresponding carbamoylated aldehyde and ethane-1,2-diamine by N-
bromosuccinimide (NBS) cyclication.218 Compound 235 was prepared by 
condensing 3-cyanophenol with 2-amino-2-methylpropanol using bismuth triflate 
catalysis under microwave irradiation.219 Unfortunately this method gave poor 
yields. Thus, for the preparation of intermediates 236a-238, the method by Witte 
and Seeliger220 was applied. Compounds 239a-240b were prepared in high yields 
via acidic Pinner-imidates209.  
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NC a
O
N
b
223-224
c
b
225-229,
234
R= (S)-Me, 236a
(R)-Me, 236b
(S)-Bn, 237a
(R)-Bn, 237b
(S)-(1H-indol-3-yl)methyl, 238
OH
OH
235
OH
O
N
OH
O
N
R
R
1
R
2
d
b
230-233
239a; R1= (R)-CO2Me, R
2= H
239b; R1= (S)-CO2Me, R
2= H
240a; R1= H, R2= (R)-Me
240b; R1= H, R2= (S)-Me
OH
H
O
b, e O
H
N
O
N
N
H
222
 
Scheme 9. a) 2-Amino-2-methylpropanol, Bi(OTf)3, MW / reflux, 3 min / 4 h, 29%; 
b) RNCO (R= c-pentyl or c-hexyl), Et3N, toluene, rt or 90 oC, 4-24 h, 52-95%; c) 
Aminoalcohol, ZnCl2, PhCl, reflux, 22 h, 33-90%; d) i. HCl-gas, MeOH, CH2Cl2, 2 
oC, 3 d, 92%; ii. Aminoalcohol, (Et3N in case of serine hydrochlorides), CH2Cl2, 
reflux, 2-18 h, 68-95%; e) Ethane-1,2-diamine, NBS, CH2Cl2, -2 oC-rt, 85%. 
Discussion 
2-Imidazoline (222, 215 nM) gave clearly lower FAAH inhibition than the 
corresponding 2-oxazoline derivative (221, 1.2 nM). Thus 2-oxazolyl was chosen as 
the heterocyclic part of compounds in the enantiomeric pair study. Substitution in 
the 4-position of the oxazoline ring decreased inhibition. A clear relationship 
between the activity against FAAH and stereochemistry of the 4-position of 
oxazoline was revealed by the data of compounds 226-233. With 4-methyl (226 vs. 
227) and 4-benzyl (228 vs. 229) substituents, the difference in activity between 
enantiomers was only 3-fold, but with methyl carboxylate (230 vs. 231) already 10-
fold. This could be explained by the methyl ester’s additional hydrogen bonding site 
or by the optimal size of the substituent. The lower activity of benzyl substituent 
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analogues in general indicates that the enantiomeric differences arise from a rather 
hindered region. It might be that interactions between FAAH active site and benzyl 
group lead to a suboptimal positioning of the carbamate functionality in the vicinity 
of the catalytic serine. Thus the effect of a substituent in 5-position of oxazoline was 
studied with 5-methyl analogs 232-233. A bulky S-indolyl group (234) decreased the 
activity, and the other enantiomer was not prepared. None of the compounds tested 
showed good activity against MGL at 100 µM compound concentration. 
 
Figure 24. Compounds 231 and 233 are 10-fold more active than their enantiomeric 
pairs. 
 
The stereochemistry of the compounds is illustrated in Figure 24. In these Newman 
projections the more active compounds 231 and 233 are the ones with their chiral 
carbon substituent “up” from the plane of the ring. This trend was also present in 
other enantiomeric pairs. These examples suggest that the stereochemistry in the 
oxazoline is more important than the regiochemistry of substitution (C4 or C5). This 
implies that the oxazoline ring conformation is locked within the enzyme's active 
site. This would explain the activity difference between the enantiomeric pairs since 
the substituent of the chiral carbon is pointing to a specific direction and thus filling 
the possible hydrophobic pocket or conversely causing steric hindrance. 
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4.2.6. 5-Membered aromatic heterocycles as O-phenyl carbamate 
substituents 
During the study of chiral 2-oxazoline derivatives (previous chapter) other 
heterocycles were also evaluated as possible FAAH-inhibitors. At this point N-
cyclopentylcarbamate was kept as the N-alkyl moiety of the lead (Figure 23). Later 
cyclopentyl was replaced with cyclohexyl.   
 
Figure 23. General structure of the lead for the optimization of the X-substituent.  
Oxazoles, imidazoles and thiazole 
The first modification was to prepare the aromatic derivative of 212, and compounds 
241-253 were prepared for this purpose (Table 12). Compound 241 appeared to be 
such a potent FAAH inhibitor (IC50 5.2 nM) that a small series of N-alkyl 
carbamates (242-245) and a para-substituted (246) compound were also prepared. 
Screening concentrations for both enzyme inhibition measurements were lowered 
from 10 to 0.1 µM for FAAH, and from 100 to 1 µM for MGL. This was done since 
majority of screened carbamate compounds were active in earlier concentrations 
leading to increasing number of laborous IC50 determinations.  
Table 12. 
Compd Structure FAAH (nM)a MGLb 
241 
 
5.2 (4.6-5.9) 11%c 
242 
 
0.74 (0.59-0.92) 26% 
243 
 
6.6 (5.0-8.7) 9%c 
76 
 
244 
 
11.9 (9.5-15.0) 6%c 
245 
 
91 (74-113) 8%c 
246 
 
0%d 10% 
247 
 
0%d 0%c 
248 
 
0%d 8%c 
249 
 
5.7 (5.0-6.6) 22% 
250 
 
11 (10-13) 14% 
251 
 
43 (37-48) 13% 
252 
 
3.3 (2.8-3.8) 14%c 
253 
 
6.9 (5.5-8.7) 8%c 
a IC50 values represent the mean of three independent experiments (n= 3) performed in duplicate 
(95% confidence intervals (95% CI) are given in parentheses) or enzyme inhibition (%) at 10 µM 
compound concentration (n= 2).  
b
 Enzyme inhibition (%) at 100 µM compound concentration (n= 2). 
c
 Inhibition of enzymatic activity (% of control) at 1 µM (n=2). 
d
 Enzyme inhibition (%) at 100 nM compound concentration (n= 2). 
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Synthesis 
Microwave-assisted condensation for preparation of 2-oxazoles, 4-oxazoles and 2-
thiazole moieties was developed for preparation of the most of this series. First 3- or 
4-methoxybenzamides (254a-b) or 3-methoxybenzothioamide (257) were condensed 
with bromoacetaldehyde diethyl acetal to gain 2-oxazoles 255a-c and 2-thiazole 259. 
The reactions were fast and selective. In addition, solvents or other reagents were 
not needed, except for the preparation of thiazole 258 THF was used as a solvent. 
MW-assisted condensation was productive also for the preparation of 4-oxazole 261 
from 3-methoxy-2’-bromoacetophenone 260 and formamide. Heating the same 
starting materials in an oil bath gave the corresponding imidazole (263) as product. 
This result correlates with the Brederecks reports about formamide reactions.221 The 
demethylations of phenyl methyl ethers were carried out using an excess of ionic 
liquid (N-butylpyridinium bromide or N,N,-dimethylimidazolium bromide) under 
microwave irradiation.205 Unfortunately the cleavage of methyl ether of the 
imidazole derivative 263 in similar conditions failed, giving N-butylated 
compounds. The desired product was eventually achieved by using classical BBr3-
demethylation222 or by adding two equivalents of aq. 48% HBr in N-BuPyBr / MW -
demethylation. 2-(3-Nitrophenyl)benzo[d]oxazole 266 was prepared by MW-
assisted condensation (as pyridineoxazoles in chapter 4.4.6.). Reduction to amine 
267 provided the desired nucleophile for carbamoylation, resulting in compound 
247. Method for the preparation of 3-(benzo[d]thiazol-2-yl)phenol 268 was found 
from literature223, utilizing ionic liquid for (oxidative) condensation of aldehyde and 
2-thiophenol. Scheme 10. 
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Scheme 10. Reagents and conditions: a) 2-Bromoacetaldehyde diethyl acetal (2-
bromo-1-phenylethanone for 17c), neat, MW-irradiation, 5 min, 45-79%; b) 1-
Butyl-3-methylimidazolium bromide or N-butylpyridinium bromide, MW-
irradiation, 4 x 20 s, 100 oC 60-65%; c) Et3N, RNCO, toluene, reflux, 43-90%; d) 2-
Bromoacetaldehyde diethyl acetal, THF, MW-irradiation, 30 min, 100 oC, 42%; e) 
Formamide, MW-irradiation, 100 oC, 51%; f) Formamide, 165 oC, 85%; g) N-
79 
 
Butylpyridinium bromide, HBr, MW-irradiation, 5 x 20 s, 100 oC, 53%; or BBr3, 
CH2Cl2, -78 oC-rt, 80%; h) NaOH, MeOH, CH2Cl2, rt, 72 h, 71%; i) MeI, DMF, 0 
oC-rt, 48%; j) 2-Aminophenol, boric acid, MW, 250 oC, 5 min, 77%; k) H2, Pd/C, 
THF:EtOH (1:9), rt, 90 min, 90%; m) 2-Aminothiophenol, 1-butyl-3-
methylimidazolium bromide, MW, 200 oC, 5 min, 73%. 
 
In some cases the carbamoylation of phenol as the last reaction step was found 
difficult. In the carbamoylation conditions used (isocyanate, TEA) the imidazole 
group of 264 was found to be more nucleophilic than the phenolic hydroxyl, and 
both functionalities were carbamoylated, resulting in compound 251. Ureas are 
known to react with alcohols224, and selective alcoholysis of 251 was attempted and 
compound 252 was achieved. This method was poorly reproducible, since when the 
reaction was repeated, the cleavage of both carbamate and urea took place as a main 
reaction, and desired compound was found as a minor product only. The better 
nucleophilicity of the imidazole compared to the phenol was then exploited in 
methylation of compound 264 by iodomethane giving compound 265 (Scheme 10). 
Discussion 
Compound 242 appeared to be the most active compound against FAAH prepared 
within this work so far. This correlates to the findings of Piomelli et al.141,143 that in 
many cases cyclohexylcarbamate functionality with the phenyl having a suitable 
polar group in 3-position gives best activities against FAAH. Although other N-alkyl 
derivatives of 242 with similar lipophilicity (241 and 243-244) were also active, 242 
was ten-fold more active than these. These differences can be explained by a rather 
hindered substrate recognition site, ACB-channel, where the N-alkyl group is 
pointing.  
Adding a bulky phenyl substituent to 4-position of the oxazole (245) resulted in loss 
of nanomolar activity. Compound 246 was also clearly less active (91 nM) than its 
meta-substituted derivative 241. This supports our previous findings concerning 
activity differences of meta- and para-substituted O-phenyl carbamates as FAAH 
inhibitors. Compounds 247-248 were tested to fill out the series. These were not 
able to attain nanomolar inhibition activity, as was expected. Compound 249 having 
a thiazole moiety instead of oxazole and compound 250 in which the oxazole is 4-
substituted gave a clearly lower activity than 242, indicating that CA-channel 
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probably contains some backbone hydrogen bond donor sites serving as points of 
recognition.  
With the imidazole series (251-253) an interesting result was found. The rather 
bulky “double electrophile” containing 251 was able to inhibit FAAH at 43 nM 
concentration, albeit being less active than the smaller derivatives 252-253 (3.3 and 
6.9 nM). The slight difference in activity of 252 and 253 could be explained by 
steric hindrance in active site, as with chiral oxazolines earlier, but the activity of 
251 does not support this idea.   
5-Tetrazoles 
Tetrazoles are widely used in medicinal chemistry as rigid functional groups and 
nitrogen bioisosteres of carboxyl group.225 Tetrazole compounds prepared for this 
study are presented in Table 13. In addition, one methyl ester was included to this 
series as a bioisostere of methyltetrazole.  
Table 13. 
Compd Structure FAAH (nM)a MGLb 
269 
 
21 (18-24) 16% 
270 
 
2.5 (2.0-3.1) 13% 
271 
 
39 (33-45) 17% 
272 
 
17 (13-21) 44% 
273a 
 
1.1 (0.9-1.4) 24%c 
273b 
 
66 (56-76) 24%c 
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a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses). 
b
 Enzyme inhibition (%) at 100 µM compound concentration (n= 2). 
c
 Assay: human recombinant MGL. Inhibition activity in 100 µM compound concentration (n= 2).  
Synthesis 
5-Tetrazole moiety was constructed by cycloaddition reaction of 3-cyanophenol and 
sodium azide in the presence of triethylammonium hydrochloride. The resulting 
phenol 274 was then carbamoylated by either cyclopentyl- or cyclohexylisocyanate. 
Compounds 270-271 and 273a-b were prepared from 269 and 275 by the alkylation 
of the tetrazole. In the methylation of tetrazole the isomeric ratio was 4:1 in favor of 
the less hindered 2-position (270 and 273a). In the benzylation reaction a similar 
trend in regioselectivity was observed, albeit with the ratio of 8:1 for the 2-isomer. 
1-Substituted methyltetrazole 273b was isolated from the mixture of these 
regioisomers by flash chromatography (Scheme 11). Ester 272 was prepared in the 
usual way. 
 
O
H
N
O
R
NN
HN
N
269; R= cyclopentyl
275; R= cyclohexyl
O
H
N
O
NN
N
N
R
270; R= Me, 20% of 1-Me product
271; R= Bn, 12% of 1-Bn product
OH
OH
NN
HN
N
NC
a b
c269
275 c
274
4:1 mixt. of 273a : 273b
 
Scheme 11. Reagents and conditions: a) NaN3, Et3NHCl, toluene, reflux, 85%; b) 
Et3N, RNCO, toluene, reflux, 80%; c) MeI, Et3N, acetone, 2 oC, 44% or BnBr, KI, 
Et3N, acetone, 2 oC, 60%. 
Discussion 
In addition to N-cyclohexylcarbamates, a series of N-cyclopentylcarbamates with 5-
tetrazole and methyl ester substituents in the O-phenyl ring were prepared. The 
compound 269 exists most likely in an ionized form at physiological pH, which 
probably affects its inhibition activity, thus explaining the activity difference 
between 269 and 270. Interestingly, the benzyl group (271) did not notably decrease 
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the FAAH inhibition. As a conclusion, the FAAH inhibition by tetrazolyl 
compounds elucidated that the position of the tetrazole’s substituent (273a vs 273b) 
was as important a factor as its size (270 vs 271). With the tetrazole compounds, the 
replacement of N-cyclopentyl with N-cyclohexyl group (270 vs 273b) resulted in 
only two-fold improvement of the inhibition potency against FAAH. Methyl ester 
272 (17 nM) was found to be a 7-fold less potent FAAH inhibitor as its bioisostere 
271 (2.5 nM), but roughly as active as the rest of the series.  Compound 272 was 
chosen to be the lead for next modifications.   
4.2.7. Small polar groups as O-phenyl carbamate meta-substituents 
After discovering the inhibition potency of methyl ester 272 (IC50 17 nM) some 
other polar groups were prepared and tested against the enzymes. 
Table 14. 
 
Compd R FAAH (nM)a MGL (µM)a 
276 3-CO2Me 3.9 (3.3-4.7) 34% 
277 3-CO2H 9% 14% 
278 3-CHO 100 (87-115) 31% 
279 3-CONH2 62 (54-72) 18% 
280 3-CN 49 (42-58) 34 (26-45)b 
281 3,4-di-CO2Me 23 (19-27) 12 (9.3-15) 
a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses) or enzyme inhibition (%) at 100 nM (for FAAH) and 
100 µM (for MGL) compound concentrations (n= 2).  
b Inhibition of enzymatic activity was 86% at 1 mM. 
Synthesis 
Esters 272, 276 and 281 were prepared from corresponding carboxylic acids by 
refluxing them in methanol in the presence of catalytic amount of H2SO4. 
Carbamoylations were carried out in the usual way. The amide 283 was prepared by 
oxidation of the nitrile with sodium perborate226 prior to carbamoylation. Scheme 
12. 
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Scheme 12. a) Et3N, RNCO, toluene, reflux, 80-95%; b) NaBO3 • 4 H2O, H2O, 
MeOH, 54%; c) MeOH, H2SO4, reflux, 98%. 
Discussion 
The free acid 277 (9% inhibition at 100 nM) was not as potent against FAAH as the 
ester 276 (3.9 nM). This supports the hypothesis found with tetrazoles, that acidic 
(anionic) species are not tolerated.  Aldehyde 278, amide 279 and nitrile 280 were 
all clearly less active than the ester 276. The diester 281 revealed to be interesting by 
relatively good MGL-inhibition (12 µM). This was one of the rare compounds tested 
in this study that inhibited MGL fully at higher concentration. Most of the 
carbamates inhibiting MGL are not able to fully block the enzyme and some 
“residual” enzymatic activity is found with even 1 mM concentration.  
4.2.8. para-Substituted phenolic N-alkyl carbamates
153
 
SPB01403 (120), found by virtual screen of compounds agains CB2 receptor,152 was 
used as the lead to a series of para-substituted phenolic alkyl carbamates against 
MGL and FAAH (Table 14). Consequently, the structurally similar compound, 
SEW01169 (286, Figure 25), was purchased and tested for its FAAH and MGL 
inhibitory activity, and it was found to be a slightly more potent FAAH inhibitor 
(IC50 160 nM) than 120, albeit less potent inhibitor against 2-AG hydrolysis with 
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IC50 value of 43 µM. Being even more active than 120 (IC50: FAAH, 520 nM, MGL 
31 µM) against FAAH, 286 was used as a another lead (Table 15).   
 
Figure 25. The lead structures for study of para-substituted carbamates, SPB01403 
(120) and SEW01169 (286). 
4-(2-Thiazolin-2-yl)- and 4-(2-oxazolin-2-yl)-phenyl N-alkyl carbamates 
 Table 14. 
O
H
N
R
ON
X
 
Compd X R FAAH (nM)a MGL (µM)a 
287 S ethyl 15000 (10000-22000) 102 (80-131)b 
288 S n-propyl 1700 (1300-2300) 46 (38-56)c 
120 S n-butyl 520 (390-700) 31 (25-39) 
289 O n-butyl 168 (145-197) 34 (28-41) 
290 S n-hexyl 8.2 (6.8-9.9) 8.2 (6.4-10) 
291 S dodecyl 6.3 (4.5-8.7) 2.4 (1.8-3.2) 
292 S t-butyl 7000 (5000-10000) 0% 
293 S c-pentyl 127 (109-148) 11 (9-13)c 
294 O c-pentyl 100 (77-130) 11 (9-14)d 
295 S c-hexyl 262 (198-346) 27 (21-35)b 
296 S benzyl 273 (236-316) 30 (24-39)b 
297 S 2-methylbenzyl 62 (56-60) 35 (30-42)b 
298 O 2-methylbenzyl 34 (31-38) 31 (27-36)b 
299 S 4-methylbenzyl 281 (198-399) 67 (57-80)b 
300 O 4-methylbenzyl 182 (136-243) 85 (70-102)c 
301 S 4-methoxybenzyl 317 (252-340) 46 (38-55)d 
302 S (CH2)2Ph 38 (35-42) 28 (25–31) 
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a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses) or enzyme inhibition (%) at 100 µM (for MGL) 
compound concentrations (n= 2).  
b
 Remaining enzyme activity at 1 mM was 12-19%.  
c
 Remaining enzyme activity at 1 mM  was 6-7%.  
d
 Remaining enzyme activity at 1 mM  was 21-26%.  
Synthesis 
4-(4,5-Dihydrothiazol-2-yl)phenol 303227 was prepared by simply heating a mixture 
of cysteamine and 4-cyanophenol (Scheme 13). Unfortunately this method was not 
suitable for the preparation of 4-(4,5-dihydrooxazol-2-yl)phenol 304, thus it was 
obtained by the reaction described by Witte and Seeliger220. For this purpose the 
hydroxyl group of 4-cyanophenol was protected as the benzyl ether 305 228. 
 
Scheme 13. Reagents and conditions: a) 2-Aminoethanethiol, 100 oC, 10 min, 88%; 
b) i. BnBr, K2CO3, KI, acetone, reflux, 2 h, 98%; ii. 2-Aminoethanol, ZnCl2, 
C6H5Cl, reflux, 48 h, 50%; c) H2, Pd/C, ethanol, rt, 90 min, 75%. 
Discussion 
Among the dihydrothiazoline moiety containing open chain N-alkyl carbamates 
(120, 387-391), the chain length was the main factor affecting the inhibition 
potencies toward both enzymes. Compounds 390 and 391 inhibited hrMGL-
mediated 2-AG hydrolysis with IC50 values of 8.4 µM and 2.1 µM, respectively. 
FAAH inhibition with these compounds was in low nanomolar range.  Replacement 
of the open chain N-alkyl groups with the bulky N-tert-butyl group (292) reduced 
the inhibitory potencies toward FAAH and MGL (IC50s; 7.0 µM and >100 µM, 
respectively). This is probably due to steric hindrance near the carbamate group, 
thus interfering with crucial interactions within the active sites of the enzymes. The 
differences in the FAAH and MGL inhibition potencies among the other 
dihydrothiazoline derivatives with different N-alkyl groups (293-302) were mainly 
not notable. However, with cycloalkyl and benzylic groups (293-301) complete 
MGL inhibition was not observed, even at the highest concentrations tested (1 mM). 
This remaining enzyme activity can be explained by either an additional enzyme 
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activity distinct from MGL or by the low aqueous solubility of these compounds. An 
interesting observation concerning FAAH inhibition was that the N-2-methylbenzyl 
derivatives 297, 298 (IC50: 62 and 34 nM) and phenethyl derivative 302 (IC50 38 
nM) were more potent FAAH inhibitors than the other derivatives with cyclic or 
benzylic N-alkyl moiety (IC50s: 0.10–0.32 µM). When comparing the activities of 
thiazoline and oxazoline derivatives, no clear difference in the inhibition potencies 
toward either FAAH or MGL was seen.  
Thiadiazolyl-derivatives 
Table 15. 
 
Compd o, m, p R FAAH (nM)a MGL (µM)a 
286 para n-butyl 160 (130-200) 43 (27–66)b,c 
306 para n-hexyl 19 (15-24) 11 (9.8–13) 
307 para dodecyl 12 (11-14) 
1.9 (1.7–2.1) 
1.0 (0.8–1.4)b 
308 para c-pentyl 20 (14-29) 44%b 
309 para c-hexyl 21 (18-25) 28% 
310 para benzyl 44 (34-56) 24 (15–39)b,c 
311 ortho n-butyl 0% 27%b 
312 ortho dodecyl 50 (42-58) 18 (12-26)b,c 
313 meta n-butyl 6.9 (5.4-8.8) 13% 
314 meta n-dodecyl 0.24 (0.2-0.3) 8.0 (5.9–11.0)b,d 
a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses) or enzyme inhibition (%) at 100 nM (for FAAH) and 
100 µM (for MGL) compound concentrations (n= 2).  
b
 Inhibition of hrMGL. 
c
 Remaining enzyme activity 22–26% at 1 mM. 
d
 Remaining enzyme activity was 13% at 1 mM. 
Discussion 
Compounds presented in the Table 15 were prepared by Ms Anna Minkkilä, thus 
their preparation is not described in this thesis.  
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Not surprisingly, in this series of 1,2,3-thiadiazol-4-yl substituted derivatives (286, 
306-314), the length and the shape of the N-alkyl group had a similar effect on the 
inhibitory potencies against both enzymes, FAAH and MGL, as it has been in the 
previous series. Thus, by replacing the N-n-butyl chain of 286 with N-n-hexyl (306) 
or N-dodecyl (307), the inhibitory potencies toward FAAH and MGL were 
improved, resulting in the most potent MGL-inhibitor in this series. Compound 307 
inhibited FAAH with an IC50 value of 12 nM and, hydrolysis of 2-AG in rat brain 
membranes as well as hrMGL-mediated 2-AG hydrolysis with IC50 values of 1.9 
µM and 1.0 µM, respectively. When comparing these results to those observed with 
the corresponding dihydrothiazoline derivatives 290 and 291, it can concluded that 
the heterocyclic moiety in these two compounds has a minor effect on their FAAH 
and MGL inhibitory capacities. However, the compounds with N-cyclopentyl (308), 
N-cyclohexyl (309) and N-benzyl (310) moieties were ten-fold more potent FAAH 
inhibitors than the corresponding thiazoline and oxaxoline derivatives 293-296. This 
effect was not seen for MGL.  
To support our previous results of the influence of the substituent’s position in the 
phenyl ring on the FAAH and MGL inhibitory activities (i.e. para-substitution is 
more favourable to the MGL inhibitory activities)197, meta- and ortho-analogues of 
286 and its most potent derivative with N-dodecyl group (307) were prepared and 
tested (compounds 311-314). Compound 311, the ortho-substituted analogue of 286, 
did not inhibit either of the enzymes; only 27% inhibition of MGL was observed at 
100 mM, and no inhibition of FAAH could be detected at 0.1 mM. On the contrary, 
the meta-substituted analogue 313 inhibited FAAH with an IC50 value of 6.9 nM. 
However, only 13% inhibition of MGL by 313 was observed, which is similar to the 
results obtained with the ortho-substituted 311 and the para-substituted 286. The 
meta-substituted compound 314 with a more lipophilic N-dodecyl group inhibited 
MGL with an IC50 value of 8.0 µM, being 8-fold less potent than the para-
substituted analogue 307. Moreover, 314 inhibited FAAH with an IC50 value of 240 
pM. The ortho-substituted compound 312 with N-dodecyl group inhibited both 
FAAH and MGL, although with higher IC50 values than para- and meta-substituted 
analogues 307 and 314. These data clearly support the findings that para-
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substitution is more favourable to MGL inhibition, whereas meta-substitution is 
favourable for FAAH.197 
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The effect of para-substituents with different electronic properties 
The catalytic site serine of FAAH and MGL is expected to have a strong interaction 
with the reactive carbonyls of the ligands. Therefore, it was decided to study 
whether the electronic properties of the para-substituent in O-phenyl carbamates 
have an effect on the FAAH and MGL inhibitory activities by preparing and testing 
the compounds 315-328 (Table 16). The presumption was that compounds 
containing electron withdrawing groups (EWG) in para-position on the phenyl ring 
would increase the electrophilicity of the carbonyl carbon, thus having higher 
inhibitory activity than corresponding compounds with electron donating groups 
(EDG).  
Table 16. 
 
Compd X R FAAH (nM)a MGL (µM)a 
315 -H n-hexyl 91 (75-110) 41%
 
316 -H dodecyl 92 (76-112) 36%
 
317 -Me n-hexyl 27% 0%
b 
318 -Br n-hexyl 18 (16-20) 17 (11-26)
b,c
 
319 -OMe n-butyl 5% 0%
b 
320 -CO2Me n-butyl 35% 19 (12-29)
b
 
321 
-CO2Me n-hexyl 31 (23-41) 35 (30-41.5) 
19 (16-24)b 
322 -CO2Me dodecyl 25 (22-30) 2.8 (2.5-3.2) 
323 -CO2Me c-hexyl 41% 14 (12-18) 
324 -NO2 n-butyl 16% 24 (18-33)
b
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325 -NO2 n-hexyl 27 (21-35) 18 (12–27)
b
 
326 -NO2 c-hexyl 25% 19 (17-21) 
327 -CN n-butyl 25% 30 (20–45)
b
 
328 -CN n-hexyl 13 (12-14) 12 (9.0–17)
b
 
a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses) or enzyme inhibition (%) at 100 nM (for FAAH) and 
100 µM (for MGL) compound concentrations (n= 2).  
b
 Inhibition of hrMGL. 
c
 Remaining enzyme activity at 1 mM was 16%. 
Discussion 
The synthesis of compounds presented in the Table 16 was carried out by Ms Anna 
Minkkilä, except compounds 317, 318, 327, 328. These were prepared from 
commercially available phenols and isocyanates in the usual way. The EWG and 
EDG had opposite effects on the inhibitory potencies against MGL. EWG (methyl 
ester, nitro, and cyano) substituted compounds 320-328 maintained the potencies 
against MGL similar to those of the corresponding N-alkyl heterocycle derivatives 
presented in Tables 14-15. EDG (methyl and methoxy) substituted compounds 317 
and 319 had clearly diminished inhibition potencies. However, differences in 
inhibitory potencies against FAAH were hardly notable when comparing the results 
of EWG-substituted N-n-butyl derivatives 320, 324, and 327 with that of 
corresponding methoxy-substituted 319. On the contrary, within N-n-hexyl 
derivatives EWG-substituted 318, 321, 325 and 328 were more potent than methyl-
substituted 317. Clear correlation was not achieved by trying to fit data values of N-
n-hexyl into a plot of pIC50 vs. Hammet constant (σp). However, a rough correlation 
of FAAH inhibition activity to substituent σp-constants is presented in Figure 26, 
which illustrates the electronic effect. 
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Figure 26. pIC50 vs. σp-constant229 of 317 (-Me), 315 (-H), 318 (-Br), 320 (CO2Me), 
325 (-NO2), 328 (-CN). Correlation is excellent when (-Br) and (-NO2) are excluded. 
IC50 of 317 (-Me) was converted from 27% of inhibition at 100 nM to IC50 value of 
185 nM. 
 
Surprisingly, the nonsubstituted compounds 315 and 316 were quite potent FAAH 
inhibitors (IC50s; 91-92 nM) in comparison with the EWG-substituted compounds, 
while Tarzia et al. have reported that phenylcarbamic acid cyclohexyl ester lacks 
inhibitory activity against FAAH141. This observed increase in FAAH inhibition 
potencies might be due to the more flexible and lipophilic nature of N-n-hexyl and 
N-dodecyl groups. A similar observation can be made when comparing the results of 
N-cyclohexyl (323, 326) and/or N-n-butyl derivatives (320, 324, and 327) to those of 
corresponding N-n-hexyl (321, 325, 328) and N-dodecyl derivatives (322). 
Altogether, these results indicate that both FAAH and MGL inhibition potencies can 
be enhanced by EWG at para-position in the carbamates phenyl ring. 
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The effect of ortho-substituent 
In order to study the effects of steric and electronic properties of ortho-substituents 
to MGL and FAAH inhibitory activity, four derivatives of 321 with ortho-
substituent in the phenyl ring were prepared (Table 17). 
Table 17. 
 
Compd R1 R2 FAAH (nM)a MGL (µM)a 
329 -OMe H 5.5 (4.9-6.2) 4.2 (2.7–6.2)
b 
330 -Me H 55 (38-79) 22 (18–27)
b
 
331 -I H 24 (21-25) 14 (11–16)
b 
332 -t-Bu -t-Bu 4% 18%
b
 
a IC50 values represent the mean of three independent experiments performed in duplicate (95% 
confidence intervals are given in parentheses) or enzyme inhibition (%) at 100 nM (for FAAH) and 
100 µM (for MGL) compound concentrations (n= 2).  
b
 Inhibition of hrMGL. 
Discussion 
Compounds presented in the Table 17 were prepared by Ms Anna Minkkilä, thus 
their preparation and chemical data is not described in this thesis.  
The ortho-methoxy substituent (329) improved the inhibitory potency toward both 
FAAH and hrMGL when compared to the results obtained with the parent 
compound 321. This might be due to favourable interactions between the oxygen 
atom in the methoxy group and the active site residues of the enzymes. Me- or I-
substitution (331 and 330) did not have a significant effect on the affinity toward 
either FAAH or MGL. As expected, a bulky di-tert-butyl substituent (332) 
diminished the affinity toward these enzymes notably.  
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5. SUMMARY 
5.1. General discussion 
Endocannabinoid hydrolyzing enzymes FAAH and MGL are very interesting target 
proteins. They are considered to be the most important enzymes in the endogenous 
cannabinoid system. FAAH efficiently hydrolyzes amides, both primary and 
secondary, and its main substrate is the endocannabinoid AEA. The role of MGL is 
to hydrolyze 2-AG, which is more abundant and a full agonist of cannabinoid 
receptors, and it seems that MGL could serve as the more important target enzyme. 
However, the first potent FAAH inhibitors were developed already over a decade 
ago, and since then numerous compounds from a variety of chemical classes have 
been introduced. MGL inhibitors have been presented to a much lesser extent in the 
literature, probably because of the speculative accuracy of homology models 
compared to a proper crystal structure, which is yet to be published. The current lack 
of selective and potent inhibitors of MGL and MGL gene-depleted animals are also 
disadvances in MGL studies, compared to FAAH. However, recent reports have 
revealed breakthroughs on selective and highly potent MGL inhibitors, which will 
most likely boost the scientific output on this field.  
FAAH inhibitors are traditionally divided into two groups, reversible and 
irreversible inhibitors. The largest structural class of reversible inhibitors are α-
ketoheterocycles; the most important irreversible inhibitors are carbamates and 
ureas. Other important irreversible inhibitors are fluorophosphonates, which have 
served as pharmacological tools in seminal enzyme studies (e.g. MAFP bound 
FAAH -crystal, FP-compounds in ABPP). The reversibility of activated ketones is 
based on a hemiacetal inhibitor-Ser241 intermediate, compared to irreversible 
inhibitors giving carbamoylated (or phosphorylated) Ser241. Obviously, the 
hemiacetal is more easily reverted to the active enzyme, than N-alkyl,O-Ser241-
carbamate is hydrolyzed, which in turn is more easily hydrolyzed than the 
phosphorylated or alkylated (maleimide as Michael acceptor) species. As an 
example, complete recovery of central FAAH activity occurs 24 h after 
administration of covalent inhibitor URB597.104 This is shorter than the enzyme 
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turnover in mice (T1/2 about 52 h in mouse brain)230, indicating either slow turnover 
of inhibitor in vivo or a more rapid resynthesis of FAAH. 
Due to their reactive nature, irreversible inhibitors are often considered less selective 
than reversible ones. Fortunately, enzymes are constructed in a way that requires for 
substances to fulfill numerous properties, e.g. lipophilicity, shape, functionality, to 
reach the place of action. In the case of FAAH inhibitors, there are several examples 
indicating that reversibility/irreversibility does not correlate with selectivity. 
Some of the recent FAAH inhibitors have also been well evaluated for their 
selectivity. This concerns at least piperidinyl and piperazidinyl ureas 125 and 126 
and their analogues. Highly potent compounds of urea class have been presented, 
and this functional group can be considered as the next generation of carbamoylating 
inhibitors following carbamates. FAAH inhibitor efficacy is mainly ruled by shape 
and steric and lipophilic properties within the alkyl part of urea/carbamate, which is 
based on the structure of ACB channel and a yet unrevelealed entrance cavity in the 
FAAH active site. The leaving group cavity (CA channel) is wider, having possibly 
a better tolerance of structural differences. On the other hand, it consists of 
hydrophilic parts and leads to an aqueous environment, thus setting corresponding 
demands for leaving group properties. These have been shown to have an effect on 
activity of carbamoylating inhibitors. Phenol and aniline are good leaving groups 
providing easily tunable structures to gain more efficient inhibitors. Moreover, this 
study and others have shown that steric and hydrogen bond interactions in the CA 
channel also have a role in substrate recognition.  
5.2. Conclusions 
The present study includes design, preparation and characterization of 101 
compounds, which were tested against FAAH and MGL enzymes. Various synthesis 
methods were used to achieve the desired compounds. Microwave-assisted novel or 
little known reactions applied in synthesis include condensation of carboxylic acids 
and 2-aminophenol/2-amino-3-hydroxypyridine to prepare corresponding fused 2-
oxazoles, oxazole formation via condensation of bromoketones and amides, and 
cleavage of benzyl and methyl ethers using ionic liquids. 
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The compounds were almost exclusively novel (100) by the time they were 
prepared. FAAH inhibition of IC50 value below 100 nM was reached by 47 
compounds and value between 0.1-1 µM by 22 compounds. The most potent FAAH 
inhibitor of this study was 3-(oxazol-2-yl)phenyl N-cyclohexylcarbamate (242) with 
an IC50 value of 740 pM. As a comparison, substrate-like 3-(1,2,3-thiadiazol-4-
yl)phenyl dodecylcarbamate 314, prepared by Anna Minkkilä, was only three-fold 
more active (IC50; 240 pM).  
MGL inhibition values were three orders of magnitude higher, and the most potent 
compounds were para-substituted O-phenyl carbamates with a n-hexyl, dodecyl, c-
hexyl, or alkylphenyl as lipophilic part and an electron withdrawing group as phenyl 
substituent. None of the MGL inhibiting compounds were selective over FAAH. N-
Alkyl phenyl carbamates can provide various modification sites to improve the 
selectivity and potency, but for the determination of selectivity it is important to 
have a proper method for selectivity screening. 
 
The following conclusions can be made from the present study: 
1. Activated ketones as FAAH inhibitors are very well studied by other groups, 
but their use as MGL-inhibitors has not yet been reported.   
2. Both enantiomers of α-methylated derivatives of compound 61 are less 
potent FAAH inhibitors than the non-substituted parent compound. The 
steric hindrance in that position apparently reduces the affinity.  
3. Within phenolic N-alkyl carbamates as enzyme inhibitors, FAAH prefers 
meta-substituted and MGL para-substituted compounds. This observation is 
based on studying several carbamate compounds. 
4. Electron withdrawing substituent in phenolic N-alkyl carbamate can improve 
the potency of the inhibitors of both enzymes. This is apparently due to 
increased electrophilicity of the carbamate carbonyl, positive interactions to 
the active site residues, and/or improved leaving group properties of the 
phenol. 
5. 4,5-Dihydrooxazol-2-yl, thiazolin-2-yl, oxazol-2-yl, 2-methyltetrazol-5-yl, 
imidazol-4-yl and 1,2,3-thiadiazol-4-yl were found to be the best heterocycle 
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substituents of the O-phenyl of carbamates. Methyl ester was the best acyclic 
substituent. 
6. Chiral 4- or 5- monosubstituted 4,5-dihydrooxazol-yl compounds were less 
active than the unsubstituted one. Based on inhibition activity data collected 
from a series of enantiomeric pairs, 10:1 stereoselectivity was observed for 
FAAH. 
7. FAAH/MGL-selectivity was high (>1000) for most of the meta-substituted 
phenolic N-alkyl carbamates. 
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6. EXPERIMENTAL 
Experimental part includes all the compounds prepared in this work, in case their 
preparation and/or data are not fully described in the literature.  
Commercially available starting materials were used without further purification. All 
dry reactions were performed under argon in flame-dried glassware and solvents 
were distilled. In microwave reactions CEM Discover -microwave reactor was used. 
Analytical thin-layer chromatography was carried out on Merck silica gel F254 (60 
Å, 40-63 µm, 230-400 mesh) precoated aluminium sheets and detected under UV-
light. Purification of reaction products was carried out by flash chromatography 
(FC) on J. T. Bakers silica gel for chromatography (pore size 60 Å, particle size 50 
nM). The 1H NMR and 13C NMR spectra were recorded on a Bruker Avance 400 
spectrometer operating at 400 MHz for 1H and 100 MHz for 13C. Chemical shifts are 
reported in ppm on the δ scale from an internal standard (TMS 0.00 ppm) or residual 
solvent (CDCl3 7.26 and 77.0 ppm; DMSO-d6 2.50 and 39.52 ppm). Melting points 
were determined in open capillaries using Stuart SMP3 and are uncorrected. Optical 
rotation data was recorded on Perkin Elmer 343 polarimeter using Na lamp (589 
nm) and 100 mm cuvette at room temperature. HRMS-spectra were recorded on 
Waters Micromass LCT Premier (ESI) spectrometer. Chiral HPLC-analysis was 
carried out using Waters pump and UV-detector (254 nm) and Daicel Chiralcel AD 
analytical chiral column. Retention time (Rt) and ee-% are reported. Elemental 
analyses (CHN) were recorded using a Perkin Elmer 2400 CHN -elemental analyzer. 
Analyses indicated by the symbols of the elements were within ± 0.4% of the 
theoretical values. 
6.1. 2-Hydroxy-cis-10-nonadecenenitrile (165a)124 
H
O
CN
OH
164a 165a
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Cis-9-octadecenal 164a (320 mg, 1.2 mmol, 100 mol-%) was stirred with potassium 
cyanide (780 mg, 12 mmol, 1000 mol-%) in THF (4.0 ml) and water (4.5 ml) for 48 
h at rt. Water (5 ml) and Et2O (20 ml) were added and organic phase was separated. 
Aqueous phase was extracted with Et2O (3 x 20 ml). Combined organic phases were 
washed with sat. NaHCO3 (10 ml) and brine (10 ml), dried (MgSO4) and evaporated 
giving compound 165a (350 mg, 98%) as yellow oil; Rf (EtOAc) 0.7; 1H NMR 
(CDCl3) 5.38-5.29 (m, 2H), 4.44 (t, 1H, J = 6.6 Hz), 3.42 (br s, 1H), 2.10-2.00 (m, 
4H), 1.85-1.79 (m, 2H), 1.60-1.20 (m, 22H), 0.89-0.85 (m, 3H); 13C NMR (CDCl3) 
130.0, 129.6, 120.1, 61.2, 35.1, 31.1, 29.7, 29.6, 29.5 (2 C), 29.2, 27.2, 29.0, 28.9, 
27.2, 27.1, 24.5, 22.6, 14.0. 
6.2. 1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-en-1-ol (167a)124 
CN
OH
N NH2
OH
OH
O
N
N
OH
NH.HCl
O
165a 166a
167a
 
EtOH (1.4 ml, 24 mmol, 2000 mol-%) was treated with AcCl (1.3 ml, 1600 mol-%) 
in CHCl3 (3.0 ml) at 0 oC. After 10 min 2-hydroxy-cis-10-nonadecenenitrile 165a 
(350 mg, 1.2 mmol, 100 mol-%) was added in CHCl3 (3 ml) and mixture was 
allowed to warm to rt for 20 h. The reaction mixture was evaporated to dryness 
giving compound 166a (300 mg, 93%) as yellow solid: 1H NMR (CDCl3) 11.89 (s, 
1H), 10.57 (s, 1H), 5.41-5.30 (m, 2H), 4.79-4.65 (m, 2H), 4.47 (dd, 1H, J = 8.0, 4.5 
Hz), 2.05-1.98 (m, 4H), 1.80-1.75 (m, 2H), 1.51-1.40 (m, 5H), 1.38-1.23 (m, 20H), 
0.89-0.85 (m, 3H); 13C NMR (CDCl3) 182.5, 130.0, 129.7, 71.9, 69.8, 33.7, 31.9, 
29.8, 29.7, 29.5, 29.3 (3 C), 29.2, 29.1, 27.2 (2 C), 25.1, 22.7, 14.1, 13.7. 
Crude imidate 166a (100 mg, 0.29 mmol, 100 mol-%) was dissolved in 2-
ethoxyethanol (1.5 ml) followed by addition of 2-amino-3-hydroxypyridine (48 mg, 
0.44 mmol, 150 mol-%) under argon at rt. The reaction mixture was refluxed 
(Toilbath= 130 oC) for 13 h, cooled and quenched by EtOAc:Et2O (2:1, 30 ml) and 1 
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M NaOH (10 ml). Aqueous phase was extracted with EtOAc:Et2O (2:1, 3 x 30 ml). 
Combined organic phases were washed with brine (3 x 20 ml), dried (MgSO4), 
filtered and evaporated. Purification two times by FC (eluent, 50% EtOAc/hex) gave 
compound 167a (5 mg, 4%) as yellow oil: Rf (10% MeOH/CH2Cl2) 0.6; 1H NMR 
(CDCl3) 8.59 (dd, 1H, J = 4.8, 1.1 Hz), 7.83 (dd, 1H, J = 8.2, 1.1 Hz), 7.30 (dd, 1H, 
J = 8.2, 4.8 Hz), 5.38-5.29 (m, 2H), 5.01 (dd, 1H, J = 7.4, 5.3 Hz), 3.01 (br s, 1H), 
2.16-1.92 (m, 6H), 1.49 (quint, 2H, J = 7.4 Hz), 1.4-1.2 (m, 20H), 0.89-0.85 (m, 
3H).  
6.3. Oxazolo[4,5-b]pyridin-2-yl-octadec-9-en-1-one (61)124 
167a
OH
O
N
N
61
O
O
N
N
 
Iodoxybenzoic acid (160 mg, 0.57 mmol, 1000 mol-%) was stirred in DMSO (2 ml) 
at rt until all solids dissolved. Compound 167a (22 mg, 0.057 mmol, 100 mol-%) in 
DMSO (4 ml) was added and the mixture was stirred at rt for 2 h and quenched with 
water (10 ml) which caused formation of white precipitate. The suspension was 
filtered through cotton (flushed with water and EtOAc) and the filtrate was extracted 
with CH2Cl2 (4 x 25 ml). Combined organic phases were washed with brine (20 ml), 
dried (MgSO4), filtered and evaporated. Purification by FC (eluent, 10% 
EtOAc/hex) gave compound 61 (20 mg, 92%) as yellow oil: Rf (50% EtOAc/hex) 
0.47; 1H NMR (CDCl3) 8.76 (dd, 1H, J = 4.8, 1.4 Hz), 8.00 (dd, 1H, J = 8.3, 1.4 
Hz), 7.49 (dd, 1H, J = 8.3, 4.8 Hz), 5.39-5.30 (m, 2H), 3.27 (t, 1H, J = 7.4 Hz), 2.05-
1.98 (m, 4H), 1.82 (quint, 2H, J = 7.4 Hz), 1.44-1.25 (m, 20H), 0.87 (t, 3H, J = 6.9 
Hz); 13C NMR (CDCl3) 190.4, 158.3, 154.2, 148.7, 143.6, 130.0, 129.7, 123.1, 
120.2, 39.8, 31.9, 29.8, 29.7, 29.5, 29.3 (2 C), 29.2, 29.1 (2 C), 27.2 (2 C), 23.8, 
22.7, 14.1. 
6.4. (R)-2-Methyl-cis-9-octadecenol (163b)231 
O
OH
162b
OH
163b
 
100 
 
LiAlH4 (0.7 g, 18 mmol, 280 mol-%) was stirred in THF (60 ml) for 15 min at 0 oC. 
Carboxylic acid 162b (2.0 g, 6.6 mmol, 100 mol-%) was added dropwise during 10 
min and the mixture was allowed to warm to rt and stirred additional 4.5 h. The 
mixture was cooled on ice bath and quenched with water (0.5 ml), 10% NaOH (1.0 
ml) and water (1.5 ml) in this order. Filtration through a pad of Celite, drying over 
anhydrous Na2SO4, evaporation and purification by FC (eluent, CH2Cl2) gave 
compound 163b (1.7 g, 92%) as colourless oil; Rf (CH2Cl2) 0.4; 1H NMR (CDCl3) 
5.38-5.29 (m, 2H), 3.51-3.38 (m, 2H), 2.07-1.98 (m, 4H), 1.64-1.54 (m, 1H), 1.4-1.2 
(m, 22H), 0.91-0,87 (m, 6H); 13C NMR (CDCl3) 129.9, 129.8, 68.4, 35.8, 33.1, 31.9, 
29.8, 29.7 (2 C), 29.6, 29.5, 29.3 (2 C), 27.2 (2 C), 26.9, 22.7, 16.6, 14.1; HRMS 
(ESI) calcd for [M+H]+ C19H39O: 283.3001, found 283.3013.  
6.5. (R)-2-Methyl-cis-9-octadecenal (164b)231 
OH H
O
163b 164b
 
Iodoxybenzoic acid (2.3 g, 8.3 mmol, 150 mol-%) was stirred in DMSO (10 ml) at rt 
until all solids dissolved. (R)-2-methyl-cis-9-octadecenol 163b (1.6 g, 5.5 mmol, 
100 mol-%) was added in DMSO (4 ml) and the mixture was stirred at rt for 3 h and 
quenched with water (10 ml) which caused formation of white precipitate. The 
suspension was filtered through cotton (flushed with Et2O) and the filtrate was 
extracted with Et2O (3 x 100 ml). Combined organic phases were washed with brine 
(2 x 50 ml), dried (MgSO4) and evaporated. Purification by FC (eluent, 5% 
EtOAc/hex) gave compound 164b (1.4 g, 88%) as yellow oil; Rf (50% EtOAc/hex) 
0.7; 1H NMR (CDCl3) 9.60 (d, 1H, J= 2.0 Hz), 5.39-5.29 (m, 2H), 2.32 (d of sext, 
1H, J = 2.0, 6.8 Hz), 2.07-1.98 (m, 4H), 1.72-1.62 (m, 1H, J = 7.4 Hz), 1.4-1.2 (m, 
21H), 1.08 (d, 3H, J= 6.8 Hz), 0.89-0.85 (m, 3H); 13C NMR (CDCl3) 205.2, 130.0, 
129.7, 46.3, 31.9, 30.5, 29.7, 29.6 (2 C), 29.5, 29.4, 29.3, 29.1, 27.2, 27.1, 26.9, 
22.7, 14.1, 13.3; HRMS (ESI) calcd for [M+Na]+ C19H36ONa: 303.2664, found 
303.2666.  
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6.6. (R)-3-Methyl-2-hydroxy-cis-10-nonadecenenitrile (165b)231 
H
O
CN
OH
164b 165b
 
This compound was prepared as described for 165a. FC (eluent, CH2Cl2) gave 
compound 165b (1.2 g, 87%) as yellow oil: Rf (EtOAc) 0.8; 1H NMR (CDCl3) 5.39-
5.30 (m, 2H), 4.37 (dd, 1H, J = 12.3, 6.5 Hz), 2.35 (dd, 1H, J = 17.1, 6.5 Hz), 2.08-
2.01 (m, 4H), 1.92-1.82 (m, 1H), 1.40-1.20 (m, 22H), 1.08 (dd, 3H, J = 7.5, 7.0 Hz), 
0.90-0.86 (m, 3H); 13C NMR (CDCl3) two signals were found for carbons next to 
chiral centers; 130.1, 129.7, 119.3, 118.9, 66.3, 66.0, 37.9 (2 C), 32.0, 31.9, 31.5, 
29.7 (2 C), 29.5, 29.3, 29.1 (2 C), 27.2, 27.1, 26.8, 26.7, 22.7, 14.7, 14.5, 14.1; 
HRMS (ESI) calcd for [M+Na]+ C20H37NONa: 330.2773, found 330.2780. 
6.7. (R)-2-Methyl-1-oxazolo[4,5-b]pyridin-2-yl-cis-octadec-9-en-1-ol (167b)231 
CN
OH
N NH2
OH
OH
O
N
N
OH
O
NH.HCl
165b 166b
167b
 
This compound was prepared as described for 167a. FC (eluent 25% 
EtOAc/cyclohexane) gave compound 167b (43 mg, 17%) as yellow oil: Rf (EtOAc) 
0.6; 1H NMR (CDCl3) 8.54 (d, 1H, J = 4.5 Hz), 7.81 (d, 1H, J = 8.1 Hz), 7.49 (dd, 
1H, J = 8.1, 4.5 Hz), 5.40-5.27 (m, 2H), 4.94 (d, ½H, J = 4.2 Hz), 4.86 (d, ½H, J = 
5.5 Hz), 3.66 (br s, 1H), 2.20-2.10 (m, 1H), 2.05-1.90 (m, 4H), 1.4-1.2 (m, 22H), 
0.97 (d, 1½H, J = 7.0 Hz), 0.94 (d, 1½H, J = 7.0 Hz), 0.88-0.84 (m, 3H). 13C NMR 
(CDCl3) two signals were found for carbons next to chiral centers; 171.1, 170.7, 
154.8, 146.4, 129.9, 129.7, 120.1, 118.6, 118.5, 72.6, 71.6, 38.5, 38.2, 32.8, 31.9, 
31.4, 29.7 (2 C), 29.6 (2 C), 29.5, 29.3, 29.2, 27.2, 27.1, 26.9, 22.6, 15.4, 14.1, 14.0; 
HRMS (ESI) calcd for [M+Na]+ C25H40N2O2Na: 423.2987, found 423.2991. 
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6.8. (R)-2-Methyl-1-oxazolo[4,5-b]pyridin-2-yl-cis-octadec-9-en-1-one (156)231 
167b
OH
O
N
N
156
O
O
N
N
 
This compound was prepared as described for 61. FC (eluent, 10% EtOAc/hex) gave 
compound 156 (23 mg, 58%, ee% = 37%) as yellow oil: Rf (EtOAc) 0.6; [α]20 = -2 
(CH2Cl2, c = 1); Rt 19.33 min (Chiralcel AD, 0.5% 2-propanol in hexane, 1.0 
ml/min, 254 nm); 1H NMR (CDCl3) 8.75 (dd, 1H, J = 4.8, 1.5 Hz), 8.00 (dd, 1H, J = 
8.3, 1.5 Hz), 7.49 (dd, 1H, J = 8.3, 4.8 Hz), 5.40-5.28 (m, 2H), 3.84 (sext, 1H, J = 
6.8 Hz), 2.06-1.88 (m, 5H), 1.60-1.51 (m, 1H), 1.4-1.2 (m, 24H), 0.88-0.85 (m, 3H). 
13C NMR (CDCl3) 190.4, 158.3, 154.3, 148.7, 143.6, 130.0, 129.7, 123.1, 120.2, 
39.8, 31.9, 29.8, 29.7, 29.5, 29.3 (2 C), 29.2, 29.1 (2 C), 27.2 (2 C), 23.8, 22.7, 16.4, 
14.1; HRMS (ESI) calcd for [M+Na]+ C25H38N2O2Na: 421.2831, found 421.2840. 
6.9. (S)-2-Methyl-cis-9-octadecenol (163c)231 
O
OH OH
162c 163c
 
 
This compound was prepared as described for 163b. Yellow oil (2.3 g, 88%): Rf 
(CH2Cl2) 0.4; 1H NMR and 13C NMR (CDCl3) match to those of 163b; HRMS (ESI) 
calcd for [M+H]+ C19H39O: 283.3001, found 283.3000. 
6.10. (S)-2-methyl-cis-9-octadecenal (164c)231 
OH H
O
163c 164c
 
This compound was prepared as described for 164b. Yellow oil (1.8 g, 92%): Rf 
(10% EtOAc/hex) 0.6; 1H NMR and 13C NMR (CDCl3) match to those of 164b; 
HRMS (ESI) calcd for [M+Na]+ C19H36ONa: 303.2664, found 303.2692. 
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6.11. (S)-3-Methyl-2-hydroxy-cis-10-nonadecenenitrile (165c)231 
H
O
CN
OH
164c 165c
 
This compound was prepared as described for 165a. Colourless oil: (1.4 g, 85%): Rf 
(50% EtOAc/hex) 0.7; 1H NMR and 13C NMR (CDCl3) match to those of 165b; 
HRMS (ESI) calcd for [M+Na]+ C20H37NONa: 330.2773, found 330.2796. 
6.12. (S)-2-Methyl-1-oxazolo[4,5-b]pyridin-2-yl-cis-octadec-9-en-1-ol (167c)231 
OH
N
N NH2
OH
OH
O
N
N
OH
O
NH.HCl
165c 166c
167c
 
This compound was prepared as described for 167a. Yellow oil: Rf (EtOAc) 0.6; 1H 
NMR and 13C NMR (CDCl3) match to those of 167b; HRMS (ESI) calcd for 
[M+Na]+ C25H40N2O2Na: 423.2987, found 423.2986. 
6.13. (S)-2-Methyl-1-oxazolo[4,5-b]pyridin-2-yl-octadec-9-en-1-one (157)231 
167c
OH
O
N
N
157
O
O
N
N
 
This compound was synthesized as described for 61. FC (eluent, 10% 
EtOAc/cyclohexane) gave compound 157 (47 mg, 79%, ee%= 37%) as yellow oil: 
Rf (EtOAc) 0.6; [α]20 = -2 (CH2Cl2, c = 1); Rt 25.41 min (Chiralcel AD; 0.5 % 2-
propanol in hexane, 1.0 ml/min, 254 nm); 1H NMR and 13C NMR (CDCl3) match to 
those of 156; HRMS (ESI) calcd for [M+Na]+ C25H38N2O2Na: 421.2831, found 
421.2839. 
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6.14. 2-Ethyl-oxazolo[4,5-d]pyrimidine (159c) 
 
4-Aminopyrimidin-5-ol (30 mg, 0.2 mmol, 100 mol-%), triethylortho propionate 
(350 mg, 2.0 mmol, 1000 mol-%) and p-TsOH (2 mg, 0.02 mmol, 8 mol-%) were 
heated progressively during 2 h untill 165 oC and kept at this temperature for 1 h. 
The mixture was cooled, evaporated, eluted (EtOAc) through a pad silica gel and 
recrystallized from petroleum ether giving compound 159c (23 mg, 77%) as red 
crystals: Rf (EtOAc) 0.25; mp. 49 °C; 1H NMR (CDCl3) 9.10 (s, 1H), 8.88 (s, 1H), 
3.06 (q, 2H, J = 7.6 Hz), 1.48 (t, 3H, J = 7.6 Hz). 13C NMR (CDCl3) 174.6, 162.0, 
155.0, 142.2, 138.3, 22.7, 10.4; HRMS (ESI) calcd for [M+H]+ C7H8N3O: 150.0667, 
found 150.0630. 
6.15. 2-Propyl-oxazolo[4,5-d]pyrimidine (159d) 
 
This compound was prepared as 158c. Light red crystals (20 mg, 61%): Rf (EtOAc) 
0.25; mp. 51-52 °C; 1H NMR (CDCl3) 9.11 (s, 1H), 8.90 (s, 1H), 3.01 (t, 2H, J = 7.5 
Hz), 1.96 (sext, 2H, J = 7.5 Hz), 1.06 (t, 3H, J = 7.5 Hz). 13C NMR (CDCl3) 173.8, 
162.0, 155.0, 142.1, 138.3, 30.9, 19.9, 13.6, HRMS (ESI) calcd for [M+H]+ 
C8H10N3O 164.0824, found 164.0810. 
6.16. 1-(3’-Cyanophenyl)6-phenylhexan-1-one (174) 
CN
O
Br
CN
O
H
173 174
 
5-Phenyl-1-bromopentane 173 (360 mg, 1.6 mmol, 100 mol-%) in THF (2.0 ml) was 
cannulated to a mixture of Mg-chips (42 mg, 1.7 mmol, 110 mol-%) in THF (3.0 ml) 
at rt. Mixture was heated up to reflux and I2-crystal was added. After the mixture 
had cleared it was cooled to rt and cannulated to a mixture of 2-cyanobenzaldehyde 
(210 mg, 1.6 mmol, 100 mol-%) in THF (2.0 ml). The mixture was refluxed for 17 h 
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and cooled to rt followed by addition of ice (10 ml) and 2 drops of conc. H2SO4. The 
mixture was extracted with EtOAc (3 x 50 ml) and combined organic phases were 
washed with water (50 ml) and brine (50 ml), dried (Na2SO4) and evaporated. 
Purification by FC (5% EtOAc/hex) gave compound 174 (27 mg, 6%) as yellow oil: 
Rf (20% EtOAc/hex) 0.4; 1H NMR (CDCl3) 8.22-8.21 (m, 1H), 8.16 (ddd, 1H, J = 
7.9, 1.6, 1.4 Hz), 7.82 (dt, 1H; J = 7.8, 1.4 Hz), 7.59 (td, 1H, J = 7.9, 0.4 Hz), 7.29-
7.25 (m, 2H), 7.19-7.16 (m, 3H), 2.96 (t, 2H, J = 7.3 Hz), 2.63 (t, 2H, J = 7.8 Hz), 
1.78 (qui, 2H, J = 7.6 Hz), 1.68 (qui, 2H, J = 7.6 Hz), 1.47-1.39 (m, 2H). 13C NMR 
(CDCl3) 198.1, 142.4, 137.7, 135.8, 131.9, 131.7, 129.6, 128.4, 128.3, 125.7, 117.9, 
113.1, 38.5, 35.7, 31.2, 28.8, 23.8; HRMS (ESI) calcd for [M+Na]+ C19H19NONa: 
300.1364, found 300.1364. 
6.17. 3-(6’-Phenylhexan-1-onyl)benzamide (161) 
 
Compound 174 (24 mg, 0.087 mmol, 100 mol-%) was treated with 0.5 M aq. NaOH 
(170 µl, 0.087 mmol, 100 mol-%) and 30% aq. H2O2 (100 µl, 0.87 mmol, 1000 mol-
%) in EtOH (1 ml) at rt The mixture was heated to 50 oC for 3 h and then neutralized 
with 0.2 M aq. HCl. The mixture was diluted with H2O (10 ml), extracted with 
CH2Cl2 (3 x 20 ml) and the combined organic phases were washed with brine (2 x 
10 ml), dried (Na2SO4) and evaporated resulting in white solid. Purification by FC 
(hex) gave compound 161 (20 mg, 80%) as white solid: mp. 128 oC, Rf (5% MeOH 
in CH2Cl2) 0.3; 1H NMR (CDCl3) 8.38 (t, 1H, J = 1.6 Hz), 8.10 (dt, 1H, J = 7.7, 1.4 
Hz), 8.04 (ddd, 1H, J = 7.7, 1.1, 0.6 Hz), 7.56 (t, 1H, J = 7.8 Hz), 7.29-7.25 (m, 2H), 
7.19-7.16 (m, 3H), 6.29 (br s, 1H), 5.94 (br s, 1H), 3.00 (t, 2H, J = 7.4 Hz), 2.63 (t, 
3H, J = 7.8 Hz), 1.78 (qui, 2H, J = 7.6 Hz), 1.68 (qui, 2H, J = 7.6 Hz), 1.47-1.39 (m, 
2H); 13C NMR (CDCl3) 199.6, 168.3, 142.5, 137.3, 133.8, 131.7, 131.3, 129.0, 
128.4, 128.3, 126.7, 125.7, 38.6, 35.7, 31.2, 28.9, 24.0; HRMS (ESI) calcd for 
[M+Na]+ C19H21NO2Na: 318.1470, found 318.1455.  
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6.18. 3-(4,5-Dihydro-1H-imidazol-2-yl)phenyl cyclohexylcarbamate (222) 
 
To a mixture of 3-formylphenyl cyclohexylcarbamate (278, see 6.57. 3-
Formylphenyl cyclohexylcarbamate (278), 300 mg, 1.2 mmol, 100 mol-%) in 
CH2Cl2 (10 ml) was added ethane-1,2-diamine (85 µL, 1.3 mmol, 105 mol-%) at -2 
oC (Tbath). The mixture was stirred for 30 min and N-bromosuccinimide (230 mg, 1.3 
mmol, 105 mol-%) was added. The mixture was allowed to warm to rt during 1 h 
and evaporated to dryness. Resulting solid was dissolved to 10% TEA in EtOAc, 
filtered through a pad of silica, solvents were evaporated and residue recrystallized 
from EtOAc/CH2Cl2 (6:5) giving 222 (290 mg, 83%) as white crystals: mp. 139-141 
oC; Rf (10% TEA in EtOAc) 0.3; 1H NMR (CDCl3) 7.60 (dt, 1H, J = 7.7, 1.3 Hz), 
7.53 (s, 1H) 7.37 (t, 1H, J = 7.9 Hz), 7.20 (dd, 1 H, J = 8.2, 1.5 Hz), 5.07 (br d, 1H, J 
= 7.5 Hz), 3.77 (br s, 4H), 3.60-3.48 (m, 1H), 2.05-1.96 (m, 2H), 1.79-1.69 (m, 2H), 
1.67-1.58 (m, 1H), 1.43-1.31 (m, 2H), 1.28-1.13 (m, 3H); 13C NMR (MeOD) 166.7, 
156.0, 152.8, 132.5, 130.4, 125.4, 125.0, 121.8, 51.7, 50.4 (2 C), 34.0, 26.6, 26.1; 
Anal. calcd for C16H21N3O2: C, 66.88; H, 7.37; N, 14.62; Found C, 66.54; H, 7.33; 
N, 14.27. 
6.19. 2-(3-Methoxyphenyl)oxazole (255a)232 
 
3-Methoxybenzamide (254a, 2.0 g, 13 mmol, 100 mol-%) and 2-bromoacetaldehyde 
diethyl acetal (2.5 ml, 16 mmol, 120 mol-%) were placed to a round bottomed flask 
and MW-irradiated for 5 min (power 300 W for 30 s, then 50 W, air cooling, Tmax= 
100 oC). The reaction mixture was dissolved in a mixture of EtOAc (150 ml), MeOH 
(10 ml) and water (50 ml). The organic phase was washed with NaHCO3, water and 
brine, dried (Na2SO4), and evaporated. The tan oil was Kugelrohr-distilled to yield 
2.05 g of clear oil. The oil was diluted with hex (5 ml) and put to freezer overnight, 
which caused crystallization. The solid was filtrated, washed with ice-cold hex (20 
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ml) and dried under reduced pressure giving 255a (1.0 g, 45%) as a white crystals: 
mp. 23-24 oC; Rf (EtOAc) 0.62; 1H NMR (CDCl3) 7.69 (d, 1H, J = 0.7 Hz), 7.65-
7.62 (ddd, 1H, J = 7.7, 1.4, 0.9 Hz), 7.59 (dd, 1H, J = 1.4 Hz), 7.36 (t, 1H, J = 7.5 
Hz) , 1H, 7.23 (d, 1H, J = 0.7 Hz), 6.99, (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 3.86 (s, 3H), 
13C NMR (CDCl3) 161.8, 159.8, 138.5, 129.8, 128.6, 128.3, 118.7, 116.9, 110.9, 
55.3; Anal. calcd for C10H9NO2: C, 68.56; H, 5.18; N, 8.00; Found C, 68.43; H, 
4.84; N, 7.86. 
6.20. 2-(3-Hydroxyphenyl)oxazole (256a)232,233 
 
2-(3-Methoxyphenyl)oxazole (255a, 0.9 g, 5.1 mmol, 100 mol-%) and 1-butyl-3-
methylimidazolium bromide (2.2 g, 10 mmol, 200 mol-%) were MW-irradiated in a 
round bottomed flask for 4 x 20 s (power 300 W, air cooling, Tmax 200 oC). The 
reaction mixture was dissolved in EtOAc (200 ml) and water (50 ml). The organic 
phase was washed with water and brine, dried (Na2SO4), filtered and evaporated. FC 
(25% EtOAc/hex) gave 256a (0.5 g, 60%) as a white solid: mp. 130-131 oC; Rf (40% 
EtOAc/hex) 0.5; 1H NMR (CDCl3) 9.81 (s, 1H), 8.19 (d, 1H, J = 0.8 Hz), 7.43-7.38 
(m, 2H), 7.36 (d, 1H, J = 0.8 Hz), 7.33 (t, 1H, J = 7.9 Hz), 6.91 (ddd, 1H, J = 1.1, 
2.5, 8.1 Hz), 5.05 (br s, 1H), 4.43 (app t, 2H, J = 9.5 Hz), 4.06 (app t, 2H, J = 9.5 
Hz), 3.24 (q, 2H, J = 6.7 Hz), 1.60 (sext, 2H, J = 7.3 Hz), 0.97 (t, 3H, J = 7.4 Hz); 
13C NMR (CDCl3) 160.8, 157.8, 139.9, 130.3, 128.4, 128.1, 117.7, 116.6, 112.4.  
6.21. General procedure for the preparation of phenolic carbamates; 3-(Oxazol-2-
yl)phenyl cyclopentylcarbamate (241) 232 
 
To a solution of 2-(3-hydroxyphenyl)oxazole 256a (64 mg, 0.40 mmol, 100 mol-%) 
in dry toluene (4 ml) were added triethylamine (29 mg, 0.28 mmol, 100 mol-%) and 
cyclopentyl isocyanate (180 mg, 1.6 mmol, 400 mol-%). After stirring at rt for 12 h, 
the reaction was complete as judged by TLC (10% Et2O/CH2Cl2), and the mixture 
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was diluted with EtOAc (8 ml), filtered through a pad of silica gel and evaporated to 
dryness. Recrystallization from EtOAc/hex (1:10 ml) gave compound 241 (103 mg, 
94%) as white crystals: mp. 120-122 oC; Rf (10% Et2O in CH2Cl2) 0.50; 1H NMR 
(DMSO-d6) 8.25 (s, 1H), 7.90 (d, 1H, J = 7.1 Hz), 7.81 (d, 1H, J = 7.8 Hz), 7.66 (s, 
1H), 7.54 (t, 1H, J = 8.0 Hz), 7.41 (s, 1H), 7.27 (dd, 1H, J = 1.6, 8.1 Hz), 3.90-3.82 
(m, 1H), 1.80-1.90 (m, 2H), 1.61-1.72 (m, 2H); 1.56-1.45 (m, 4H); 13C NMR 
(DMSO-d6) 160.1, 153.4, 151.5, 140.4, 130.3, 128.6, 128.0, 123.9, 122.3, 119.0, 
52.4, 32.2, 23.3; Anal. calcd for C15H16N2O3: C, 66.16; H, 5.92; N, 10.29; Found C, 
65.99; H, 5.81; N, 10.20. 
6.22. 3-(Oxazol-2-yl)phenyl cyclohexylcarbamate (242)232 
 
Recrystallization from EtOAc/hex gave 242 (115 mg, 80%) as white crystals: mp. 
142-143 oC; Rf (10% Et2O/CH2Cl2) 0.30; 1H NMR (CDCl3) 7.88 (d, 1H, J = 7.8 Hz), 
7.82-7.80 (m, 1H), 7.70-7.69 (m, 1H), 7.44 (t, 1H, J = 8.0 Hz), 7.25-7.21 (m, 2H), 
5.06 (br d, 1H, J = 7.5 Hz), 3.66-3.51 (m, 1H) 2.08-1.97 (m, 2H), 1.79-1.69 (m, 2H), 
1.66-1.58 (m, 1H), 1.43-1.31 (m, 2H), 1.29-1.13 (m, 3H); 13C NMR (CDCl3) 161.2, 
153.3, 151.4, 138.7, 129.7, 128.6, 128.5, 123.6, 123.0, 119.7, 50.2, 33.2, 25.4, 24.7; 
Anal. calcd for C16H18N2O3: C, 67.12; H, 6.34; N, 9.78; Found C, 66.72; H, 6.44; N, 
9.74. 
6.23. 3-(Oxazol-2-yl)phenyl 2-methylbenzylcarbamate (243) 232 
 
Recrystallization from EtOAc/hex gave 243 (154 mg, 89%) as white crystals: mp. 
120-121 oC; Rf (5% Et2O/CH2Cl2) 0.5; 1H NMR (DMSO-d6) 8.35 (t, 1H, J = 5.9 
Hz), 8.24 (s, 1H), 7.85-7.81 (m, 1H), 7.70 (t, 1H, J = 1.8 Hz), 7.56 (t, 1H, J = 8.0 
Hz), 7.41 (s, 1H), 7.33-7.27 (m, 2H), 7.23-7.17 (m, 3H), 4.29 (d, 1H, J = 5.9 Hz), 
2.32 (s, 3H); 13C NMR (DMSO-d6) 160.1, 154.2, 151.5, 140.4, 136.7, 135.5, 130.4, 
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130.0, 128.6, 128.0, 127.4, 127.0, 125.9, 123.9, 122.5, 119.0, 42.1, 18.6; Anal. calcd 
for C18H16N2O3: C, 70.12; H, 5.23; N, 9.09; Found C, 69.78; H, 5.14; N, 9.02. 
6.24. 3-(Oxazol-2-yl)phenyl phenethylcarbamate (244) 232 
 
Recrystallization from EtOAc/hex gave compound 244 (83 mg, 73%) as white 
crystals: mp. 112-113 oC; Rf (5% Et2O/CH2Cl2) 0.50; 1H NMR (DMSO-d6) 8.25 ( d, 
1H, J = 0.6 Hz), 7.96 (t, 1H, J = 5.6 Hz), 7.83-7.79 (m, 1H), 7.64 (t, 1H, J = 1.9 Hz), 
7.54 (t, 1H, J= 8.0 Hz), 7.41 (d, 1H, J = 0.9 Hz), 7.35-7.20 (m, 6H), 3.36-3.29 (m, 
2H), 2.82 (t, 2H, J = 7.4 Hz); 13C NMR (DMSO-d6) 160.1, 154.0, 151.5, 140.4, 
139.1, 130.3, 128.7, 128.6, 128.3, 128.0, 126.2, 123.8, 122.4, 119.0, 42.0, 35.2; 
Anal. calcd for C18H16N2O3: C, 70.12; H, 5.23; N, 9.09; Found C, 70.04; H, 5.09; N, 
9.02. 
6.25. 2-(4-Methoxyphenyl)oxazole (255b)234 
 
This compound was synthesized and worked up as described for 255a using 4-
methoxybenzamide (2.0 g, 13 mmol, 100 mol-%) as starting material. Purification 
by FC (Eluent 33% EtOAc/hex) gave 255b (2.0 g, 90%) as a yellow oil: Rf (EtOAc) 
0.50; 1H NMR (CDCl3) 7.98 (d, 2H, J = 9.0 Hz), 7.66 (s, 1H), 7.19 (s, 1H), 6.97 (d, 
2H, J = 8.8 Hz), 3.86 (s, 3H). 
6.26. 2-(4-Hydroxyphenyl)oxazole (256b)232 
 
This compound was synthesized and worked up as described for 256a using 255b 
(1.5 g, 9.3 mmol, 100 mol-%) as starting material. Purification by FC (Eluent 33% 
EtOAc/hex) and recrystallization (MeOH/CH2Cl2/hex) gave 256b (0.97 g, 65%) as a 
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white solid: mp. 173-175 oC; Rf (50% EtOAc/hex) 0.3; 1H NMR (DMSO-d6) 7.87-
7.83 (m, 3H), 7.21 (d, 1H, J = 0.8 Hz), 6.92-6.88 (m, 2H), 4.93 (br s, 1H); 13C NMR 
(MeOD) 164.0, 161.4, 140.0, 129.2, 128.4, 119.6, 116.8.  
6.27. 4-(Oxazol-2-yl)phenyl cyclopentylcarbamate (245) 232 
 
A white solid (168 mg, 95%): mp. 168-169 oC; Rf (5% Et2O/CH2Cl2) 0.20; 1H NMR 
(DMSO-d6) 8.21 (s, 1H), 7.98 (d, 2H, J = 8.7 Hz), 7.90 (d, 1H, J = 7.2 Hz), 7.37 (s, 
1H), 7.28 (d, 2H, J = 8.6 Hz), 3.92-3.81 (m, 1H), 1.92-1.80 (m, 2H), 1.72-1.60 (m, 
2H), 1.58-1.45 (m, 4H); 13C NMR (DMSO-d6) 160.4, 153.2, 152.8, 140.0, 128.5, 
127.1, 123.6, 122.4, 52.4, 32.2, 23.3; Anal. calcd for C15H16N2O3 C, 66.16; H, 5.92; 
N, 10.29; Found C, 66.29; H, 5.66; N, 10.32. 
6.28. 2-(3-Methoxyphenyl)4-phenyloxazole (255c) 
 
3-Methoxybenzamide (254a, 1.5 g, 10 mmol, 100 mol-%) and 2-bromo-1-
phenylethanone (2.4 g, 12 mmol, 120 mol-%) were added to round bottomed flask 
and MW-irradiated for 5 min (power 200 W for 30 s, then 50 W, air cooling, Tmax= 
125 oC). The reaction mixture was dissolved to EtOAc (150 ml), MeOH (10 ml) and 
water (50 ml). The organic phase was washed with sat. NaHCO3, water and brine, 
dried (Na2SO4), and evaporated. Purification by FC (5% EtOAc/hex) gave 255c (2.0 
g, 79%) as a red oil (impure): Rf (50% EtOAc/hex) 0.58; 1H NMR (CDCl3) 7.96 (s, 
1H), 7.84-7.81 (m, 2H), 7.72-7.70 (ddd, 1H), 7.66 (dd, 1H, J = 2.6, 1.6 Hz), 7.46-
7.41 (m, 2H), 7.39 (t, 1H, J = 8.0 Hz), 7.36-7.30 (m, 1H), 7.01 (ddd, 1H, J = 8.3, 
2.6, 1.0 Hz), 3.90 (s, 3H); HRMS (ESI) calcd for [M+Na]+ C16H13NO2: 274.0844; 
Found 274.0839. 
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6.29. 3-(4-Phenyloxazol-2-yl)phenol (256c) 
 
Compound 255c (150 mg, 0.6 mmol, 100 mol-%) and N-butylpyridinium bromide 
(320 mg, 1.5 mmol, 250 mol-%) were MW-irradiated in a sealed tube for 3 x 30 s 
(power 125 W, Tmax= 100 oC). The reaction mixture was dissolved to EtOAc (50 ml) 
and the organic phase was washed with water and brine, dried (Na2SO4), and 
evaporated. Purification by FC (CH2Cl2) gave 256c (84 mg, 60%) as a yellow wax: 
Rf (EtOAc) 0.50; 1H NMR (MeOD-d4) 8.29 (s, 1H), 7.85-7.81 (m, 2H), 7.57 (ddd, 
1H, J = 7.7, 1.5, 1.0 Hz), 7.51 (dd, 1H, J = 2.3, 1.7 Hz), 7.45-7.40 (m, 2H), 7.36-
7.31 (m, 2H), 6.9 (ddd, 1H, J = 8.2, 2.5, 1.0 Hz), 4.17-4.03 (m, 1H), 2.10-1.99 (m, 
2H), 1.79-1.59 (m, 4H), 1.57-1.46 (m, 2H); 13C NMR (MeOD-d4) 163.6, 159.2, 
143.2, 135.6, 132.4, 131.2, 129.8, 129.6, 129.2, 126.7, 118.9, 118.7, 114.1; HRMS 
(ESI) calcd for [M-H]+ C15H10NO2: 236.0712, found 236.0717. 
6.30. 3-(4-Phenyloxazol-2-yl)phenyl cyclopentylcarbamate (246) 
 
Recrystallization from EtOAc/hex gave 246 (60 mg, 66%) as white crystals: mp. 
159-161 oC; Rf (10% Et2O in CH2Cl2) 0.50; 1H NMR (CDCl3) 7.97-7.93 (m, 2H), 
7.91-7.88 (m, 1H), 7.84-7.79 (m, 2H), 7.49-7.40 (m, 3H), 7.36-7.30 (m, 1H), 7.27-
7.23 (m, 1H), 5.03 (br d, 1H, J = 6.8 Hz), 4.17-4.03 (m, 1H), 2.10-1.99 (m, 2H), 
1.79-1.59 (m, 4H), 1.57-1.46 (m, 2H); 13C NMR (CDCl3) 161.6, 154.1, 151.8, 142.5, 
134.0, 131.4, 130.1, 129.2, 129.1, 128.6, 126.1, 124.2, 123.7, 120.2, 53.5, 33.6, 
24.0; Anal. calcd for C21H20N2O3: C, 72.40; H, 5.79; N, 8.04; Found C, 72.05; H, 
5.55; N, 7.99. 
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6.31. 2-(3-Nitrophenyl)benzo[d]oxazole (266)235 
 
3-Nitrobenzoic acid (170 mg, 1.0 mmol, 100 mol-%), 2-aminophenol (110 mg, 1.0 
mmol, 100 mol-%) and boric acid (62 mg, 1.0 mmol, 100 mol-%) were irradiated by 
microwave reactor (300 W, 4 min ramp to 250 oC, hold 1 min). The tan solid was 
collected with EtOAc (150 mL) washed with sat. aq. NaHCO3 (50 mL), water (50 
mL) and brine (50 mL), dried with Na2SO4, filtered and evaporated. 
Recrystallization (EtOAc/hex) gave compound 266 (170 mg, 71 %) as crystals: mp 
209-210 oC, Rf (50% EtOAc/hex) 0.8; 1H NMR (CDCl3), 9.10 (t, 1H, J = 1.8 Hz), 
8.59 (ddd, 1H, J = 7.8, 1.5, 1.1 Hz), 8.39 (ddd, 1H, J = 8.2, 2.3, 1.1 Hz), 7.83-7.80 
(m, 1H), 7.73 (t, 1H, J = 8.0 Hz), 7.65-7.60 (m, 1H), 7.45-7.39 (m, 2H). 
6.32. 3-(Benzo[d]oxazol-2-yl)aniline (267)235 
 
Compound 266 (210 mg, 0.88 mmol, 100 mol-%) was dissolved in THF (5 mL) and 
EtOH (50 mL) and 10% Pd/C (64 mg, 0.06 mmol, 7 mol-%) was added. The 
mixture was stirred under H2-gas for rt for 90 min and the mixture was eluted 
through a pad of silica with EtOAc and evaporated to dryness. Recrystallization 
(EtOH) gave compound 267 (170 mg, 90%) as red crystals: mp 177-178 oC; Rf (50% 
EtOAc/hex) 0.5; 1H NMR (CDCl3) 7.78-7.74 (m, 1H), 7.64 (ddd, 1H, J = 1.0, 1.5, 
7.7 Hz), 7.58-7.54 (m, 2H), 7.36-7.28 (m, 3H); 6.84 (ddd, 1H, J = 0.9, 2.4, 8.0 Hz), 
3.85 (s, 2H). 
6.33. 1-(3-(Benzo[d]oxazol-2-yl)phenyl)3-cyclopentylurea (247) 
 
113 
 
Recrystallization (MeOH) gave compound 247 (44 mg, 65%) as a light brown 
crystals: mp. 244-246 oC, Rf (20% Et2O/CH2Cl2) 0.67; 1H NMR (DMSO-d6) 8.90 (s, 
1H), 8.49 (s, 1H), 7.82-7.80 (m, 2H), 7.75-7.72 (m, 1H), 7.46-7.39 (m, 4H), 6.25 (d, 
1H, J = 7.1 Hz), 4.02-3.93 (m, 1H), 1.91-1.83 (m, 2H), 1.70-1.51 (m, 4H), 1.44-1.36 
(m, 2H); 13C NMR (DMSO-d6) 162.5, 154.7, 150.2, 141.5, 141.4, 129.7, 126.8, 
125.5, 124.8, 120.7, 119.8 (2 C), 115.9, 110.9, 51.0, 32.8, 23.2; Anal. calcd for 
C19H19N3O2; C, 71.01; H, 5.96; N, 13.08; Found C, 70.20; H, 6.25; N, 12.78; HRMS 
(ES+) m/z 322.1564 (MH+, calc. for C19H20N3O2 322.1556). 
6.34. 3-(Benzo[d]thiazol-2-yl)phenol (268)223 
 
3-Hydroxybenzaldehyde (120 mg, 1.0 mmol, 100 mol-%), 2-aminothiophenol (130 
mg, 1.0 mmol, 100 mol-%) and 1-butyl-3-methylimidazolium bromide (90 mg, 0.4 
mmol, 40 mol-% ) were irradiated with microwaves (50 W, 2 min ramp to 200 oC, 
hold 3 min). The tan solid was collected with EtOAc (50 ml) and washed with sat. 
aq. NaHCO3 (30 mL) and brine (30 ml), dried with Na2SO4, filtered and evaporated. 
Recrystallization (EtOAc/hex) gave compound 268 (167 mg, 73 %) as a yellow 
solid: mp. 168-169 oC; Rf (50% EtOAc/hex) 0.53; 1H NMR (CDCl3) 8.07 (d, 1H, J = 
8.2 Hz), 7.89 (dd, 1H, J = 8.0, 0.6 Hz), 7.67 (dd, 1H, J = 2.3, 1.8 Hz), 7.58 (ddd, 1H, 
J = 7.7, 1.5, 0.9 Hz), 7.49 (ddd, 1H, J = 8.3, 7.3, 1.3 Hz), 7.39 (ddd, 1H, J = 8.2, 7.3, 
1.1 Hz), 7.33 (t, 1H, J = 7.9 Hz), 6.98 (ddd, 1H, J = 8.1, 2.5, 0.9 Hz), 6.51 (s, 1H). 
6.35. 3-(Benzo[d]thiazol-2-yl)phenyl cyclopentylcarbamate (248) 
 
Recrystallization (EtOAc/hex) gave compound 248 (70 mg, 91%) as white crystals: 
mp. 178-179 oC; Rf (10% Et2O/CH2Cl2) 0.50; 1H NMR (DMSO-d6) 8.17 (d, 1H, J = 
7.6 Hz), 8.09 (d, 1H, J = 8.0 Hz), 7.92 (t, 2H, J = 7.8 Hz), 7.84-7.82 (m, 1H), 7.60-
7.55 (m, 2H), 7.51-7.47 (m, 1H), 7.33 (dd, 1H, J = 1.6, 8.1 Hz), 3.93-3.84 (m, 1H), 
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1.92-1.81 (m, 2H), 1.72-1.64 (m, 2H), 1.58-1.42 (m, 4H); 13C NMR (DMSO-d6) 
166.4, 153.4 (2 C), 151.7, 134.5, 133.9, 130.5, 126.8, 125.7, 124.7, 123.8, 123.0, 
122.4, 120.0, 52.4, 32.2, 23.3; Anal. calcd for C19H18N2O2S; C, 67.43; H, 5.36; N, 
8.28; Found C, 67.18; H, 5.65; N, 8.22. 
6.36. 2-(3-Methoxyphenyl)thiazole (258)236 
 
To a mixture of 3-methoxybenzothioamide (420 mg, 2.5 mmol, 100 mol-%) in THF 
(2.5 ml) was added 2-bromoacetaldehyde diethyl acetal (0.5 ml, 3.3 mmol, 130 mol-
%), and the mixture was MW-irradiated in a sealed tube for 30 min (power 300 W, 
air cooling, Tmax= 115 oC). Purification of the resulting mixture by FC (Eluent 1% 
EtOAc in toluene) gave 258 (200 mg, 42%) as an oil: Rf (10% EtOAc/toluene) 0.50; 
1H NMR (CDCl3) 7.85 (d, 1H, J = 3.3 Hz), 7.55 (dd, 1H, J = 2.4, 1.7 Hz) 7.51 (ddd, 
1H, J = 7.7, 1.5, 1.0 Hz) 7.33 (t, 1H, J = 8.1 Hz), 7.30 (d, 1H, J = 3.3 Hz), 6.96 (ddd, 
1H, J = 8.2, 2.6, 0.9 Hz), 3.86 (s, 3H); 13C NMR (CDCl3) 168.2, 159.9, 143.5, 134.7, 
129.9, 119.1, 118.8, 116.2, 111.0, 55.3.  
6.37. 2-(3-Hydroxyphenyl)thiazole (259)236 
 
Compound 258 (170 mg, 0.9 mmol, 100 mol-%) and 1-butyl-3-methylimidazolium 
bromide (700 mg, 3.2 mmol, 350 mol-%) were MW-irradiated for 2 x 30 s (power 
300 W, air cooling, Tmax 100 oC). The reaction mixture was partitioned between 
EtOAc (30 ml) and water (30 ml). The organic phase was dried (Na2SO4), and 
evaporated. Resulting crude product was purified by FC (Eluent 25% EtOAc/hex) 
and recrystallized from EtOAc/hex giving 259 (70 mg, 44%) as a white solid: mp. 
141-143 oC, Rf (35% EtOAc/hex) 0.50; 1H NMR (CDCl3) 7.87 (d, 1H, J = 3.2 Hz), 
7.52 (ddd, 1H, J = 2.5, 1.6, 0.4 Hz), 7.49 (ddd, 1H, J = 7.7, 1.6, 1.0 Hz), 7.34 (d, 1H, 
J = 3.3 Hz), 7.31 (ddd, 1H, J = 8.1, 7.7, 0.4 Hz), 6.92 (ddd, 1H, J = 8.1, 1.6, 1.0 Hz), 
5.68 (br s, 1H).   
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6.38. 3-(Thiazol-2-yl)phenyl cyclohexylcarbamate (249)232 
 
Purification by FC (Eluent 1-2% MeOH/CH2Cl2) and recrystallization from 
EtOAc/hex gave 249 (35 mg, 50%) as white crystals; mp. 147 oC; Rf (EtOAc) 0.80; 
1H NMR (CDCl3) 7.86 (d, 1H, J = 3.2 Hz), 7.81-7.74 (m, 2H), 7.42 (t, 1H, J = 7.9 
Hz), 7.34 (d, 1H, J = 3.2 Hz), 7.21 (dd, 1H, J = 8.1, 1.6 Hz) 4.98, (br d, 1H, J = 7.3 
Hz), 3.67-3.52 (m, 1H), 2.10-1.98 (m, 2H), 1.80-1.70 (m, 2H), 1.68-1.58 (m, 2H), 
1.45-1.32 (m 2H), 1.30-1.14 (m, 3H); 13C NMR (CDCl3) 167.4, 153.3, 151.6, 143.7, 
134.8, 129.8, 123.3, 123.2, 119.8, 119.1, 50.2, 33.2, 25.4, 24.7; Anal. calcd for 
C16H18N2O2S: C, 63.55; H, 6.00; N, 9.26; Found C, 63.38; H, 5.78; 9.14. 
6.39. 4-(3-Methoxyphenyl)oxazole (261)232 
 
2-Bromo-1-(3-methoxyphenyl)-ethanone (260, 230 mg, 1.0 mmol, 100 mol-%) and 
formamide (0.4 ml, 10 mmol, 1000 mol-%) were MW-irradiated (300 W) in a sealed 
tube until the temperature reached 100 oC (30 s) and kept at that temperature for 30 
s. The irradiation was repeated and the mixture was partitioned between EtOAc (30 
ml) and water (30 ml). The organic phase was dried (Na2SO4), and evaporated. 
Purification by FC (Eluent 10% EtOAc/hex) and recrystallization from CH2Cl2/hex 
gave 261 (90 mg, 51%) as light yellow crystals; mp. 81-82 oC; Rf (EtOAc) 0.60; 1H 
NMR (CDCl3) 7.93-7.92 (m, 2H), 7.34-7.32 (m, 1H), 7.32-7.30 (m, 2H), 6.90-6.85 
(m, 1H), 3.85 (s, 3H); 13C NMR (CDCl3) 160.0, 151.2, 140.3, 133.9, 132.0, 129.8, 
117.9, 114.1, 110.8, 55.2; Anal. calcd for C10H9NO2 C, 68.56; H, 5.18; N, 8.00; 
Found C, 68.04; H, 5.10; N, 7.74; HRMS (ESI) calcd for [M+Na]+ C10H9NO2: 
198.0531, found 198.0524.  
116 
 
6.40. 4-(3-Hydroxyphenyl)oxazole (262)232 
 
Compound 261 (200 mg, 1.1 mmol, 100 mol-%) and 1-butylpyridinimium bromide 
(490 mg, 2.2 mmol, 200 mol-%) were MW-irradiated (300 W) in a sealed tube until 
the temperature reached 100 oC (took 30 s) and kept at that temperature for 30 s. 
Another portion of ionic liquid (430 mg, 2.0 mmol, 180 mol-%) was added and 
irradiation was repeated for five times. The mixture was diluted with CH2Cl2 (10 ml) 
and purified by FC (Eluent CH2Cl2). Recrystallization from MeOH/CH2Cl2/hex gave 
262 (100 mg, 56%) as light yellow crystals: mp. 123-124 oC; Rf (10% 
MeOH/CH2Cl2) 0.50; 1H NMR (DMSO-d6) 9.53 (s, 1H), 8.56 (d, 1H, J = 0.9 Hz), 
8.43 (d, 1H, J = 0.9 Hz), 7.23-7.20 (m, 3H), 6.76-6.70 (m, 1H); 13C NMR (DMSO-
d6) 157.7, 152.5, 139.3, 135.0, 131.9, 129.8, 116.1, 115.0, 112.0; Anal. calcd for 
C9H7NO2: C, 67.07; H, 4.38; N, 8.69; Found C, 66.89; H, 4.30; N, 8.32. 
6.41. 3-(Oxazol-4-yl)phenyl cyclohexylcarbamate (250)232 
 
Purification by FC (Eluent 1% MeOH/CH2Cl2) and recrystallization from 
EtOAc/hex gave 250 (160 mg, 90%) as white crystals; mp. 139.5-140.5 oC; Rf (10% 
MeOH/CH2Cl2) 0.40; 1H NMR (CDCl3) 7.93 (d, 2H, J = 6.9 Hz), 7.58 (d, 1H, J = 
7.8 Hz), 7.53 (s, 1H), 7.39 (t, 1H, J = 7.9 Hz), 7.10 (dd, 1H, J = 8.1, 1.6 Hz), 4.95 
(br d, 1H, J = 6.8 Hz), 3.64-3.52 (m, 1H), 2.08-1.97 (m, 1H), 1.80-1.70 (m, 2H), 
1.67-1.58 (m, 1H), 1.44-1.32 (m, 2H), 1.30-1.14 (m, 3H); 13C NMR (CDCl3) 153.5, 
151.5, 151.2, 139.8, 134.0, 132.0, 129.6, 122.3, 121.4, 118.9, 50.1, 33.2, 25.4, 24.7; 
Anal. calcd for C16H18N2O3: C, 67.12; H, 6.34; N, 9.78; Found C, 67.05; H, 6.61; N, 
9.71. 
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6.42. 4-(3-Methoxyphenyl)-1H-imidazole (263)232,237 
 
2-Bromo-1-(3-methoxyphenyl)-ethanone (260, 530 mg, 2.3 mmol, 100 mol-%) and 
formamide (2.0 ml, 50 mmol, 2200 mol-%) were heated up until the temperature 
(Toil) reached 165 oC, during 90 min. The mixture was cooled to rt and partitioned 
between EtOAc (30 ml) and water (50 ml). The pH of aqueous layer was adjusted to 
12 with 35% NaOH, and extracted with EtOAc. The organic phase was dried 
(Na2SO4), and evaporated to dryness. Recrystallization from H2O/MeOH) gave 263 
(340 mg, 85%) as light yellow crystals: mp. 121-122 oC; Rf (EtOAc) 0.1; 1H NMR 
(CDCl3) 11.16 (br s, 1H), 7.68 (d, 1H, J = 1.0 Hz), 7.34 (d, 1H, J = 1.0 Hz), 7.31-
7.23 (m, 3H), 6.80-6.76 (m, 1H), 3.74 (s, 3H); 13C NMR (CDCl3) 159.9, 138.4, 
135.7, 134.3, 129.8, 117.4, 115.9, 112.7, 110.2, 55.1; Anal. calcd for C10H10N2O: C, 
68.95; H, 5.79; N, 16.08; Found C, 68.83; H, 5.43; N, 16.32.  
6.43. 4-(3-Hydroxyphenyl)1H-imidazole (264)232,238 
 
Method A: Compound 263 (1.5 g, 8.6 mmol, 100 mol-%) was dissolved to dry 
CH2Cl2 (90 ml) and cooled to –78 oC. BBr3 (1 M in CH2Cl2, 25 ml, 300 mol-%) was 
added dropwise during 5 min. The mixture was allowed to warm to rt and stirred 
overnight, quenched by addition of water (150 ml). The organic phase was separated 
and extracted with H2O (90 ml). Combined aqueous phases were neutralized with 
35% NaOH (pH adjusted to 6) and extracted with EtOAc. The combined organic 
phases were dried (Na2SO4), evaporated and purified by FC giving 264 (1.1 g, 80%) 
as a white solid: mp. 213-215 oC; Rf (20% MeOH/CH2Cl2) 0.1; 1H NMR (CDCl3) 
9.35 (br s, 1H), 7.81 (br s, 1H), 7.53 (br s, 1H), 7.19-7.11 (m, 3H), 6.62 (dt, J = 7.1, 
2.1 Hz, 1H); 13C NMR (DMSO-d6) 157.7, 138.2, 136.0, 135.2, 129.6, 115.4 (2 C), 
113.4, 111.4.  
Method B222: Compound 263 (400 mg, 2.3 mmol, 100 mol-%), N-butylpyridinium 
bromide (990 mg, 4.6 mmol, 200 mol-%) and 48% aq. HBr (780 mg, 4.6 mmol, 200 
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mol-%) were placed in a 10 mL tube and MW-irradiated for 5 x 20 s (300 W, Tmax 
100 oC). Temperature of the reaction raised to 148 oC and pressure to 250 psi. The 
mixture was worked up and purified as described in Method A resulting in title 
compound 264 (240 mg, 53%).  
6.44. 3-[1-(Cyclohexylcarbamoyl)1H-imidazol-4-yl]phenyl cyclohexylcarba-mate 
(251)232 
OH
N
HN
O
N
N H
N
O
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Purification by FC (Eluent 25-70% EtOAc/hex) and recrystallization from 
EtOAc/hex gave 251 (154 mg, 43%) as a white solid; mp. 158-165 oC; Rf (EtOAc) 
0.55; 1H NMR (CDCl3) 8.06 (d, 1H, J = 1.2 Hz), 7.54-7.44 (m, 3H), 7.28 (t, 1H, J = 
7.8 Hz), 6.97 (dd, 1H, J = 8.0, 1.6 Hz), 6.22 (d, 1H, J = 7.6 Hz), 5.12 (d, 1H, J = 8.1 
Hz), 3.82-3.71 (m, 1H), 3.63-3.51 (m, 1H), 2.10-1.95 (m, 4H), 1.82-1.71 (m, 4H), 
1.71-1.59 (m, 2H), 1.45-1.31 (m, 4H), 1.31-1.14 (m, 6H); 13C NMR (CDCl3) 154.0, 
151.2, 148.0, 141.9, 136.2, 134.5, 129.4, 122.0, 120.6, 118.4, 111.4, 50.4, 50.3, 33.2, 
32.9, 25.4, 25.3, 24.9, 24.7; Anal. calcd for C23H30N4O3: C, 67.29; H, 7.37; N, 
13.65; Found C, 67.30; H, 7.37; 13.63. 
6.45. 3-(1H-Imidazol-4-yl)phenyl cyclohexylcarbamate (252)232 
 
Compound 251 (240 mg, 0.58 mmol, 100 mol-%) was suspended in CH2Cl2 (10 ml) 
at rt followed by addition of MeOH (0.048 ml, 1.5 mmol, 260 mol-%) and grinded 
NaOH (23 mg, 0.58 mmol, 100 mol-%). The mixture was stirred at rt for 72 h and 
then directly purified by FC (Eluent 0-100% EtOAc/hex) and recrystallized from 
toluene giving 252 (120 mg, 71%) as a white solid: mp. 163-164.5 oC; Rf (EtOAc) 
0.2; 1H NMR (DMSO-d6) 12.19 (s, 1H), 7.73-7.54 (m, 4H), 7.46 (s, 1H), 7.32 (t, 1H, 
J = 7.9 Hz), 6.89 (d, 1H, J = 7.9 Hz), 3.36-3.28 (m, 1H), 1.87-1.79 (m, 2H), 1.75-
1.68 (m, 2H), 1.60-1.53 (m, 1H), 1.33-1.20 (m, 4H), 1.18-1.01 (m, 1H); 13C NMR 
(DMSO-d6) 153.6, 151.5, 139.3, 136.3, 136.0, 129.3, 120.7, 119.4, 117.6, 113.2, 
119 
 
49.8, 32.6, 25.2, 24.6; Anal. calcd for C16H19N3O2: C, 67.35; H, 6.71; N, 14.73; 
Found C, 66.88; H, 6.61; 14.28; HRMS (ESI) calcd [M+Na]+ for 
C16H19N3O2Na, 308.1375, found 308.1366. 
6.46. 3-(1-Methyl-1H-imidazol-4-yl)phenol (265)232 
OH
N
HN
OH
N
N
264 265
 
To a mixture of 264 (250 mg, 1.6 mmol, 100 mol-%) in N,N-dimethylformamide (10 
ml) was added MeI (110 µL, 1.7 mmol, 110 mol-%) and stirred at 0 oC for 90 min. 
The mixture was allowed to warm to rt and another portion of MeI (110 µL, 1.7 
mmol, 110 mol-%) was added, and stirring continued for 12 h at rt. Solvent was 
evaporated and residue purified by FC (Eluent 0-5% MeOH/CH2Cl2) giving 265 
(131 mg, 48%) as an off-white solid: Rf (10% MeOH/CH2Cl2) 0.47; mp. 160-166 
oC; 1H NMR (MeOD-d4) 7.61 (s, 1H), 7.35 (s, 1H), 7.18-7.11 (m, 3H), 6.68-6.62 (m, 
1H), 3.74 (s, 3H).   
6.47. 3-(1-Methyl-1H-imidazol-4-yl)phenyl cyclohexylcarbamate (253)232 
 
Recrystallization from EtOAc/ Et2O/hex gave 253 (125 mg, 66%) as a red solid: mp. 
139.5-140.5 oC; Rf (10% MeOH/CH2Cl2) 0.58; 1H NMR (DMSO-d6) 7.69 (d, 1H, J 
= 7.7 Hz), 7.65-7.62 (m, 2H), 7.55 (d, 1H, J = 7.8 Hz), 7.43 (t, 1H, J = 1.9 Hz); 7.31 
(t, 1H, J = 7.9 Hz), 6.89 (ddd, 1H, J = 8.0, 2.1, 0.8 Hz), 3.68 (s, 3H), 3.37-3.29 (m, 
1H), 1.88-1.79 (m, 2H), 1.77-1.68 (m, 2H), 1.66-1.51 (m, 1H), 1.35-1.01 (m, 5H); 
13C NMR (DMSO-d6) 154.4, 152.4, 140.7, 139.4, 136.9, 130.1, 121.4, 120.2, 118.3, 
118.2, 50.6, 33.9, 33.4, 26.0, 25.4; Anal. calcd for C17H21N3O2: C, 68.20; H, 7.07; 
N, 14.04; Found C, 68.47; H, 7.47; N, 13.82. 
6.66. 5-(3-Hydroxyphenyl)1H-tetrazole (274)239 
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3-Hydroxybenzonitrile (1.43 g, 12 mmol, 100 mol-%), Et3NHCl (3.3 g, 24 mmol, 
200 mol-%) and NaN3 (1.6 g, 8 mmol, 200 mol-%) were refluxed in dry toluene 
(120 ml) for 20 h. The mixture was cooled to rt, diluted with H2O (90 ml) and 
EtOAc (20 ml), and extracted with H2O (20ml). Water phase was acidified by a 
dropwise addition of 32% HCl until white solid precipitated. The precipitate was 
filtrated, washed with water and dried to give 269 (2.2 g, 90%) as a white solid: mp. 
220-222 oC; Rf (8% MeOH and 2% AcOH in CHCl3) 0.25; 1H NMR (DMSO-d6) 
9.94 (s, 1H), 7.47-7.38 (m, 2H), 7.40 (t, 1H, J = 8.0 Hz), 6.98 (ddd, 1H, J = 8.0, 2.0, 
1.0 Hz); 13C NMR (DMSO-d6) 158.0, 155.3 (br), 130.6, 125.1, 118.3, 117.6, 113.6.  
6.48. 3-(1H-Tetrazol-5-yl)phenyl cyclopentylcarbamate (269)232 
OH
NHN
N
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After a typical carbamoylation reaction, the reaction mixture was extracted with 
H2O (3 x 20 ml). The aqueous phase was acidified with 32% HCl (0.8 ml) until 
white precipitate formed. The precipitate was filtered and recrystallized from 
H2O/MeOH giving 269 (48 mg, 65%) as white crystals: mp. 174-177 oC; Rf (8% 
MeOH, 2% AcOH in CHCl3) 0.40; 1H NMR (DMSO-d6) 7.94 (d, 1H, J = 7.2 Hz), 
7.89 (d, 1H, J = 7.8 Hz), 7.77 (s, 1H), 7.62 (t, 1H, J = 8.0 Hz), 7.34 (dd, 1H, J = 8.1, 
1.6 Hz), 3.92-3.83 (m, 1H), 1.91-1.80 (m, 2H), 1.73-1.63 (m, 2H), 1.59-1.45 (m, 
4H); 13C NMR (DMSO-d6) 155.0, 153.4, 151.7, 130.6, 125.2, 124.7, 123.4, 120.3, 
52.4, 32.2, 23.3; Anal. calcd for C13H15N5O2: C, 57.13; H, 5.53; N, 25.63; Found C, 
56.90; H, 5.30; N, 25.23. 
6.49. 3-(2-Methyl-2H-tetrazol-5-yl)phenyl cyclopentylcarbamate (270)232 
 
Compound 269 (120 mg, 0.45 mmol, 100 mol-%) in acetone (2.5 ml) was cooled to 
2 oC (Tbath). Triethylamine (70 µL, 0.50 mmol, 110 mol-%) was added followed by 
addition of MeI (160 mg, 1.1 mmol, 250 mol-%). After 2 h another portion of MeI 
(450 mg, 3.2 mmol, 700 mol-%) was added. The mixture was stirred for another 1 h 
121 
 
at 2 oC and diluted with EtOAc (35 ml). The organic phase was washed with sat. 
NaHCO3 and brine, dried (Na2SO4) and evaporated giving 100 mg (74%) of 4:1 
mixture of 2-methylated and 1-methylated tetrazoles. The isomers were separated by 
FC (Eluent 0.5-1% MeOH/CH2Cl2) and major product was recrystallized from 
EtOAc/hex giving 270 (60 mg, 46%) as a white solid: mp. 145-147 oC; Rf (3% 
MeOH/CH2Cl2) 0.7; 1H NMR (CDCl3) 7.97 (d, 1H, J = 7.7 Hz), 7.91 (s, 1H), 7.47 
(t, 1H, J = 7.9 Hz), 7.28-7.22 (m, 1H), 5.05 (d, 1H, J = 5.8 Hz), 4.39 (s, 3H), 4.14-
4.01 (m, 1H), 2.10-1.98 (m, 2H), 1.79-1.58 (m, 4H), 1.56-1.46 (m, 2H); 13C NMR 
(CDCl3) 164.6, 153.7, 151.5, 129.8, 128.5, 123.6, 123.5, 120.1, 53.0, 39.5, 33.1, 
23.5; Anal. calcd for C14H17N5O2: C, 58.52; H, 5.96; N, 24.37; Found C, 58.52; H, 
5.85; N, 24.35.  
6.50. 3-(2-Benzyl-2H-tetrazol-5-yl)phenyl cyclopentylcarbamate (271)232 
 
Compound 269 (100 mg, 0.37 mmol, 100 mol-%) in acetone (2.5 ml) was cooled to 
2 oC (Tbath). Triethylamine (60 µL, 0.41 mmol, 110 mol-%) was added followed by 
addition of BnBr (50 µL, 0.41 mmol, 110 mol-%) and KI (30 mg, 0.19 mmol, 50 
mol-%). After 90 min the mixture was diluted with EtOAc (40 ml). The organic 
phase was washed with sat. NaHCO3 and brine, dried (Na2SO4) and evaporated 
giving 105 mg (78%) of 9:1 mixture of 2-benzylated and 1-benzylated tetrazoles 
respectively. The isomers were separated by FC (Eluent CH2Cl2) and major product 
was recrystallized from EtOAc/hex giving compound 271 (81 mg, 60%) as a white 
solid: mp. 129-130 oC; Rf (3% MeOH/CH2Cl2) 0.9; 1H NMR (CDCl3) 7.97 (d, 1H, J 
= 7.2 Hz), 7.90 (s, 1H), 7.48-7.34 (m, 6H), 7.26-7.20 (m, 1H), 5.79 (s, 2H), 5.02 (br 
s, 1H), 4.11-4.00 (m, 1H), 2.08-1.96 (m, 2H), 1.76-1.56 (m, 4H), 1.54-1.46 (m, 2H); 
13C NMR (CDCl3) 164.8, 153.7, 151.4, 133.3, 129.8, 129.0, 128.9, 128.6, 128.3, 
123.7, 123.6, 120.2, 56.8, 53.0, 33.1, 23.5; Anal. calcd for C20H21N5O2: C, 66.10; H, 
5.82; N, 19.27; Found C, 65.71; H, 5.85; N, 19.28. 
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6.51. Methyl 3-(cyclopentylcarbamoyloxy)benzoate (272)232 
 
Recrystallization from EtOAc/hex gave 272 (1.36 g, 79%) as colourless crystals: 
mp. 112-114 oC; Rf (10% Et2O/CH2Cl2) 0.5; 1H NMR (CDCl3) 7.85 (d, 1H, J = 7.6 
Hz), 7.78 (s, 1H), 7.39 (t, 1H, J = 7.9 Hz) 7.34-7.29 (m, 1H), 5.53 (br d, 1H, J = 7.0 
Hz), 4.08-3.97 (m, 1H), 3.89 (s, 3H), 2.01-1.91 (m, 2H), 1.72-1.40 (m, 6H); 13C 
NMR (CDCl3) 166.2, 153.6, 150.9, 131.1, 128.9, 126.2, 126.0, 122.6, 52.8, 52.0, 
32.7, 23.3; Anal. calcd for C14H17NO4: C, 63.87; H, 6.51; N, 5.32; Found C, 63.96; 
H, 6.30; N, 5.39.  
6.52. 3-(1H-Tetrazol-5-yl)phenyl cyclohexylcarbamate (275) 
 
This compound isolated as described for 269 and recrystallized from H2O/MeOH 
giving 275 (1.1 g, 62%) as white crystals: mp. 180-182 oC; Rf (8% MeOH, 2% 
AcOH in CHCl3) 0.25; 1H NMR (DMSO-d6) 7.89 (t, 1H, J = 8.0 Hz), 7.78 (s, 1H), 
7.62 (t, 1H, J = 7.9 Hz), 7.35 (d, 1H, J = 7.8 Hz), 3.42-3.29 (m, 1H), 1.91-1.81 (m, 
2H), 1.77-1.66 (m, 2H), 1.62-1.53 (m, 1H), 1.36-1.20 (m, 4H), 1.19-1.06 (m, 1H); 
13C NMR (DMSO-d6) 155.0, 153.1, 151.7, 130.6, 125.3, 124.6, 123.4, 120.2, 49.9, 
32.5, 25.1, 24.6; HRMS (ESI) calcd for [M+Na]+ C14H17N5O2Na: 310.1280, found 
310.1291.  
6.53. 3-(2-Methyl-2H-tetrazol-5-yl)phenyl cyclohexylcarbamate (273a) 
 
This compound was prepared and worked up as described for 270. The isomers were 
separated by FC (Eluent 0.5-1% MeOH/CH2Cl2) and major product was 
recrystallized from EtOAc/hex giving 273a (270 mg, 35%) as a white solid: mp. 
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158-160 oC; Rf (3% MeOH/CH2Cl2) 0.5; 1H NMR (CDCl3) 7.97(d, 1H, J = 7.8 Hz), 
7.93-7.90 (m, 1H), 7.47 (t, 1H, J = 7.9 Hz), 7.28-7.23 (m, 1H), 4.39 (s, 3H), 3.65-
3.52 (m, 1H), 2.07-1.98 (m, 2H), 1.80-1.70 (m, 2H), 1.68-1.59 (m, 1H), 1.45-1.33 
(m, 2H), 1.30-1.17 (m, 3H); 13C NMR (CDCl3) 164.7, 153.3, 151.5, 129.8, 128.5, 
123.6, 123.5, 120.1, 50.2, 39.5, 33.2, 25.4, 24.7; Anal. calcd for C15H19N5O2: C, 
59.79; H, 6.36; N, 23.24; Found C, 59.49; H, 6.20; N, 23.13.  
6.54. 3-(1-Methyl-1H-tetrazol-5-yl)phenyl cyclohexylcarbamate (273b) 
O
NN
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The minor product from preparation of 273a was recrystallized from EtOAc/hex 
giving 273b (26 mg, 3%) as white crystals: mp. 157-161 oC; Rf (3% MeOH/CH2Cl2) 
0.30; 1H NMR (CDCl3) 7.61-7.51 (m, 3H), 7.40-7.32 (m, 1H), 5.08-4.97 (br d, 1H), 
4.19 (s, 3H), 3.64-3.51 (m, 1H), 2.10-1.97 (m, 2H), 1.82-1.70 (m, 2H), 1.69-1.57 (m, 
1H), 1.46-1.33 (m, 2H), 1.32-1.14 (m, 3H); 13C NMR (CDCl3) 153.8, 153.0, 151.5, 
130.3, 125.2, 124.6, 124.4, 122.1, 50.3, 35.1, 33.2, 25.4, 24.7; Anal. calcd for 
C15H19N5O2: C, 59.79; H, 6.36; N, 23.24; Found C, 59.80; H, 6.30; N, 23.07.  
6.55. Methyl 3-(cyclohexylcarbamoyloxy)benzoate (276)232 
 
Recrystallization from EtOAc/hex gave 276 (400 mg, quant.) as white crystals: mp. 
131-132 oC; Rf (10% Et2O/CH2Cl2) 0.5; 1H NMR (CDCl3) 7.87 (d, 1H, J = 7.7 Hz), 
7.80 (t, 1H, J = 1.9 Hz), 7.42 (t, 1H, J = 7.9 Hz), 7.36-7.31 (m, 1H), 4.95 (d, 1H, J = 
7.0 Hz), 3.91 (s, 3H), 3.64-3.51 (m, 1H), 2.07-1.98 (m, 2H), 1.80-1.70 (m, 2H), 
1.67-1.60 (m, 1H), 1.45-1.32 (m, 2H), 1.29-1.17 (m, 3H); 13C NMR (CDCl3) 166.3, 
153.3, 151.0, 131.3, 129.1, 126.3, 126.2, 122.7, 52.1, 50.2, 33.1, 25.3, 24.7; Anal. 
calcd for C15H19NO4: C, 64.97; H, 6.91; N, 5.05; Found C, 65.32; H, 6.96; N, 5.19. 
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6.56. 3-(Cyclohexylcarbamoyloxy)benzoic acid (277) 
 
Recrystallization from EtOAc/hex gave 277 (280 mg, 73%) as a white solid: mp. 
205-206 oC; Rf (10% MeOH/CH2Cl2) 0.3; 1H NMR (DMSO-d6) 13.13 (s, 1H), 7.83-
7.75 (m, 2H), 7.61-7.58 (m, 1H), 7.50 (t, 1H, J = 7.9 Hz), 7.38-7.34 (m, 1H), 3.40-
3.27 (m, 1H), 1.89-1.79 (m, 2H), 1.76-1.66 (m, 2H), 1.61-1.52 (m, 1H), 1.34-1.05 
(m, 5H); 13C NMR (DMSO-d6) 166.6, 153.2, 151.1, 132.0, 129.6, 126.2, 125.7, 
122.3, 49.8, 32.5, 25.1, 24.5; Anal. calcd for C14H17NO4 C, 63.87; H, 6.51; N, 5.32; 
Found C, 63.95; H, 6.60; N, 5.61. 
6.57. 3-Formylphenyl cyclohexylcarbamate (278) 
 
Recrystallization from EtOAc/hex gave 278 (2.9 g, 69%) as white crystals; mp. 120-
122 oC; Rf (2% MeOH/CH2Cl2) 0.8; 1H NMR (CDCl3); 9.92 (s, 1H), 7.71 (d, 1H, J = 
7.6 Hz), 7.67-7.65 (m, 1H), 7.52 (t, 1H, J = 7.8 Hz), 7.43-7.39 (m, 1H), 5.01 (br d, 
1H, J = 6.8 Hz), 3.63-3.51 (m, 1H), 2.09-1.98 (m, 2H), 1.81-1.71 (m, 2H), 1.68-1.59 
(m, 1H), 1.45-1.32 (m, 2H), 1.30-1.14 (m, 3H); 13C NMR (CDCl3) 191.4, 153.1, 
151.7, 137.6, 129.9, 127.8, 126.4, 122.4, 50.3, 33.2, 25.4, 24.7; Anal. calcd for 
C14H17NO3: C, 68.00; H, 6.93; N, 5.66; Found C, 67.83; H, 6.86; N, 5.65. 
6.58. 3-Hydroxybenzamide (283)226  
 
3-Cyanophenol (295 mg, 2.48 mmol, 100 mol-%) and NaBO3 ·  4H2O (1.15 g, 7.45 
mmol, 300 mol-%) in H2O (8 ml) were heated to 50 oC and MeOH (14 ml) was 
added until mixture was clear. The mixture was stirred at 50 oC for 70 h and excess 
MeOH was evaporated, and the pH of remaining mixture was adjusted to 5 with 
conc. HCl (aq). Mixture was extracted with CH2Cl2 and EtOAc (5 x 15 ml). Organic 
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phases were combined, washed with brine and dried (Na2SO4). Evaporation of 
solvent gave 283 (183 mg, 54%) as white solid: mp. 165-168 oC; Rf (50% 
EtOAc/hex) 0.10; 1H NMR (DMSO-d6) 9.58 (s, 1H), 7.84 (br s, 1H), 7.29-7.20 (m, 
4H), 6.89 (ddd, 1H, J = 7.9, 2.5, 1.0 Hz). 
6.59. 3-Carbamoylphenyl cyclohexylcarbamate (279)232 
 
Purification by FC (Eluent 10% MeOH/CH2Cl2) and recrystallization (EtOAc) gave 
279 (40 mg, 15%) as white crystals; mp. 169-179 oC; Rf (15% MeOH/CH2Cl2) 0.36; 
1H NMR (DMSO-d6) 8.01 (s, 1H), 7.78 (d, 1H, J = 7.9 Hz), 7.71 (d, 1H, J = 7.8 Hz), 
7.58 (s, 1H), 7.44 (m, 2H), 7.26-7.24 (m, 1H), 3.36-3.28 (m, 1H), 1.86-1.80 (m, 2H), 
1.74-1.68 (m, 2H), 1.59-1.53 (m, 1H), 1.30-1.20 (m, 4H), 1.17-1.08 (m, 1H); 13C 
NMR (DMSO-d6) 167.8, 154.2, 151.9, 136.3, 130.0, 125.6, 124.8, 121.7, 50.7, 33.4, 
26.0, 25.4; Anal. calcd for C14H18N2O3: C, 64.10; H, 6.92; N, 10.68; Found C, 
64.32; H, 6.97; N, 10.47. 
6.60. 3-Cyanophenyl cyclohexylcarbamate (280) 232 
NC OH NC O
O
H
N
280
 
Recrystallization from EtOAc/hex gave compound 280 (1.47 g, 68%) as white 
needles: mp. 117-120 oC; Rf (50% EtOAc/hex) 0.56; 1H NMR (CDCl3) 7.50-7.38 
(m, 4H), 4.98 (d, 1H, J = 7.3 Hz), 3.61-3.51 (m, 1H), 2.05-1.98 (m, 2H), 1.80-1.71 
(m, 2H), 1.68-1.60 (m, 1H), 1.44-1.33 (m, 2H), 1.29-1.15 (m, 3H); 13C NMR 
(CDCl3) 152.6, 151.2, 130.1, 128.8, 126.5, 125.3, 118.0, 113.2, 50.3, 33.1, 25.3, 
24.7; Anal. calcd for C14H16N2O2: C, 68.83; H, 6.60; N, 11.47; Found C, 68.89; H, 
6.55; N, 11.36. 
6.61. Dimethyl 4-hydroxyphthalate (285)240 
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3-Hydroxyphthalic acid (284, 360 mg, 2.0 mmol, 100 mol-%) was dissolved in 
MeOH (20 ml), and conc. H2SO4 (11 µL, 0.2 mmol, 10 mol-%) was added to the 
mixture. The mixture was refluxed for 24 h, cooled to rt, poured to sat. NaHCO3 (30 
ml), and most of the MeOH was evaporated to dryness. The mixture was extracted 
with EtOAc and combined organic phases were dried (Na2SO4), and evaporated 
giving 285 (400 mg, 95%) as a white solid: mp. 110-111 oC; Rf (EtOAc) 0.6; 1H 
NMR (CDCl3) 7.74 (d, 1H, J = 8.6 Hz), 7.24 (br s, 1H), 7.01 (d, 1H, J = 2.6 Hz), 
6.92 (dd, 1H, J = 8.4, 2.6 Hz), 3.90 (s, 3H), 3.86 (s, 3H); 13C NMR (CDCl3) 169.6, 
167.2, 159.4, 135.6, 131.9, 121.5, 117.3, 115.3, 53.0, 52.5. 
6.62. Dimethyl 4-(cyclohexylcarbamoyloxy)phthalate (281) 232 
 
Recrystallization from EtOAc/hex gave 281 (190 mg, 80%) as white crystals: mp. 
112-112.5 oC; Rf (EtOAc) 0.5; 1H NMR (CDCl3) 7.75 (d, 1H, J = 8.5 Hz), 7.46 (d, 
1H, J = 2.1 Hz) 7.32 (dd, 1H, J = 8.5, 2.1 Hz), 5.05 (d, 1H, J = 7.4 Hz) 3.90 (s, 3H), 
3.89 (s, 3H), 3.62-3.49 (m, 1H), 2.06-1.95 (m, 2H), 1.80-1.70 (m, 2H), 1.67-1.59 (m, 
1H), 1.44-1.30 (m, 2H), 1.28-1.16 (m, 3H); 13C NMR (CDCl3) 167.5, 167.1, 153.2, 
152.4, 133.9, 130.5, 127.8, 123.7, 121.8, 52.7, 52.6, 50.3, 33.1, 25.3, 24.7; Anal. 
calcd for C17H21NO6: C, 60.89; H, 6.31; N, 4.18; Found C, 60.98; H, 6.38; N, 4.27. 
Biological testing protocols 
Enzyme inhibition assays were organized and carried out by Ph. D. Susanna M. 
Saario and co-workers in the Department of Pharmaceutical Chemistry, University 
of Kuopio.12,49,152,179,241,242  
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